0001144204-12-043389.txt : 20120807 0001144204-12-043389.hdr.sgml : 20120807 20120807163816 ACCESSION NUMBER: 0001144204-12-043389 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120807 DATE AS OF CHANGE: 20120807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 121013912 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 v318145_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-32587

PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2726770
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One Park Place, Suite 450, Annapolis, MD		21401
(Address of principal executive offices)		(Zip Code)

(410) 269-2600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨		Accelerated Filer x

Non-Accelerated Filer ¨		Smaller Reporting Company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: The number of shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding as of August 1, 2012 was 48,365,984.

PHARMATHENE, INC.

TABLE OF CONTENTS

		Page

PART I — FINANCIAL INFORMATION		1

Item 1. Financial Statements		1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3. Quantitative and Qualitative Disclosures about Market Risk		20

Item 4. Controls and Procedures		20

PART II — OTHER INFORMATION		20

Item 1. Legal Proceedings		20

Item 1A. Risk Factors		21

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		21

Item 3. Default Upon Senior Securities		21

Item 4. Mine Safety Disclosures		21

Item 5. Other Information		21

Item 6. Exhibits		22

Certifications

Item 1. Financial Statements

PHARMATHENE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30,			December 31,
	2012			2011
	(unaudited)

ASSETS
Current assets:
Cash and cash equivalents	$	11,776,921		$	11,236,771
Accounts receivable (billed)		3,444,830			4,424,442
Unbilled accounts receivable		4,786,304			3,021,208
Prepaid expenses and other current assets		675,047			830,585
Restricted cash		-			100,000
Total current assets		20,683,102			19,613,006

Property and equipment, net		625,534			788,666
Other long term assets and deferred costs		150,479			53,384
Goodwill		2,348,453			2,348,453
Total assets	$	23,807,568		$	22,803,509

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	2,062,718		$	1,445,700
Accrued expenses and other liabilities		3,141,947			3,169,642
Current portion of long term debt		454,548			-
Total current liabilities		5,659,213			4,615,342

Other long term liabilities		564,860			449,709
Long term debt, less current portion		1,983,544			-
Derivative instruments		2,054,505			1,886,652
Total liabilities		10,262,122			6,951,703

Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively		4,835			4,824
Additional paid-in-capital		209,662,510			208,525,917
Accumulated other comprehensive income		1,003,989			1,010,522
Accumulated deficit		(197,125,888	)		(193,689,457	)
Total stockholders' equity		13,545,446			15,851,806
Total liabilities and stockholders' equity	$	23,807,568		$	22,803,509

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended June 30,						Six months ended June 30,
	2012			2011			2012			2011

Revenue	$	6,316,998		$	6,428,840		$	12,466,050		$	12,766,562

Operating Expenses:
Research and development		4,918,655			5,984,098			9,624,012			11,804,472
General and administrative		2,780,099			3,409,372			5,728,580			8,349,026
Depreciation and amortization		76,448			116,690			162,358			234,319
Total operating expenses		7,775,202			9,510,160			15,514,950			20,387,817

Loss from operations		(1,458,204	)		(3,081,320	)		(3,048,900	)		(7,621,255	)
Other income (expense):
Interest income		4,819			3,381			7,807			6,535
Interest expense		(111,353	)		(15,173	)		(114,381	)		(30,608	)
Other income (expense)		519			(32,722	)		53,434			(44,628	)
Change in fair value of derivative instruments		823,809			688,221			(167,853	)		3,176,686
Total other income (expense)		717,794			643,707			(220,993	)		3,107,985

Net loss before income taxes		(740,410	)		(2,437,613	)		(3,269,893	)		(4,513,270	)
Income tax expense		(16,133	)		-			(166,538	)		-
Net loss	$	(756,543	)	$	(2,437,613	)	$	(3,436,431	)	$	(4,513,270	)

Basic and diluted net loss per share	$	(0.02	)	$	(0.05	)	$	(0.07	)	$	(0.10	)

Weighted average shares used in calculation of basic and diluted net loss per share		48,325,945			46,631,396			48,297,919			46,454,968

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Three months ended June 30,						Six months ended June 30,
	2012			2011			2012			2011

Net loss	$	(756,543	)	$	(2,437,613	)	$	(3,436,431	)	$	(4,513,270	)
Other comprehensive (loss) income:
Foreign currency translation adjustment		(19,902	)		13,771			(6,533	)		(9,292	)
Comprehensive loss	$	(776,445	)	$	(2,423,842	)	$	(3,442,964	)	$	(4,522,562	)

See the accompanying notes to the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months ended June 30,
	2012			2011
Operating activities
Net loss	$	(3,436,431	)	$	(4,513,270	)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt recovery		-			(400,695	)
Change in fair value of derivative instruments		167,853			(3,176,686	)
Depreciation and amortization expense		162,358			234,319
Gain on the disposal of property and equipment		(66,626	)		-
Share-based compensation expense		1,060,705			1,255,325
Deferred income taxes		166,538			-
Non-cash interest expense		40,470			-
Changes in operating assets and liabilities:
Accounts receivable		979,612			760,274
Unbilled accounts receivable		(1,765,096	)		1,114,139
Prepaid expenses and other current assets		248,707			1,611,860
Accounts payable		617,014			(674,723	)
Accrued expenses and other liabilities		(87,483	)		404,230
Net cash used in operating activities		(1,912,379	)		(3,385,227	)
Investing activities
Purchases of property and equipment		-			(30,364	)
Proceeds from the sale of property and equipment		67,400			-
Net cash provided by (used in) investing activities		67,400			(30,364	)
Financing activities
Proceeds from issuance of long term debt		2,500,000			-
Deferred financing costs		(216,460	)		-
Change in restricted cash requirements		100,000			-
Proceeds from issuance of common stock and warrants		38,983			5,862,558
Other		(32,960	)		(64,362	)
Net cash provided by financing activities		2,389,563			5,798,196
Effects of exchange rates on cash		(4,434	)		(7,334	)
Increases in cash and cash equivalents		540,150			2,375,271
Cash and cash equivalents, at beginning of period		11,236,771			11,785,327
Cash and cash equivalents, at end of period	$	11,776,921		$	14,160,598
Supplemental disclosure of cash flow information
Cash paid for interest	$	73,911		$	30,608
Noncash financing activity
Warrants issued to lender in connection with loan	$	69,876		$	-

See the accompanying notes to the unaudited consolidated financial statements.

PHARMATHENE, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

June 30, 2012

Note 1 - Organization and Business

We are a biopharmaceutical company focused on developing biodefense countermeasure applications. We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties.

Historically, we have performed under government contracts and grants and raised equity, equity-linked and debt capital from investors and lenders to sustain our operations.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries PharmAthene Canada, Inc. and PharmAthene UK Limited, collectively referred to herein as “PharmAthene”, “we”, “us”, “our” or the “Company.” All significant intercompany transactions and balances have been eliminated in consolidation. Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2011 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. We currently operate in one business segment. Certain amounts within current assets in the 2011 financial statements have been reclassified to conform to the current year’s presentation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation

The functional currency of our wholly owned foreign subsidiaries located in Canada and the United Kingdom is their local currency. Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments are accumulated in a separate component of stockholders’ equity. Transaction gains or losses are included in the determination of net loss.

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit & Term Loan

As discussed in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in capital, resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are being amortized over the term of the agreement using the effective interest method.

Significant Customers and Accounts Receivable

Our primary customers are the Biomedical Advanced Research and Development Authority (“BARDA”), the U.S. Department of Defense (the “DoD”), and the National Institutes of Health (“NIH”). As of June 30, 2012 and December 31, 2011, the Company’s trade receivable and unbilled receivable balances were comprised solely of receivables from these customers.

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts. Costs consist primarily of direct subcontractor and internal labor charges incurred plus an allocation of fringe benefits, overhead and general and administrative expenses as defined in each contract.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, pursuant to the terms of the cost-plus fee contract, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments, including milestone payments for fees, contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone. Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

For fixed price contracts without substantive milestones as described above, revenue is recognized on the percentage-of-completion method in accordance with the applicable accounting guidance for long term contracts. The percentage-of-completion method recognizes income as the contract progresses; recognition of revenue and profits generally related to the costs incurred in providing the services required under the contract. The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates. The fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used. Estimating is an integral part of our business activities, and there may be a necessity to revise estimates on contracts continually as the work progresses. As a result, amounts invoiced may differ from revenue recognized. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue, a component of accrued expenses and other liabilities. We recorded approximately $19 thousand and $0.5 million as deferred revenue as of June 30, 2012 and December 31, 2011.

As revenue is recognized in accordance with the terms of the contracts, related amounts are recorded as unbilled accounts receivable in our consolidated balance sheets. As specific contract invoices are generated and sent to our customers in accordance with a contract, invoiced amounts are transferred out of unbilled accounts receivable and into billed accounts receivable. Invoicing frequency and payment terms for cost-plus-fee contracts with our customers are defined within each contract, but are typically monthly invoicing with 30-60 day payment cycles.

We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended June 30, 2012 and 2011, we recorded approximately $0.4 million and $0.1 million, respectively, of costs reimbursed by the government as an offset to research and development expenses. For the six months ended June 30, 2012 and 2011, we recorded approximately $1.0 million and $0.4 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized ratably as expense over the requisite service period. The fair value of stock option grants is determined using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of the Company’s stock price. The value of the award that is ultimately expected to vest is recognized as compensation expense on a straight line basis over the employee’s requisite service period.

Employee share-based compensation expense recognized in the three months ended June 30, 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12% for both 2012 and 2011, based on historical forfeitures.

Share-based compensation expense for the three months ended June 30, 2012 and 2011 was:

	2012		2011

Research and development	$	127,076	$	216,997
General and administrative		384,965		327,703
Total share-based compensation expense	$	512,041	$	544,700

During the three months ended June 30, 2012, we granted 185,000 options to employees and nonemployee directors and made no restricted stock grants. During the three months ended June 30, 2011, we granted 208,000 options to employees and nonemployee directors and made no restricted stock grants. At June 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.9 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.1 years.

Share-based compensation expense for the six months ended June 30, 2012 and 2011 was:

	2012		2011

Research and development	$	244,143	$	458,431
General and administrative		816,562		796,894
Total share-based compensation expense	$	1,060,705	$	1,255,325

During the six months ended June 30, 2012, we granted 200,948 options to employees and nonemployee directors and made no restricted stock grants. During the six months ended June 30, 2011, we granted 304,000 options to employees and nonemployee directors and made no restricted stock grants.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year, plus or minus discrete income tax amounts. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.

Income tax expense was approximately $16 thousand and $0.2 million for the three and six months ended June 30, 2012, respectively. No income tax expense was recorded in 2011. Income tax expense in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. The Company recorded a deferred tax liability, which cannot offset deferred tax assets, and a corresponding income tax expense. This deferred tax liability is included in our condensed consolidated balance sheet in other noncurrent liabilities.

Basic and Diluted Net Loss Per Share

Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.

For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive shares of common stock is anti-dilutive due to the net losses. A total of approximately 11.6 million and approximately 10.9 million potential dilutive shares have been excluded in the calculation of diluted net loss per share in the three and six months ended June 30, 2012 and 2011, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations or financial position.

Note 3 - Fair Value Measurements

We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value.

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the six months ended June 30, 2012:

Description	Balance as of December 31, 2011		Unrealized Losses		Balance as of June 30, 2012

Derivative liabilities related to warrants	$	1,886,652	$	167,853	$	2,054,505

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2011:

Description	Balance as of December 31, 2010		New Liabilities in 2011		Unrealized (Gains)			Balance as of June 30, 2011

Derivative liabilities related to warrants	$	8,362,995	$	668,640	$	(3,176,686	)	$	5,854,949

At June 30, 2012 and 2011, derivative liabilities are comprised of 2,899,991 warrants to purchase common stock accounted for as a derivative. The warrants are considered to be derivative liabilities due to the presence of net settlement features, including cash settlement in certain circumstances, and are recorded at fair value at each balance sheet date. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option-pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our condensed consolidated statements of operations. The $0.2 million change in the market value of derivative instruments during the six-month period ended June 30, 2012 is due primarily to the change in the closing price of our stock, which was $1.27 per share as of December 30, 2011 and $1.39 per share as of June 30, 2012. The $3.2 million change in the market value of derivative instruments during the six-month period ended June 30, 2011 is due primarily to the change in the closing price of our stock, which was $4.23 per share as of December 31, 2010 and $2.94 per share as of June 30, 2011.

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA Technologies, Inc. (“SIGA”) in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246^®(Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel. The Court awarded us the right to receive 50% of all net profits related to the sale of ST-246^® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of ST-246^® and related products. The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million. In May 2012, the Court issued its final judgment. Both parties are appealing aspects of the decision to the Delaware Supreme Court.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit of the sales of ST-246^® and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at June 30, 2012, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured.

Note 5 - Stockholders’ Equity

Long-Term Incentive Plan

In 2007, the Company’s stockholders approved the 2007 Long Term Incentive Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

At that time, we reserved 3,500,000 shares of common stock in connection with awards to be granted under the 2007 Plan, including those awards that had originally been made under a prior plan. In 2008, the Company’s shareholders approved amendments to the 2007 Plan, increasing the maximum number of shares authorized for issuance under the plan to 4,600,000 and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan will increase automatically in each year, beginning in 2009 and continuing through 2015, according to certain limits set forth in the 2007 Plan. At June 30, 2012, there are approximately 8.2 million shares approved for issuance under the 2007 Plan, of which approximately 1.6 million shares are available to be issued. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions, and the exercise price. Stock options issued under the 2007 Plan may have a maximum term of ten years.

Warrants Classified as Equity

In connection with the July 2009 private placement, we issued warrants to purchase an aggregate of 2,572,775 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrants will expire on January 28, 2015. Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017.

In connection with the March 30, 2012, debt financing (see Note 6), we issued warrants to purchase an aggregate of 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share to GE Capital. The warrants expire on March 30, 2022.

Note 6 – Financing Transactions

On March 30, 2012, we entered into a Loan and Security Agreement (the “Loan Agreement”) with General Electric Capital Corporation (“GE Capital”), as lender and agent for other lenders that may subsequently become party to the agreement. The Loan Agreement provides for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5 million based on our outstanding qualified accounts receivable. On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million. The initial draw on the revolving line of credit was for approximately $0.9 million on March 30, 2012. The revolving line of credit was repaid during the second quarter; therefore, no borrowings under the revolving line of credit were outstanding as of June 30, 2012. Under the terms of the Loan Agreement, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable. As of June 30, 2012, approximately $0.1 million was available under the Loan Agreement to borrow against the revolving line of credit as we worked to finalize customary post-closing arrangements to implement GE Capital’s security interest in our receivables. These security interest arrangements were implemented in July 2012.

The fixed interest rate on the term loan is 10.14% per annum. The revolving line of credit has an adjustable interest rate based upon 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%, plus 5%. As of June 30, 2012, this interest rate was 6.5%. Both the term loan and the revolving line of credit mature in September 2015. Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term. Principal payments on the term loan are scheduled as follows:

		Principal
Year		Payments
	2012		-
	2013	$	909,096
	2014	$	909,096
	2015	$	681,808
		$	2,500,000

If we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, we are obligated to pay a prepayment premium equal to 3% of the then outstanding principal amount of the term loan during the first two years of the loan and 2% during the third year and thereafter. In addition we are obligated to pay a final payment fee of 3% of the term loan balance. The final payment fee will be accrued and expensed over the term of the agreement, utilizing the effective interest method.

Our obligations under the Loan Agreement are collateralized by a security interest in substantially all of our assets including cash, receivables and property and equipment. While the security interest does not, except in limited circumstances, cover our intellectual property, it does cover any proceeds to us from the use or sale of intellectual property.

The Loan Agreement contains customary representations, warranties and covenants, including limitations on acquisitions, dispositions, incurrence of indebtedness and the granting of security interests. The representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of a specific date or specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Loan Agreement.

The Loan Agreement contains certain financial and non-financial covenants. Upon the occurrence and during the continuance of any event of default, GE Capital may, and at the written request of the requisite lenders shall, terminate the commitments under the facilities and declare any or all of the obligations to be immediately due and payable, without demand or notice to us; however, any event of default relating to timely payment of debts, insolvency, liquidation, bankruptcy or similar events will result in automatic acceleration. Among the remedies available to GE Capital in case of an event of default are the taking possession and disposition of any collateral under the Loan Agreement.

In connection with the Loan Agreement, we issued GE Capital warrants to purchase 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share, subject to customary anti-dilution adjustments. The warrants are classified as equity. The fair value of the warrants at March 30, 2012 of $69,876 was recorded as a discount to the carrying value of the debt and is being amortized through interest expense over the term of the loan.

Also, in connection with us entering into the Loan Agreement, we incurred approximately $216,000 of related expenses. These expenses are deferred and are being amortized to interest expense over the term of the Loan Agreement.

In June 2011, PharmAthene entered into an agreement with certain accredited investors who purchased an aggregate of 1,857,143 shares of common stock for a purchase price of $3.50 per share and warrants to purchase up to an additional 371,423 shares of common stock. The warrants became exercisable immediately at an exercise price of $3.50 per share until the fifth anniversary of the date of issuance, which is June 15, 2016. The Company received gross proceeds of approximately $6.5 million and net proceeds of approximately $5.8 million.

Note 7 – Subsequent Events

On July 31, 2012, the DoD exercised its option to continue to fund an advanced expression system for the bioproduction of PharmAthene’s rBChE nerve agent medical countermeasure program, under a contract initially awarded in 2011. The value of the option was $2.5 million out of a potential total contract value of $5.7 million.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This information may involve known and unknown risks, uncertainties and other factors that are difficult to predict and may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risk associated with the following:

•

the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates,

•

funding delays, reductions in or elimination of U.S. government funding and/or non-renewal of expiring funding for one or more of our development programs,

•

the award of government contracts to our competitors or delays caused by third parties challenging government contract awards to us,

•

unforeseen safety issues,

•

challenges related to the development, technology transfer, scale-up, and/or process validation of manufacturing processes for our product candidates,

•

unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products,

as well as risks detailed under the caption “Risk Factors” in our Report on Form 10-K for the year ended December 31, 2011 and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”) from time to time thereafter. In particular, there can be no assurance, that SIGA Technologies, Inc. (“SIGA”) will not prevail in its appeal, or that we will be successful in our appeal of certain aspects of the decision, to the Delaware Supreme Court of the ruling of the Delaware Court of Chancery awarding PharmAthene 50% of all net profits related to the sale of ST-246^® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of ST-246^® and related products. Further, the timing and amount of any future sales of ST-246^® is uncertain. Significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for all our products candidates. Future government funding to support the development of Valortim^® is unlikely in the near term and remains uncertain. It is also uncertain whether any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans. Forward-looking statements describe management’s current expectations regarding our future plans, strategies and objectives and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential” or “plan” or the negative of these words or other variations on these words or comparable terminology. Such statements include, but are not limited to:

•

statements about potential future government contract or grant awards,

•

potential payments under government contracts or grants,

•

potential regulatory approvals,

•

future product advancements, and

•

anticipated financial or operational results.

Forward-looking statements are based on assumptions that may be incorrect, and we cannot assure you that the projections included in the forward-looking statements will come to pass.

We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this Quarterly Report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements which present our results of operations for the three and six months ended June 30, 2012 and 2011, as well as our financial positions at June 30, 2012 and December 31, 2011, contained elsewhere in this Quarterly Report on Form 10-Q. The following discussion should also be read in conjunction with the Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 8, 2012, including the consolidated financial statements contained therein.

Overview

We are a biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. Our current biodefense portfolio includes the following product candidates:

•

SparVax™, a next generation recombinant protective antigen (“rPA”) anthrax vaccine,

•

rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides, and

•

Valortim^®, a fully human monoclonal antibody for the prevention and treatment of anthrax infection.

In addition, we were awarded by the Delaware Court of Chancery in September 2011 the right to receive 50% of all net profits related to the sale of SIGA Technologies, Inc. ST-246^® and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from sales of ST-246^® and related products. In May 2012, the Court issued its final judgment. Both parties are appealing aspects of the decision to the Delaware Supreme Court.

Critical Accounting Policies

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results of operations and that requires management’s most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect of matters that are inherently uncertain. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the years ended December 31, 2010 and 2011, filed with the Securities and Exchange Commission.

There were no significant changes in critical accounting policies from those at December 31, 2011.

Results of Operations

Revenue

We recognized revenue of $6.3 million and $6.4 million during the three months ended June 30, 2012 and 2011, respectively. We recognized revenue of $12.5 million and $12.8 million during the six months ended June 30, 2012 and 2011, respectively.

Our revenue was derived primarily from contracts with the U.S. government for the development of SparVax™, and our rBChE bioscavanger and in the 2011 periods for Valortim^®as well. Our revenue in the three and six months ended June 30, 2012 changed from the comparable periods of 2011 primarily due to the following:

Under our contract for the development of SparVax™, we recognized approximately $6.1 million and $5.3 million of revenue for the three months ended June 30, 2012 and 2011, respectively and approximately $11.3 million and $10.8 million of revenue for the six months ended June 30, 2012 and 2011, respectively. During the three and six months ended June 30, 2012 revenue for the Company's SparVax™ program was primarily attributable to the initiation of Bulk Drug Substance (BDS) Process Characterization to prepare for validation activities, further progression in the development of bioanalytical and analytical assays and the achievement of several contract milestones. Revenue for the six months ended June 30, 2012 is also attributable to work related to the manufacture of final drug product of SparVax™ as well as activities related to the Phase 2 clinical trial planned to commence later in 2012 and the completion of certain activities related to the development of analytical assays and ongoing stability programs for BDS and Final Drug Product. Milestone revenue received for the achievement of key technical milestones for the three and six months ended June 30, 2012 was $0.4 million and $1.3 million, respectively. During the three and six months ended June 30, 2011 revenue was primarily attributable to work related to the manufacturing platform for SparVax™ and additional activities related to the establishment of analytical and stability-indicating assays for characterization of the product, including the receipt of $0.9 million in connection with the achievement of key technical milestones under our SparVax™ development contract for the three months ended June 30, 2011 and $2.2 million for the six months ended June 30, 2011.

We recognized approximately $0.2 million and $1.0 million related to work on our second generation rBChE bioscavanger in the three and six months ended June 30, 2012 under the August 2011 fixed price contract with the DoD for the development of advanced expression system for rBChE. No revenue was recognized for the second generation rBChE bioscavanger in the three and six months ended June 30, 2011.

Under our contracts for the advanced development of Valortim^®, we recognized no revenue in the three month period ended June 30, 2012 and $1.1 million of revenue for the three month period ended June 30, 2011, and $0.1 million and $1.9 million of revenue for the six months ended June 30, 2012 and 2011, respectively. Revenue in 2012 primarily reflects completion of activities under our 2007 contract with National Institute of Allergy and Infectious Diseases (“NIAID”) for Valortim^®, which ended in accordance with its terms in the first quarter 2012, and certain work related to non-clinical and analytical assay development work to support further development of this product candidate. Additional government funding for Valortim^® is unlikely during government fiscal year 2012, which ends September 30, 2012. There can be no assurance we will be successful in obtaining additional financial support for this program.

Research and Development Expenses

Our research and development expenses were $4.9 million and $6.0 million for the three months ended June 30, 2012 and 2011, respectively and $9.6 million and $11.8 million for the six months ended June 30, 2012 and 2011. These expenses resulted from research and development activities in both periods related to our SparVax™ program as well as from activities related to Valortim^® primarily in the 2011 period and the rBChE bioscavanger primarily in the 2012 period. Direct expenses included salaries and other costs of personnel, raw materials and supplies, and an allocation of indirect expenses. We also incurred third-party costs, including contract research, consulting and clinical development costs for individual projects. Research and development expenses for the three months ended June 30, 2012 and 2011 were net of cost reimbursements under certain of our government grants of $0.4 million and $0.1 million, respectively. Research and development expenses for the six months ended June 30, 2012 and 2011 were net of cost reimbursements under certain of our government grants of $1.0 million and $0.4 million, respectively.

Research and development expenses for the three and six months ended June 30, 2012 and 2011 were attributable to research programs as follows:

	Three Months ended June 30,
($ in millions)	2012		2011
Anthrax therapeutic and vaccines	$	4.6	$	5.2
Chemical nerve agent protectants		0.3		-
Internal research and development		-		0.8
Total research and development expenses	$	4.9	$	6.0

	Six Months ended June 30,
($ in millions)	2012		2011
Anthrax therapeutic and vaccines	$	8.8	$	10.3
Chemical nerve agent protectants		0.7		0.2
Internal research and development		0.1		1.3
Total research and development expenses	$	9.6	$	11.8

For the three and six months ended June 30, 2012, research and development expenses decreased approximately $1.1 and $2.2 million respectively, from the same periods in the prior year, primarily due to a reduction in non-government funded internal research and development and decreased costs related to our Valortim^®program as a result of the completion in the first quarter 2012 of work under our 2007 contract with NIAID.

General and Administrative Expenses

General and administrative functions include executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal, and compliance. For each function, we may incur expenses such as salaries, supplies and third-party consulting and other external costs and non-cash expenditures such as expense related to stock option and restricted share awards. An allocation of indirect costs such as facilities, utilities and other administrative overhead is also included in general and administrative expenses.

Expenses associated with general and administrative functions were $2.8 and $3.4 million for the three months ended June 30, 2012 and 2011, respectively. Legal and professional fees in the second quarter 2011 were approximately $0.7 million higher than in the same period in 2012 primarily due to the increased fees incurred for post trial activities in the litigation with SIGA and higher professional fees in the second quarter 2011. In addition, general and administrative labor costs decreased as a result of planned reductions. The three months ended June 30, 2011 also reflect a bad debt recovery of approximately $0.4 million.

Expenses associated with general and administrative functions were $5.7 million for the six months ended June 30, 2012 and $8.3 million for the six months ended June 30, 2011. Legal and professional fees in the first six months of 2011 were approximately $2.4 million higher than in the same period in 2012 primarily due to the increased fees incurred for the trial and post trial activities in the litigation with SIGA as well as higher professional fees in the first half of 2011. In addition, general and administrative labor costs decreased as a result of planned reductions. The six months ended June 30, 2011 also includes a bad debt recovery of approximately $0.4 million.

Depreciation and Amortization

Depreciation and amortization expenses were approximately $0.1 million for the three months ended June 30, 2012 and 2011, respectively. Depreciation and amortization expenses were approximately $0.2 million for the six months ended June 30, 2012 and 2011, respectively.

Other Income (Expense)

Other income (expense) primarily consists of interest income on our cash and cash equivalents, interest expense on our debt and other financial obligations, changes in fair value of our derivative financial instruments, foreign currency transaction gains or losses, and the gain on the disposal of property and equipment.

We incurred approximately $0.1 million and $15 thousand in interest expense during the three months ended June 30, 2012 and 2011, respectively. We incurred $0.1 million and $31 thousand in interest expense during the six months ended June 30, 2012 and 2011, respectively. Interest expense in 2012 is the result of the term loan and revolving line of credit we entered into on March 30, 2012. We anticipate that we will incur higher interest expense as a result of the term loan and use of the revolving line of credit in future periods.

The other income related to the change in the fair value of our derivative instruments was approximately $0.8 million and $0.7 million for the three months ended June 30, 2012 and 2011, respectively. The warrants are considered to be derivative liabilities due to the presence of net settlement features, including cash settlement in certain circumstances, and are recorded at fair value at each balance sheet date. The fair value of these derivative instruments is estimated using the Black-Scholes option pricing model. The decrease in fair value recognized for the three months ended June 30, 2012 was primarily the result of the decrease in our stock price from $1.77 per share on March 30, 2012 to $1.39 per share on June 30, 2012. The $0.7 million change in the fair value of derivative instruments during the three month period ended June 30, 2011 is due primarily to the change in the closing price of our stock, which was $3.19 per share as of March 31, 2011 to $2.94 per share as of June 30, 2011.

The other expense related to the change in the fair value of our derivative instruments was approximately $0.2 million for the six months ended June 30, 2012. The other income related to the change in fair value of our derivative instruments was approximately $3.2 million for the six months ended June 30, 2011. The fair value of these derivative instruments is estimated using the Black-Scholes option pricing model. The increase in fair value recognized for the six months ended June 30, 2012 was primarily the result of the increase in our stock price from $1.27 per share on December 31, 2011 to $1.39 per share on June 30, 2012. The $3.2 million change in the fair value of derivative instruments during the six month period ended June 30, 2011 is due primarily to the change in the closing price of our stock, which was $4.23 per share as of December 31, 2010 and $2.94 per share as of June 30, 2011. For more information, please refer to Note 3 - Fair Value Measurements in the notes to the unaudited condensed consolidated financial statements.

Income Taxes

Income tax expense was approximately $16 thousand and $0.2 million for the three and six months ended June 30, 2012, respectively. No income tax expense was recorded in 2011. Income tax expense in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. Generally Accepted Accounting Principles. The Company recorded a deferred tax liability, which cannot offset deferred tax assets, and a corresponding income tax expense. This deferred tax liability is included in our condensed consolidated balance sheet in other noncurrent liabilities.

Liquidity and Capital Resources

Overview

Our primary cash requirements for 2012 are to fund our operations (including our research and development programs) and support our general and administrative activities. Our future capital requirements will depend on many factors, including, but not limited to, timing, amount and profitability of sales of ST-246^®, if any (and our ability to collect our portion of net profits related to ST-246^®); the progress of our research and development programs; the progress of pre-clinical and clinical testing; the time and cost involved in obtaining regulatory approval; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; changes in our existing research relationships; competing technological and marketing developments; our ability to establish collaborative arrangements and to enter into licensing agreements and contractual arrangements with others; and any future change in our business strategy. These cash requirements could change materially as a result of shifts in our business and strategy.

During 2011 and the first quarter of 2012, we implemented certain cost reduction activities that we believe have reduced our net operating cash needs for 2012 and 2013 significantly as compared to 2010 and 2011. In addition, during the first quarter of 2012, we closed on a term loan for $2.5 million and have access to additional debt capital pursuant to a revolving line of credit for up to an additional $5 million dollars based on a percentage of our accounts receivable. No borrowings under the revolving line of credit were outstanding as of June 30, 2012. As of June 30, 2012, approximately $0.1 million was available under the Loan Agreement to borrow against the revolving line of credit as we worked to finalize customary post-closing arrangements to implement GE Capital’s security interest in our receivables. These security interest arrangements were implemented in July 2012. We currently anticipate that our current cash on hand, amounts available under the line of credit, and collection of accounts receivables at June 30, 2012, as well as cash to be collected from contract revenue under contracts currently in place, will be sufficient to meet the Company’s ongoing expenses and capital requirements through at least June 30, 2013.

Since our inception, we have not historically generated positive cash flows from operations. To bridge the gap between payments made to us under our government contracts and grants and our operating and capital needs, we have had to rely on a variety of financing sources, including the issuance of equity securities and convertible notes, proceeds from loans and other borrowings. For the foreseeable future, we will continue to need these types of financing vehicles and potentially others to help fund our future operating and capital requirements.

While in March 2012, the Company was successful in securing credit financing, the renewed turmoil affecting the global financial system threatens to once again tighten the credit markets. As a result, there can be no assurance that future funding will be available to us on reasonably acceptable terms, or at all. In addition, due to the U.S. government’s continuing substantial efforts to stabilize the economy, the U.S. government may be forced or choose to reduce or delay spending in the biodefense field, which could decrease the likelihood of future government contract awards, the likelihood that the government will exercise its right to extend any of its existing contracts with us and/or the likelihood that the government would procure products from us.

Our condensed consolidated financial statements have been prepared on a basis which assumes that we will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business and do not include any adjustments that might result if the carrying amount of recorded assets and liabilities are not realized.

Sources and Uses of Cash

Cash and cash equivalents were $11.8 million and $11.2 million at June 30, 2012 and December 31, 2011, respectively. The $0.6 million increase at June 30, 2012 was primarily attributable to the $2.5 million term loan, which we closed in the first quarter 2012, partially offset by $1.9 million of cash used in operations, while for the corresponding 2011 period, cash and cash equivalents included $5.8 million in proceeds from the June 2011 issuance of stock and warrants, partially offset by $3.4 million of cash used in operations.

Operating Activities

Net cash used in operating activities was $1.9 million and $3.4 million for the six months ended June 30, 2012 and 2011, respectively.

Net cash used in operations during the six months ended June 30, 2012 reflects our net loss of $3.4 million, adjusted for non-cash share-based compensation expense of $1.1 million, the increase in the fair value of derivative instruments of $0.2 million and other noncash expenses of $0.3 million. The increase in unbilled accounts receivable of approximately $1.8 million was partially offset by a decrease in accounts receivable of approximately $1.0 million. The increase in the fair value of the derivative instruments primarily relates to the change in our stock price from $1.27 per share at December 30, 2011 to $1.39 per share at June 30, 2012.

Net cash used in operations during the six months ended June 30, 2011 reflects our net loss of $4.5 million, adjusted for the change in market value of derivative instruments of $3.2 million and recovery of bad debt expenses of $0.4 million. These were offset by non-cash stock option expense of $1.3 million, decrease in accounts receivable of $0.8 million, decrease in unbilled receivables of $1.1 million and a decrease in prepaid expenses and other current assets of $1.6 million and minor decreases in current liabilities. The change in market value of the derivative instruments primarily relates to the change in PharmAthene’s stock price from $4.23 per share at December 30, 2010 to $2.94 per share at June 30, 2011.

Investing Activities

There were no significant investing activities during the six months ended June 30, 2012 and June 30, 2011.

Financing Activities

Net cash provided by financing activities was $2.4 million for the six months ended June 30, 2012 as compared to $5.8 million for the six months ended June 30, 2011.

The majority of our cash provided by financing for the six months ended June 30, 2012, was a result of us entering into a senior fully-secured debt facility with GE Capital as described in Note 6 to the unaudited condensed consolidated financial statements. On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million. The initial draw on the revolving line of credit was, for approximately $0.9 million, on March 30, 2012. The revolving line of credit was repaid during the second quarter, therefore, none of the $5 million revolving line of credit was being used as of June 30, 2012.

In June 2011, PharmAthene entered into an agreement with certain accredited investors who purchased an aggregate of 1,857,143 shares of common stock for a purchase price of $3.50 per share and warrants to purchase up to an additional 371,423 shares of common stock. The warrants were exercisable immediately at an exercise price of $3.50 per share until the fifth anniversary of the date of issuance, which is June 15, 2016. The Company received gross proceeds of approximately $6.5 million and net proceeds of approximately $5.8 million.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations

The following are contractual commitments at June 30, 2012 primarily associated with leases and research and development arrangements:

Contractual Obligations⁽¹⁾	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 years

Operating facility leases		4,000,200		785,850		1,595,400		1,618,950		-
Research and development agreements		17,465,985		17,309,885		156,100		-		-
Term loan		2,500,000		454,548		1,818,192		227,260		-
Total contractual obligations	$	23,966,185		18,550,283		3,569,692		1,846,210		-

(1) This table does not include any royalty payments relating to future sales of products subject to license agreements the Company has entered into in relation to its in-licensed technology, as the timing and likelihood of such payments are not known.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

We have limited exposure to interest rate and foreign currency exchange rate risk.

Our exposure to interest rate risk is currently confined to our cash and cash equivalents. Because of the short-term maturities of our cash and cash equivalents, we do not believe that an increase in market interest rates would have a material impact on the realized value of our holdings. Our term loan with GE Capital is at a fixed 10.14% rate. Because of the fixed rate, we do not think that a change in market interest rates would have a material impact on our amounts payable under the loan. Due to the short term nature of the revolving line of credit, we do not anticipate an interest rate risk even though the interest rate is variable.

The Company’s current operations in foreign countries are minimal. We have closed our active operations in Canada and maintain nominal operations in the United Kingdom. A 10% change in exchange rates (against the U.S. dollar) would have no material impact on earnings or cash flow.

We currently do not hedge interest rate exposure or foreign currency exchange exposure. We have also not used derivative financial instruments for speculation or trading purposes.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2012. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended June 30, 2012, and has concluded that there was no change that occurred during the quarterly period ended June 30, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleges, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246^®, pursuant to a merger agreement between the parties that was terminated in October 2006. The complaint also alleges that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal of certain aspects of the decision, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit interest in sales of ST-246® and related products (once SIGA earns $40 million in net profits). We have not recorded any amount due from SIGA in relation to this case.

Item 1A. Risk Factors

Investing in our securities involves risks. In addition to the other information in this quarterly report on Form 10-Q, stockholders and potential investors should carefully consider the risks and uncertainties discussed in the section "Item 1A. Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2011 as supplemented by the risks and uncertainties discussed below. If any of the risks and uncertainties set forth below or in our 2011 annual report on Form 10-K actually materialize, our business, financial condition and/or results of operations could be materially adversely affected, the trading price of our common stock could decline and a stockholder could lose all or part of his or her investment. The risks and uncertainties set forth below and described in our 2011 annual report on Form 10-K are not the only ones that may materialize. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations.

Risks Related to Our Financial Condition

There are risks presented by our obligations under our fully-secured loan agreement with GE Capital

In the first quarter 2012, we closed on a senior fully-secured debt facility with GE Capital providing for a $2.5 million term loan and a revolving line of credit of up to $5 million based on a percentage of our outstanding qualified accounts receivable. The Company’s obligations under the loan and security agreement with GE Capital (“Loan Agreement”) are secured by a security interest in substantially all of the Company’s assets. While the security interest does not, except in limited circumstances, cover the Company’s intellectual property, it does cover any proceeds to the Company from the use of intellectual property. The Loan Agreement contains customary representations, warranties and covenants, including limitations on acquisitions, dispositions, incurrence of indebtedness and the granting of security interests. Upon the occurrence and during the continuance of any event of default, GE Capital may, and at the written request of the requisite lenders shall, terminate the commitments under the facilities and declare any or all of the obligations to be immediately due and payable, without demand or notice to the Company. However, any event of default relating to timely payment of debts, insolvency, liquidation, bankruptcy or similar events will result in automatic acceleration. Among the remedies available to GE Capital in case of an event of default are the taking possession and disposition of any collateral under the Loan Agreement.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable

Item 3. Default upon Senior Securities

Not applicable

Item 4. Mine Safety Disclosures

Not applicable

Item 5. Other Information

Not applicable

Item 6. Exhibits.

No.		Description
31.1		Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
31.2		Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARMATHENE, INC.

Dated: August 7, 2012	By:	/s/ Eric I. Richman
		Eric I. Richman
		President and Chief Executive Officer

Dated: August 7, 2012	By:	/s/ Linda Chang
		Linda Chang
		Senior Vice-President and Chief Financial Officer

EX-31.1 2 v318145_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Eric I. Richman, certify that:

I have reviewed this report on Form 10-Q of PharmAthene, Inc. for the quarter ended June 30, 2012;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 7, 2012	/s/ Eric I. Richman
	Name: Eric I. Richman
	Title: President and Chief Executive Officer

EX-31.2 3 v318145_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Linda Chang, certify that:

I have reviewed this report on Form 10-Q of PharmAthene, Inc. for the quarter ended June 30, 2012;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 7, 2012	/s/ Linda Chang
	Name: Linda Chang
	Title: Senior Vice President and Chief Financial Officer

EX-32.1 4 v318145_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report of PharmAthene, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2012, as filed with the Securities and Exchange Commission (the “Report”), I, Eric I. Richman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Eric I. Richman
Eric I. Richman
President and Chief Executive Officer
August 7, 2012

A signed original of this written statement required by Section 906 has been provided to PharmAthene, Inc. and will be retained by PharmAthene, Inc. and furnished to the Securities and Exchange Commission upon request.

EX-32.2 5 v318145_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report of PharmAthene, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2012, as filed with the Securities and Exchange Commission (the “Report”), I, Linda Chang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Linda Chang
Linda Chang
Senior Vice President and Chief Financial Officer
August 7, 2012

EX-101.INS 6 pip-20120630.xml XBRL INSTANCE DOCUMENT 5700000 2500000 48365984

3500000

14160598

2899991

1857143

371423

3.50

5854949

46584

1.61

2022-03-30

900000

5000000

2500000

675047

2348453

69876

209662510

150479

909096

13545446

0.1014

0.015

2900000

1003989

100000000

3444830

48345984

10262122

2062718

564860

-197125888

23807568

4786304

23807568

2500000

216000

11776921

48345984

46584

909096

5659213

19000

4835

0.0001

681808

20683102

2054505

625534

454548

1983544

3141947

2899991

0.85 0.80

100000

2054505

2572775

2.50

2015-01-28

100778

3.97

2017-03-30

1600000

8200000

0.05

4600000

11785327

8362995

830585

2348453

208525917

53384

15851806

1010522

100000000

4424442

100000

48236172

6951703

1445700

449709

-193689457

22803509

3021208

22803509

11236771

48236172

4615342

500000

4824

0.0001

19613006

1886652

788666

3169642

1886652

-7621255

-674723

-44628

12766562

-4522562

-64362

1255325

3176686

-1114139

-0.10

234319

-3385227

-30364

6535

30364

2375271

8349026

-1611860

-760274

-9292

-4513270

11804472

5798196

20387817

404230

1255325

30608

46454968

10900000

-4513270

3107985

304000

-7334

400000

30608

-400695 0 5862558 2.94

458431

796894

-3176686

668640 PIP PHARMATHENE, INC false Accelerated Filer Q2 2012 10-Q 2012-06-30 0001326190 --12-31 1.61

0.065

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 5 - Stockholders’ Equity   Long-Term Incentive Plan   In 2007, the Company’s stockholders approved the 2007 Long Term Incentive Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”)  to Company officers and employees.  Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.     At that time, we reserved 3,500,000 shares of common stock in connection with awards to be granted under the 2007 Plan, including those awards that had originally been made under a prior plan.  In 2008, the Company’s shareholders approved amendments to the 2007 Plan, increasing the maximum number of shares authorized for issuance under the plan to 4,600,000 and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan will increase automatically in each year, beginning in 2009 and continuing through 2015, according to certain limits set forth in the 2007 Plan.  At June 30, 2012, there are approximately 8.2 million shares approved for issuance under the 2007 Plan, of which approximately 1.6 million shares are available to be issued. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions, and the exercise price.  Stock options issued under the 2007 Plan may have a maximum term of ten years. Warrants Classified as Equity   In connection with the July 2009 private placement, we issued warrants to purchase an aggregate of 2,572,775 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrants will expire on January 28, 2015.  Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017.   In connection with the March 30, 2012, debt financing (see Note 6), we issued warrants to purchase an aggregate of 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share to GE Capital. The warrants expire on March 30, 2022. </div>

-3048900

216460

<div style="FONT: 10pt Times New Roman, Times, Serif"> Revenue Recognition   We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.  Costs consist primarily of direct subcontractor and internal labor charges incurred plus an allocation of fringe benefits, overhead and general and administrative expenses as defined in each contract.   Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned.  The estimate of the applicable fee earned is determined by reference to the contract:  if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, pursuant to the terms of the cost-plus fee contract, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.    Under the milestone method of revenue recognition, milestone payments, including milestone payments for fees, contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.  Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.     For fixed price contracts without substantive milestones as described above, revenue is recognized on the percentage-of-completion method in accordance with the applicable accounting guidance for long term contracts.  The percentage-of-completion method recognizes income as the contract progresses; recognition of revenue and profits generally related to the costs incurred in providing the services required under the contract.  The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates.  The fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used. Estimating is an integral part of our business activities, and there may be a necessity to revise estimates on contracts continually as the work progresses. As a result, amounts invoiced may differ from revenue recognized. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue, a component of accrued expenses and other liabilities. We recorded approximately $19 thousand and $0.5 million as deferred revenue as of June 30, 2012 and December 31, 2011.   As revenue is recognized in accordance with the terms of the contracts, related amounts are recorded as unbilled accounts receivable in our consolidated balance sheets.  As specific contract invoices are generated and sent to our customers in accordance with a contract, invoiced amounts are transferred out of unbilled accounts receivable and into billed accounts receivable.  Invoicing frequency and payment terms for cost-plus-fee contracts with our customers are defined within each contract, but are typically monthly invoicing with 30-60 day payment cycles.   We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred.  For the three months ended June 30, 2012 and 2011, we recorded approximately $0.4 million and $0.1 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.  For the six months ended June 30, 2012 and 2011, we recorded approximately $1.0 million and $0.4 million, respectively, of costs reimbursed by the government as an offset to research and development expenses. </div>

617014

53434

12466050

-3442964

-32960

<div style="FONT: 10pt Times New Roman, Times, Serif"> Cash and Cash Equivalents   Cash and cash equivalents are stated at cost which approximates market value.  We consider all highly liquid investments with original maturities of three months or less to be cash equivalents. </div>

1060705

<div style="FONT: 10pt Times New Roman, Times, Serif"> Basis of Presentation   Our condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries PharmAthene Canada, Inc. and PharmAthene UK Limited, collectively referred to herein as “PharmAthene”, “we”, “us”, “our” or the “Company.”  All significant intercompany transactions and balances have been eliminated in consolidation.  Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).  In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows.  The unaudited condensed consolidated balance sheet at December 31, 2011 has been derived from audited consolidated financial statements at that date.  The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year.   Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. We currently operate in one business segment. Certain amounts within current assets in the 2011 financial statements have been reclassified to conform to the current year’s presentation. </div>

67400

-167853

1765096

-0.07

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 3 - Fair Value Measurements   We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date.  We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value.  This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs.  The three levels of inputs used to measure fair value are as follows:   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18px"> </td> <td style="WIDTH: 30px">•</td> <td>Level 1 — Quoted prices in active markets for identical assets or liabilities.</td> </tr> </table>   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18px"> </td> <td style="WIDTH: 30px">•</td> <td>Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</td> </tr> </table>   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18px"> </td> <td style="WIDTH: 30px">•</td> <td>Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.  This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</td> </tr> </table>   An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value.  All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.    We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.  We have no non-financial assets and liabilities that are measured at fair value.     The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the six months ended June 30, 2012:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt"> Description</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of December 31, 2011</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Unrealized Losses</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of June 30,  2012</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 46%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to warrants</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">1,886,652</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">167,853</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">2,054,505</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2011:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt"> Description</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of December 31, 2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">New Liabilities in 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Unrealized (Gains)</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of June 30,  2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 28%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to warrants</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">8,362,995</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">668,640</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">(3,176,686</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">)</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">5,854,949</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>     At June 30, 2012 and 2011, derivative liabilities are comprised of 2,899,991 warrants to purchase common stock accounted for as a derivative. The warrants are considered to be derivative liabilities due to the presence of net settlement features, including cash settlement in certain circumstances, and are recorded at fair value at each balance sheet date.  The fair value of our warrants is determined based on the Black-Scholes option pricing model.  Use of the Black-Scholes option-pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends.  Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our condensed consolidated statements of operations.  The $0.2 million change in the market value of derivative instruments during the six-month period ended June 30, 2012 is due primarily to the change in the closing price of our stock, which was $1.27 per share as of December 30, 2011 and $1.39 per share as of June 30, 2012. The $3.2 million change in the market value of derivative instruments during the six-month period ended June 30, 2011 is due primarily to the change in the closing price of our stock, which was $4.23 per share as of December 31, 2010 and $2.94 per share as of June 30, 2011. </div>

162358

-1912379

67400

7807

100000

540150

5728580

2500000

<div style="FONT: 10pt Times New Roman, Times, Serif"> amortize over its remaining term. Principal payments on the term loan are scheduled as follows:       <table style="WIDTH: 43%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2">Principal</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Year</td> <td> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Payments</td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc; VERTICAL-ALIGN: bottom"> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: center; WIDTH: 15%">2012</td> <td style="WIDTH: 2%"> </td> <td style="WIDTH: 2%"> </td> <td style="WIDTH: 5%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">-</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td style="TEXT-ALIGN: center">2013</td> <td> </td> <td> </td> <td>$</td> <td style="TEXT-ALIGN: right">909,096</td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc; VERTICAL-ALIGN: bottom"> <td> </td> <td style="TEXT-ALIGN: center">2014</td> <td> </td> <td> </td> <td>$</td> <td style="TEXT-ALIGN: right">909,096</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid"> </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: center">2015</td> <td style="BORDER-BOTTOM: windowtext 1pt solid"> </td> <td style="BORDER-BOTTOM: windowtext 1pt solid"> </td> <td style="BORDER-BOTTOM: windowtext 1pt solid">$</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: right"> 681,808</td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc; VERTICAL-ALIGN: bottom"> <td> </td> <td style="TEXT-ALIGN: right"> </td> <td> </td> <td> </td> <td style="BORDER-BOTTOM: black 2.25pt double">$</td> <td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right"> 2,500,000</td> </tr> </table> </div>

-248707

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 7 – Subsequent Events    On July 31, 2012, the DoD exercised its option to continue to fund an advanced expression system for the bioproduction of PharmAthene’s rBChE nerve agent medical countermeasure program, under a contract initially awarded in 2011. The value of the option was $2.5 million out of a potential total contract value of $5.7 million. </div>

-979612

-6533

-3269893

<div style="FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the six months ended June 30, 2012:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt"> Description</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of December 31, 2011</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Unrealized Losses</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of June 30,  2012</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 46%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to warrants</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">1,886,652</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">167,853</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">2,054,505</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2011:    <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt"> Description</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of December 31, 2010</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">New Liabilities in 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Unrealized (Gains)</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">Balance as of June 30,  2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 28%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 14%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to warrants</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">8,362,995</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">668,640</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">(3,176,686</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">)</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt">5,854,949</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table> </div>

9624012

2389563

Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term.

<div style="FONT: 10pt Times New Roman, Times, Serif"> Income Taxes   We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year, plus or minus discrete income tax amounts. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.   Income tax expense was approximately $16 thousand and $0.2 million for the three and six months ended June 30, 2012, respectively. No income tax expense was recorded in 2011. Income tax expense in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. The Company recorded a deferred tax liability, which cannot offset deferred tax assets, and a corresponding income tax expense. This deferred tax liability is included in our condensed consolidated balance sheet in other noncurrent liabilities. </div>

15514950

40470

<div style="FONT: 10pt Times New Roman, Times, Serif"> Revolving Line of Credit & Term Loan   As discussed in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in capital, resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are being amortized over the term of the agreement using the effective interest method. </div>

-87483

66626

1060705

73911

<div style="FONT: 10pt Times New Roman, Times, Serif"> Share-Based Compensation   We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans.  The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized ratably as expense over the requisite service period.  The fair value of stock option grants is determined using the Black-Scholes option pricing model.  The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of the Company’s stock price.  The value of the award that is ultimately expected to vest is recognized as compensation expense on a straight line basis over the employee’s requisite service period.   Employee share-based compensation expense recognized in the three months ended June 30, 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12% for both 2012 and 2011, based on historical forfeitures.    Share-based compensation expense for the three months ended June 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2012</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%; FONT-SIZE: 10pt">Research and development</td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 127,076</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 216,997</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">General and administrative</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 384,965</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 327,703</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">Total share-based compensation expense</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 512,041</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 544,700</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   During the three months ended June 30, 2012, we granted 185,000 options to employees and nonemployee directors and made no restricted stock grants.  During the three months ended June 30, 2011, we granted 208,000 options to employees and nonemployee directors and made no restricted stock grants.  At June 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.9 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.1 years.     Share-based compensation expense for the six months ended June 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2012</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%; FONT-SIZE: 10pt">Research and development</td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 244,143</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 458,431</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">General and administrative</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 816,562</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 796,894</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">Total share-based compensation expense</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 1,060,705</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 1,255,325</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   During the six months ended June 30, 2012, we granted 200,948 options to employees and nonemployee directors and made no restricted stock grants.  During the six months ended June 30, 2011, we granted 304,000 options to employees and nonemployee directors and made no restricted stock grants. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 4 - Commitments and Contingencies   SIGA Litigation   In December 2006, we filed a complaint against SIGA Technologies, Inc. (“SIGA”) in the Delaware Court of Chancery.  The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, ST-246® (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006.  The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.    In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel.  The Court awarded us the right to receive 50% of all net profits related to the sale of ST-246®and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of ST-246® and related products.  The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million. In May 2012, the Court issued its final judgment. Both parties are appealing aspects of the decision to the Delaware Supreme Court.      We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit of the sales of ST-246®and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.    Government Contracting   Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows.   Registration Rights Agreements   We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants.  We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding.   We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.   Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at June 30, 2012, would be approximately $0.2 million.      Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured. </div>

48297919

166538

-3436431

-220993

<div style="FONT: 10pt Times New Roman, Times, Serif"> Foreign Currency Translation   The functional currency of our wholly owned foreign subsidiaries located in Canada and the United Kingdom is their local currency.  Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period.  Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period.  Translation adjustments are accumulated in a separate component of stockholders’ equity.  Transaction gains or losses are included in the determination of net loss. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Share-based compensation expense for the three months ended June 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2012</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%; FONT-SIZE: 10pt">Research and development</td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 127,076</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 216,997</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">General and administrative</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 384,965</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 327,703</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">Total share-based compensation expense</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 512,041</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 544,700</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   During the three months ended June 30, 2012, we granted 185,000 options to employees and nonemployee directors and made no restricted stock grants.  During the three months ended June 30, 2011, we granted 208,000 options to employees and nonemployee directors and made no restricted stock grants.  At June 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.9 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.1 years.     Share-based compensation expense for the six months ended June 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2012</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%; FONT-SIZE: 10pt">Research and development</td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 244,143</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 458,431</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">General and administrative</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 816,562</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 796,894</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">Total share-based compensation expense</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 1,060,705</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 1,255,325</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table> </div>

200948

166538

-4434

<div style="FONT: 10pt Times New Roman, Times, Serif"> Note 2 - Summary of Significant Accounting Policies   Basis of Presentation   Our condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries PharmAthene Canada, Inc. and PharmAthene UK Limited, collectively referred to herein as “PharmAthene”, “we”, “us”, “our” or the “Company.”  All significant intercompany transactions and balances have been eliminated in consolidation.  Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”).  In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows.  The unaudited condensed consolidated balance sheet at December 31, 2011 has been derived from audited consolidated financial statements at that date.  The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year.   Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission. We currently operate in one business segment. Certain amounts within current assets in the 2011 financial statements have been reclassified to conform to the current year’s presentation.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.    Foreign Currency Translation   The functional currency of our wholly owned foreign subsidiaries located in Canada and the United Kingdom is their local currency.  Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period.  Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period.  Translation adjustments are accumulated in a separate component of stockholders’ equity.  Transaction gains or losses are included in the determination of net loss.   Cash and Cash Equivalents   Cash and cash equivalents are stated at cost which approximates market value.  We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.      Revolving Line of Credit & Term Loan   As discussed in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in capital, resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are being amortized over the term of the agreement using the effective interest method.   Significant Customers and Accounts Receivable   Our primary customers are the Biomedical Advanced Research and Development Authority (“BARDA”), the U.S. Department of Defense (the “DoD”), and the National Institutes of Health (“NIH”). As of June 30, 2012 and December 31, 2011, the Company’s trade receivable and unbilled receivable balances were comprised solely of receivables from these customers.     Revenue Recognition   We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.  Costs consist primarily of direct subcontractor and internal labor charges incurred plus an allocation of fringe benefits, overhead and general and administrative expenses as defined in each contract.   Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned.  The estimate of the applicable fee earned is determined by reference to the contract:  if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, pursuant to the terms of the cost-plus fee contract, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.    Under the milestone method of revenue recognition, milestone payments, including milestone payments for fees, contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.  Milestones are considered substantive if all of the following conditions are met: (1) it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone, (2) it relates solely to past performance, and (3) the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.     For fixed price contracts without substantive milestones as described above, revenue is recognized on the percentage-of-completion method in accordance with the applicable accounting guidance for long term contracts.  The percentage-of-completion method recognizes income as the contract progresses; recognition of revenue and profits generally related to the costs incurred in providing the services required under the contract.  The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates.  The fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used. Estimating is an integral part of our business activities, and there may be a necessity to revise estimates on contracts continually as the work progresses. As a result, amounts invoiced may differ from revenue recognized. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue, a component of accrued expenses and other liabilities. We recorded approximately $19 thousand and $0.5 million as deferred revenue as of June 30, 2012 and December 31, 2011.   As revenue is recognized in accordance with the terms of the contracts, related amounts are recorded as unbilled accounts receivable in our consolidated balance sheets.  As specific contract invoices are generated and sent to our customers in accordance with a contract, invoiced amounts are transferred out of unbilled accounts receivable and into billed accounts receivable.  Invoicing frequency and payment terms for cost-plus-fee contracts with our customers are defined within each contract, but are typically monthly invoicing with 30-60 day payment cycles.   We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred.  For the three months ended June 30, 2012 and 2011, we recorded approximately $0.4 million and $0.1 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.  For the six months ended June 30, 2012 and 2011, we recorded approximately $1.0 million and $0.4 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.     Share-Based Compensation   We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans.  The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized ratably as expense over the requisite service period.  The fair value of stock option grants is determined using the Black-Scholes option pricing model.  The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of the Company’s stock price.  The value of the award that is ultimately expected to vest is recognized as compensation expense on a straight line basis over the employee’s requisite service period.   Employee share-based compensation expense recognized in the three months ended June 30, 2012 and 2011 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12% for both 2012 and 2011, based on historical forfeitures.    Share-based compensation expense for the three months ended June 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2012</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%; FONT-SIZE: 10pt">Research and development</td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 127,076</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 216,997</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">General and administrative</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 384,965</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 327,703</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">Total share-based compensation expense</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 512,041</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 544,700</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   During the three months ended June 30, 2012, we granted 185,000 options to employees and nonemployee directors and made no restricted stock grants.  During the three months ended June 30, 2011, we granted 208,000 options to employees and nonemployee directors and made no restricted stock grants.  At June 30, 2012, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.9 million, net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.1 years.     Share-based compensation expense for the six months ended June 30, 2012 and 2011 was:   <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2012</td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2">2011</td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 68%; FONT-SIZE: 10pt">Research and development</td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 244,143</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%; FONT-SIZE: 10pt"> 458,431</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">General and administrative</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 816,562</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 796,894</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt">Total share-based compensation expense</td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 1,060,705</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> 1,255,325</td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> </tr> </table>   During the six months ended June 30, 2012, we granted 200,948 options to employees and nonemployee directors and made no restricted stock grants.  During the six months ended June 30, 2011, we granted 304,000 options to employees and nonemployee directors and made no restricted stock grants.   Income Taxes   We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. For interim periods, we recognize an income tax provision (benefit) based on an estimated annual effective tax rate expected for the entire year, plus or minus discrete income tax amounts. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. We consider discontinued operations for purposes of determining the amount of tax benefits that result from a loss from continuing operations.   Income tax expense was approximately $16 thousand and $0.2 million for the three and six months ended June 30, 2012, respectively. No income tax expense was recorded in 2011. Income tax expense in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP. The Company recorded a deferred tax liability, which cannot offset deferred tax assets, and a corresponding income tax expense. This deferred tax liability is included in our condensed consolidated balance sheet in other noncurrent liabilities.   Basic and Diluted Net Loss Per Share   Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.   For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting  primarily of stock options, unvested restricted stock and stock purchase warrants.  The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.     For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive shares of common stock is anti-dilutive due to the net losses.  A total of approximately 11.6 million and approximately 10.9 million potential dilutive shares have been excluded in the calculation of diluted net loss per share in the three and six months ended June 30, 2012 and 2011, respectively, because their inclusion would be anti-dilutive.     Recent Accounting Pronouncements   We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations or financial position. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates. </div>

<div style="font: 10pt Times New Roman, Times, Serif"> Note 1 - Organization and Business   We are a biopharmaceutical company focused on developing biodefense countermeasure applications.  We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development.  There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable.  In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties.   Historically, we have performed under government contracts and grants and raised equity, equity-linked and debt capital from investors and lenders to sustain our operations. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> Basic and Diluted Net Loss Per Share   Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.   For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting  primarily of stock options, unvested restricted stock and stock purchase warrants.  The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.     For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive shares of common stock is anti-dilutive due to the net losses.  A total of approximately 11.6 million and approximately 10.9 million potential dilutive shares have been excluded in the calculation of diluted net loss per share in the three and six months ended June 30, 2012 and 2011, respectively, because their inclusion would be anti-dilutive. </div>

1000000

114381

69876 0 2015-09 <div style="FONT: 10pt Times New Roman, Times, Serif"> Recent Accounting Pronouncements   We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations or financial position. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> Note 6 – Financing Transactions   On March 30, 2012, we entered into a Loan and Security Agreement (the “Loan Agreement”) with General Electric Capital Corporation (“GE Capital”), as lender and agent for other lenders that may subsequently become party to the agreement. The Loan Agreement provides for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5 million based on our outstanding qualified accounts receivable.  On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million. The initial draw on the revolving line of credit was for approximately $0.9 million on March 30, 2012. The revolving line of credit was repaid during the second quarter; therefore, no borrowings under the revolving line of credit were outstanding as of June 30, 2012. Under the terms of the Loan Agreement, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable. As of June 30, 2012, approximately $0.1 million was available under the Loan Agreement to borrow against the revolving line of credit as we worked to finalize customary post-closing arrangements to implement GE Capital’s security interest in our receivables. These security interest arrangements were implemented in July 2012.    The fixed interest rate on the term loan is 10.14% per annum. The revolving line of credit has an adjustable interest rate based upon 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%, plus 5%. As of June 30, 2012, this interest rate was 6.5%.  Both the term loan and the revolving line of credit mature in September 2015.  Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term. Principal payments on the term loan are scheduled as follows:       <table style="WIDTH: 43%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2">Principal</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="3">Year</td> <td> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Payments</td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc; VERTICAL-ALIGN: bottom"> <td style="WIDTH: 2%"> </td> <td style="TEXT-ALIGN: center; WIDTH: 15%">2012</td> <td style="WIDTH: 2%"> </td> <td style="WIDTH: 2%"> </td> <td style="WIDTH: 5%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">-</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td style="TEXT-ALIGN: center">2013</td> <td> </td> <td> </td> <td>$</td> <td style="TEXT-ALIGN: right">909,096</td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc; VERTICAL-ALIGN: bottom"> <td> </td> <td style="TEXT-ALIGN: center">2014</td> <td> </td> <td> </td> <td>$</td> <td style="TEXT-ALIGN: right">909,096</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid"> </td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: center">2015</td> <td style="BORDER-BOTTOM: windowtext 1pt solid"> </td> <td style="BORDER-BOTTOM: windowtext 1pt solid"> </td> <td style="BORDER-BOTTOM: windowtext 1pt solid">$</td> <td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: right"> 681,808</td> </tr> <tr style="BACKGROUND-COLOR: #ccffcc; VERTICAL-ALIGN: bottom"> <td> </td> <td style="TEXT-ALIGN: right"> </td> <td> </td> <td> </td> <td style="BORDER-BOTTOM: black 2.25pt double">$</td> <td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right"> 2,500,000</td> </tr> </table>   If we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, we are obligated to pay a prepayment premium equal to 3% of the then outstanding principal amount of the term loan during the first two years of the loan and 2% during the third year and thereafter.  In addition we are obligated to pay a final payment fee of 3% of the term loan balance. The final payment fee will be accrued and expensed over the term of the agreement, utilizing the effective interest method.   Our obligations under the Loan Agreement are collateralized by a security interest in substantially all of our assets including cash, receivables and property and equipment. While the security interest does not, except in limited circumstances, cover our intellectual property, it does cover any proceeds to us from the use or sale of intellectual property.   The Loan Agreement contains customary representations, warranties and covenants, including limitations on acquisitions, dispositions, incurrence of indebtedness and the granting of security interests. The representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of a specific date or specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Loan Agreement.   The Loan Agreement contains certain financial and non-financial covenants. Upon the occurrence and during the continuance of any event of default, GE Capital may, and at the written request of the requisite lenders shall, terminate the commitments under the facilities and declare any or all of the obligations to be immediately due and payable, without demand or notice to us; however, any event of default relating to timely payment of debts, insolvency, liquidation, bankruptcy or similar events will result in automatic acceleration. Among the remedies available to GE Capital in case of an event of default are the taking possession and disposition of any collateral under the Loan Agreement.   In connection with the Loan Agreement, we issued GE Capital warrants to purchase 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share, subject to customary anti-dilution adjustments. The warrants are classified as equity. The fair value of the warrants at March 30, 2012 of $69,876 was recorded as a discount to the carrying value of the debt and is being amortized through interest expense over the term of the loan.   Also, in connection with us entering into the Loan Agreement, we incurred approximately $216,000 of related expenses. These expenses are deferred and are being amortized to interest expense over the term of the Loan Agreement.   In June 2011, PharmAthene entered into an agreement with certain accredited investors who purchased an aggregate of 1,857,143 shares of common stock for a purchase price of $3.50 per share and warrants to purchase up to an additional 371,423 shares of common stock. The warrants became exercisable immediately at an exercise price of $3.50 per share until the fifth anniversary of the date of issuance, which is June 15, 2016. The Company received gross proceeds of approximately $6.5 million and net proceeds of approximately $5.8 million. </div> <div style="FONT: 10pt Times New Roman, Times, Serif"> Significant Customers and Accounts Receivable   Our primary customers are the Biomedical Advanced Research and Development Authority (“BARDA”), the U.S. Department of Defense (the “DoD”), and the National Institutes of Health (“NIH”). As of June 30, 2012 and December 31, 2011, the Company’s trade receivable and unbilled receivable balances were comprised solely of receivables from these customers. </div> 38983 1.39

244143

816562

P3M

167853

0.03

0.02

0.03

0.02

0.03

5800000 6500000 0.50 40000000 2400000 P10Y 200000 0.010 200000 0.010 1.27 4.23 P10Y

-3081320

-32722

6428840

-2423842

688221

-0.05

116690

3381

3409372

13771

-2437613

5984098

9510160

544700

46631396

-2437613

643707

208000

100000

15173

0 0.12

216997

327703

-1458204

519

6316998

-776445

823809

-0.02

76448

4819

2780099

-19902

-740410

4918655

7775202

512041

48325945

11600000

-756543

717794

185000

16133

400000

111353

0 0.12

127076

384965

P2Y1M6D

0001326190 us-gaap:MaximumMember 2012-03-31 2012-06-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2012-03-31 2012-06-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2012-03-31 2012-06-30 0001326190 2012-03-31 2012-06-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2011-04-01 2011-06-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2011-04-01 2011-06-30 0001326190 2011-04-01 2011-06-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-01-01 2008-12-31 0001326190 pip:PharmAtheneMember 2010-01-01 2010-12-31 0001326190 pip:PharmAtheneMember 2011-01-01 2011-12-30 0001326190 pip:GroupFourMember 2012-06-01 2012-06-30 0001326190 pip:GroupThreeMember 2012-06-01 2012-06-30 0001326190 us-gaap:MaximumMemberpip:PharmAtheneMember 2011-09-01 2011-09-30 0001326190 pip:PharmAtheneMember 2011-09-01 2011-09-30 0001326190 pip:PharmAtheneMember 2011-06-01 2011-06-30 0001326190 pip:YearTwoMember 2012-01-01 2012-06-30 0001326190 pip:YearThreeMember 2012-01-01 2012-06-30 0001326190 pip:YearOneMember 2012-01-01 2012-06-30 0001326190 pip:ThereAfterMember 2012-01-01 2012-06-30 0001326190 pip:TermLoanMember 2012-01-01 2012-06-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2012-01-01 2012-06-30 0001326190 pip:LiquidityArrangementsMemberus-gaap:MaximumMember 2012-01-01 2012-06-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-06-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-06-30 0001326190 pip:PharmAtheneMember 2012-01-01 2012-06-30 0001326190 2012-01-01 2012-06-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2011-01-01 2011-06-30 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-06-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2011-01-01 2011-06-30 0001326190 pip:PharmAtheneMember 2011-01-01 2011-06-30 0001326190 2011-01-01 2011-06-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2011-12-31 0001326190 2011-12-31 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2010-12-31 0001326190 2010-12-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-12-31 0001326190 pip:PercentageOverLiborMember 2012-06-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2012-06-30 0001326190 pip:GroupTwoMember 2012-06-30 0001326190 pip:GroupOneMember 2012-06-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2012-06-30 0001326190 pip:SeniorSecuredCreditFacilityTermLoansMemberpip:RevolvingLineOfCreditMember 2012-06-30 0001326190 pip:SeniorSecuredCreditFacilityTermLoansMember 2012-06-30 0001326190 pip:DerivativeLiabilitiesMember 2012-06-30 0001326190 2012-06-30 0001326190 pip:CreditFacilitiesMemberpip:TermLoanMember 2012-03-30 0001326190 pip:SeniorSecuredCreditFacilityTermLoansMemberpip:RevolvingLineOfCreditMember 2012-03-30 0001326190 2012-03-30 0001326190 us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMember 2011-06-30 0001326190 pip:PharmAtheneMember 2011-06-30 0001326190 pip:DerivativeLiabilitiesMember 2011-06-30 0001326190 2011-06-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2007-08-03 0001326190 2012-08-01 0001326190 pip:ContractMember 2012-07-31 iso4217:USD shares iso4217:USD pip:Right iso4217:USD shares pure pip:Segment

EX-101.SCH 7 pip-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements Of Other Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Organization and Business link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Financing Transactions link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Financing Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Share-based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Financing Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Fully Amortized Term Loan (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 pip-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pip-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pip-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). In addition, includes the amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Accrued Expenses And Other Current Liabilities Accrued expenses and other liabilities Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax Accumulated other comprehensive income Additional Paid In Capital Common Stock Additional paid-in-capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allocated Share Based Compensation Expense Total share-based compensation expense Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Anti-dilutive securities excluded from computation of earnings per share Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Basis Of Presentation And Significant Accounting Policies [Text Block] Basis of Presentation Billed Contract Receivables Accounts receivable (billed) Breach of contractual commitment award period - number of years following initial commercial sale of ST-246. Breach Of Contractual Commitment Award Period SIGA breach of contractual obligation award period following initial commercial sale Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Cash And Cash Equivalents At Carrying Value Cash and cash equivalents, at end of period Cash and cash equivalents, at beginning of period Cash and cash equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash And Cash Equivalents Period Increase Decrease Increases in cash and cash equivalents Cash And Cash Equivalents Policy [Text Block] Cash and Cash Equivalents Cash Equivalents, Maturity Period Cash Equivalents Maturity Period Cash liquidity maturity period Class Of Warrant Or Right [Axis] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Warrant exercise price Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Warrants issued to purchase shares of common stock Class Of Warrant Or Right Outstanding Warrant to purchase common stock Closing Stock Price Closing Stock Price Closing stock price, per share Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies [Line Items] Common Stock Capital Shares Reserved For Future Issuance Common stock reserved Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Price Issued Per Share Common Stock Price Issued Per Share Common Stock issued price Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common Stock Share issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively Comprehensive Income Net Of Tax Comprehensive loss Contract [Member] Contract [Member] U.S. Department of Defense Contract option exercised. Contract Option Exercised Value of Option exercised Contracts Revenue Revenue Cost Of Reimbursable Expense Cost reimbursed to offset research and development expenses Court awarded fees. Court Awarded Fees Awarded 1/3 reasonable attorney's fees and expert witness fees Credit Facilities [Member] Credit Facilities [Member] Credit Facilities Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Current Fiscal Year End Date Current Fiscal Year End Date The entire disclosure of costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet. In addition, entire disclosure of gross and net proceeds from the issuance of common stock and the facts surrounding the issuance. Debt And Equity Transaction Disclosure [Text Block] Financing Transactions Debt Instrument Basis Spread On Variable Rate Fixed portion of the variable rate Debt Instrument Carrying Amount Fair value attributable to the warrant Debt Instrument Interest Rate During Period Interest rate on revolving line of credit Debt Instrument Payment Terms Term loan , payment terms Debt Instrument Period [Axis] Debt Instrument Period [Axis] Debt Instrument Period [Axis] Debt Instrument Period [Domain] Debt Instrument Period [Domain] Debt Instrument Period [Domain] Debt Instruments Maturity Date Month and Year Debt Instruments Maturity Date Month And Year Term loan and line of credit, maturity date Debt Policy [Text Block] Revolving Line of Credit & Term Loan Deferred Finance Costs Gross Debt financing costs Deferred Income Tax Expense Benefit Deferred income taxes Deferred Revenue Deferred revenue Depreciation And Amortization Depreciation and amortization Depreciation and amortization expense Derivative Financial Instruments Liabilities Fair Value Disclosure Ending Balance Beginning Balance Derivative Liabilities [Member] Derivative Liabilities [Member] Derivative Liabilities Derivative Liabilities Noncurrent Derivative instruments Disclosure - Commitments and Contingencies - Additional Information [Abstract] Disclosure Commitments And Contingencies Additional Information [Abstract] Disclosure - Commitments and Contingencies - Additional Information [Abstract] Disclosure - Fair Value Measurements - Additional Information [Abstract] Disclosure Fair Value Measurements Additional Information [Abstract] Disclosure - Fair Value Measurements - Additional Information [Abstract] Disclosure - Financing Transactions - Additional Information [Abstract] Disclosure Financing Transactions Additional Information [Abstract] Disclosure - Financing Transactions - Additional Information [Abstract] Disclosure - Fully Amortized Term Loan [Abstract] Disclosure Fully Amortized Term Loan [Abstract] Disclosure - Fully Amortized Term Loan [Abstract] Disclosure of Significant Customers. Disclosure Of Significant Customers Policy [Text Block] Significant Customers and Accounts Receivable Disclosure - Share-based Compensation Expense [Abstract] Disclosure Sharebased Compensation Expense [Abstract] Disclosure - Share-based Compensation Expense [Abstract] Disclosure - Stockholders' Equity - Additional Information [Abstract] Disclosure Stockholders Equity Additional Information [Abstract] Disclosure - Stockholders' Equity - Additional Information [Abstract] Disclosure - Subsequent Events - Additional Information [Abstract] Disclosure Subsequent Events Additional Information [Abstract] Disclosure - Subsequent Events - Additional Information [Abstract] Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities [Abstract] Disclosure Summary Of Changes In Fair Value Of Our Level 3 Liabilities [Abstract] Disclosure - Summary of Changes in Fair Value of Our Level 3 Liabilities [Abstract] Disclosure - Summary of Significant Accounting Policies - Additional Information [Abstract] Disclosure Summary Of Significant Accounting Policies Additional Information [Abstract] Disclosure - Summary of Significant Accounting Policies - Additional Information [Abstract] Document - Document and Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share Basic And Diluted Basic and diluted net loss per share Earnings Per Share Policy [Text Block] Basic and Diluted Net Loss Per Share Effect Of Exchange Rate On Cash And Cash Equivalents Effects of exchange rates on cash Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs Report Line [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Unrecognized share-based compensation expense related to unvested awards Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Extinguishment Of Debt [Line Items] Extinguishment of Debt [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value By Liability Class [Axis] Liability Class [Axis] Fair Value Disclosures [Text Block] Fair Value Measurements Rate at which loans or a loan portfolio are expected to pay on final principal balances, used as an input to measure fair value. Fair Value Inputs Final Payment Rate Percentage of final payment premium Fair Value Inputs Level 3 [Member] Fair Value, Inputs, Level 3 Fair Value Inputs Prepayment Rate Percentage of prepayment premium Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Fair Value Measurements [Line Items] Fair Value Measurements [Table] Fair Value Measurements [Table] Fair Value Measurements [Table] Financial Instrument [Axis] Financial Instrument [Axis] Foreign Currency Transactions And Translations Policy [Text Block] Foreign Currency Translation Gain Loss On Derivative Instruments Net Pretax Change in fair value of derivative instruments Change in market value of derivative instruments Change in fair value of derivative instruments Gain Loss On Sale Of Property Plant Equipment Gain on the disposal of property and equipment General And Administrative Expense General and administrative General And Administrative Expense [Member] General and Administrative Expense Goodwill Goodwill Gross proceeds from issuance of common stock and warrants. Gross Proceeds From Issuance Of Common Stock And Warrants Gross proceeds from issuance of stock Group Four [Member] Group Four [Member] Every 30 days until failure is cured Group One [Member] Group One [Member] Expiration 2015 Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure. Group Three [Member] Initial Maximum Maintenance Failure Obligation Group Two [Member] Group Two [Member] Expiration 2017 Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Net loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Expense Benefit Income tax expense Income tax expense Income Tax Policy [Text Block] Income Taxes Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued expenses and other liabilities Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Increase Decrease In Unbilled Receivables Unbilled accounts receivable Initial carrying value of derivative instruments issued during the reporting period. Initial Derivative Fair Value New Liabilities in 2011 Interest Expense Interest expense Interest Paid Cash paid for interest Interest Rate Disclosure By Reference Rate [Axis] Interest Rate Disclosure By Reference Rate [Axis] Interest Rate Disclosure By Reference Rate [Axis] Interest Reference Rate [Domain] Interest Reference Rate [Domain] Interest Reference Rate [Domain] Investment Income Interest Interest income Investment Warrants Exercise Price Common stock at an exercise price Legal Entity [Axis] Legal Entity [Axis] Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Line Of Credit Facility Amount Outstanding Revolving line of credit used Line Of Credit Facility [Axis] Lender Name [Axis] Line of Credit Facility Borrowing Base Percentage of Eligible Billed Accounts Receivable Line Of Credit Facility Borrowing Base Percentage Of Eligible Billed Accounts Receivable Percentage of withdrawal from revolving loan qualified billed Line of Credit Facility Borrowing Base Percentage of Eligible Unbilled Accounts Receivable Line Of Credit Facility Borrowing Base Percentage Of Eligible Unbilled Accounts Receivable Percentage of withdrawal from revolving loan qualified unbilled Line Of Credit Facility Lender [Domain] Line of Credit Facility, Lender [Domain] Line Of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line Of Credit Facility Maximum Borrowing Capacity Line of credit facility, maximum borrowing capacity Line Of Credit Facility Remaining Borrowing Capacity Available loan agreement to borrow Line Of Credit Facility [Table] Line of Credit Facility [Table] Liquidity Arrangements [Member] Liquidity Arrangements [Member] Liquidity Long Term Debt Senior secured debt facility Long Term Debt By Maturity [Abstract] Principal Payments Long Term Debt Current Current portion of long term debt Long Term Debt Maturities Repayments Of Principal In Year Four 2015 Long Term Debt Maturities Repayments Of Principal In Year Three 2014 Long Term Debt Maturities Repayments Of Principal In Year Two 2013 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year 2012 Long Term Debt Noncurrent Long term debt, less current portion Long Term Debt Percentage Bearing Fixed Interest Rate Fixed interest rate on term loan Loss Contingencies By Nature Of Contingency [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Domain] Loss Contingency, Nature [Domain] Maximum [Member] Maximum Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Net Cash Provided By Used In Financing Activities [Abstract] Financing activities Net Cash Provided By Used In Investing Activities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities [Abstract] Investing activities Net Cash Provided By Used In Operating Activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities [Abstract] Operating activities Net Income Loss Net loss Net loss Net profit retention on sale of ST-246 before distribution for breach of contract. Net Profit Retention From Sales Before Distribution For Breach Of Contract SIGA net profits from sales before distribution for breach of contract Non Cash Financing Activity [Abstract] Non Cash Financing Activity [Abstract] Noncash financing activity Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense [Abstract] Other income (expense): Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure. Notes Payable Aggregate Principal Repayment Amount Aggregate principal amount of obligation Number Of Operating Segments Number of operating segment Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating Expenses: Operating Income Loss Loss from operations Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Organization and Business Other Assets Noncurrent Other long term assets and deferred costs Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Foreign currency translation adjustment Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Other comprehensive (loss) income: Other Liabilities Noncurrent Other long term liabilities Other Nonoperating Income Expense Other income (expense) Paid In Kind Interest Non-cash interest expense Payments Of Financing Costs Deferred financing costs Payments To Acquire Property Plant And Equipment Purchases of property and equipment Percentage of aggregate principal amount of convertible notes relating to the affected shares. Percentage Of Aggregate Principal Amount Redemption Percentage of aggregate principal amount of convertible Notes Percentage of net profits awarded on the sales of ST-246 and related products. Percentage Of Net Profit Awarded SIGA breach of contractual obligation awarded, percentage of net profits Percentage Over Libor [Member] Percentage Over Libor [Member] Percentage Over Libor PharmAthene [Member] Pharm Athene [Member] PharmAthene Potential Contract Value Potential Contract Value Potential total contract value Prepaid Expense And Other Assets Current Prepaid expenses and other current assets EX-101.PRE 11 pip-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R25.htm IDEA: XBRL DOCUMENT

Fully Amortized Term Loan (Detail) (USD $)	Jun. 30, 2012
Principal Payments
2012
2013	909,096
2014	909,096
2015	681,808
Senior secured debt facility	$ 2,500,000

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References+ Details

XML 14 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2012

Fair Value Measurements

Note 3 - Fair Value Measurements

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the six months ended June 30, 2012:

Description	Balance as of December 31, 2011		Unrealized Losses		Balance as of June 30, 2012

Derivative liabilities related to warrants	$	1,886,652	$	167,853	$	2,054,505

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2011:

Description	Balance as of December 31, 2010		New Liabilities in 2011		Unrealized (Gains)			Balance as of June 30, 2011

Derivative liabilities related to warrants	$	8,362,995	$	668,640	$	(3,176,686	)	$	5,854,949

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X86(S-V,Q-U]F-&4X7S1B8F5?83AA-E\U-#)E M-3,T,#8R8S0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V%N9%]"=7-I;F5S M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K'!E;G,\+W@Z3F%M93X-"B`@("`\>#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K5]!;6]R=&EZ961?5&5R;5],;V%N7T1E=&$\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X86(S-V,Q-U]F M-&4X7S1B8F5?83AA-E\U-#)E-3,T,#8R8S0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO.&%B,S=C,3=?9C1E.%\T8F)E7V$X839?-30R934S-#`V M,F,T+U=O'0O:'1M;#L@8VAA2!);F9O M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6UB;VP\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M4$A!4DU!5$A%3D4L($E.0SQS<&%N/CPO'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'1087)T7SAA8C,W8S$W7V8T M93A?-&)B95]A.&$V7S4T,F4U,S0P-C)C-`T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B\X86(S-V,Q-U]F-&4X7S1B8F5?83AA-E\U-#)E-3,T,#8R M8S0O5V]R:W-H965T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D.R`T."PS M-#4L.3@T(&%N9"`T."PR,S8L,33PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X86(S-V,Q-U]F-&4X7S1B8F5?83AA-E\U-#)E-3,T,#8R8S0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.&%B,S=C,3=?9C1E.%\T8F)E7V$X M839?-30R934S-#`V,F,T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XW-BPT-#@\'!E;G-E*3H\+W-T M&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-#`L-#$P M*3QS<&%N/CPO"!E M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPQ,S,I M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X86(S-V,Q-U]F-&4X M7S1B8F5?83AA-E\U-#)E-3,T,#8R8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.&%B,S=C,3=?9C1E.%\T8F)E7V$X839?-30R934S-#`V,F,T M+U=O'0O M:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M-C(L,S4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ-C8L-3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG92!R871E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!"=7-I;F5S M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2!T:&%T(&AA$$P.R8C>$$P.U1H97)E(&-A;B!B92!N;R!A2!A<'!R;W9A;"P@;W(@=&AA M="!A;GD-"F%P<')O=F5D('!R;V1U8W0@=VEL;"!B92!C;VUM97)C:6%L;'D@ M=FEA8FQE+B8C>$$P.R8C>$$P.TEN#0IA9&1I=&EO;BP@=V4@;W!E2P@=V4@:&%V92!P97)F;W)M960@=6YD97(@9V]V M97)N;65N="!C;VYT'1087)T7SAA8C,W8S$W7V8T93A?-&)B95]A.&$V7S4T,F4U,S0P-C)C-`T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X86(S-V,Q-U]F-&4X7S1B M8F5?83AA-E\U-#)E-3,T,#8R8S0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,4,[=V4F M(W@R,#%$.RP-"B8C>#(P,4,[=7,F(W@R,#%$.RP@)B-X,C`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`T*,C`Q,BX@07,@<&%R="!O9B!T M:&%T(&%GF5D(&]V97(@=&AE('1E M6QE M/3-$)U1%6%0M24Y$14Y4.B`Y<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M2!C=7-T;VUE#(P,40[*2X@07,@;V8@2G5N92`S,"P@ M,C`Q,B!A;F0@1&5C96UB97(@,S$L#0HR,#$Q+"!T:&4@0V]M<&%N>28C>#(P M,3D[$$P.R8C>$$P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE$$P.R8C>$$P.U1H92!E$$P.R8C>$$P.VEF('1H M92!C;VYT6UE;G1S M+`T*:6YC;'5D:6YG(&UI;&5S=&]N92!P87EM96YTF5D(&%S(')E=F5N=64@=VAE;CH-"BAI*28C>$$P M.W1H92!M:6QE$$P.VYO(&9U M6UE;G0@=&5R;7,@*&EN8VQU9&EN9R!O=&AE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M$$P.R8C>$$P.U1H92!P97)C96YT M86=E+6]F+6-O;7!L971I;VX@;65T:&]D#0IR96-O9VYI>F5S(&EN8V]M92!A M2!A2!B M92!A(&YE8V5S2!T;R!R979I2`D,3D@=&AO M=7-A;F0@86YD#0HD,"XU(&UI;&QI;VX@87,@9&5F97)R960@$$P.SPO<#X-"CQP M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UEF5D(&EN(&%C8V]R M9&%N8V4@=VET:"!T:&4@=&5R;7,@;V8@=&AE#0IC;VYT7!I8V%L;'D@;6]N=&AL>2!I;G9O:6-I;F<@=VET:"`S,"TV,"!D M87D-"G!A>6UE;G0@8WEC;&5S+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE7IE(&5A8V@@8V]S="!R96EM8G5R$$P.R8C>$$P.T9O`T*;6]N=&AS M(&5N9&5D($IU;F4@,S`L(#(P,3(@86YD(#(P,3$L('=E(')E8V]R9&5D(&%P M<')O>&EM871E;'D@)#$N,`T*;6EL;&EO;B!A;F0@)#`N-"!M:6QL:6]N+"!R M97-P96-T:79E;'DL(&]F(&-O'!E;G-E('1H92!E$$P.R8C>$$P.U1H92!F86ER('9A;'5E(&]F('-T M;V-K(&]P=&EO;B!G$$P.R8C>$$P M.U1H92!";&%C:RU38VAO;&5S(&UO9&5L(&-O;G-I9&5R'!E8W1E9"!L:69E(&]F('1H92!A=V%R9"!A M;F0@=&AE(&5X<&5C=&5D('9O;&%T:6QI='D-"F]F('1H92!#;VUP86YY)B-X M,C`Q.3MS('-T;V-K('!R:6-E+B8C>$$P.R8C>$$P.U1H92!V86QU92!O9B!T M:&4-"F%W87)D('1H870@:7,@=6QT:6UA=&5L>2!E>'!E8W1E9"!T;R!V97-T M(&ES(')E8V]G;FEZ960@87,-"F-O;7!E;G-A=&EO;B!E>'!E;G-E(&]N(&$@ M6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!E>'!E8W1E9"!T;R!V97-T(&%N9"!H M87,@8F5E;B!R961U8V5D(&9O'!E;G-E(&9O6QE/3-$ M)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`Q<'0@$$P.SPO=&0^#0H\+W1R M/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)U=)1%1(.B`R M)3L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$ M5$@Z(#$R)3L@1D].5"U325I%.B`Q,'!T)SX-"C(Q-BPY.3<\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U3 M25I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$ M)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T M=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-) M6D4Z(#$P<'0G/D=E;F5R86P@86YD#0IA9&UI;FES=')A=&EV93PO=&0^#0H\ M=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^ M#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\+W1D M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O M=6)L93L@5$585"U!3$E'3CH@$$P.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U325I%.B`Q,'!T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@ M$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!#3TQ/4CH@8FQA8VLG M/G=E(&AA9"!T;W1A;"!U;G)E8V]G;FEZ960-"G-H87)E+6)A'!E;G-E(')E;&%T960@=&\@=6YV97-T960@87=AF4@ M87,@97AP96YS92!O=F5R(&$@=V5I9VAT960M879E6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E M.R!#3TQ/4CH@8FQA8VLG/B8C>$$P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE'!E M;G-E(&9O$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@,3`P)3L@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE$$P.SPO=&0^ M#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X] M,T0R/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C M>$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0R/@T*)B-X03`[ M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO M=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<@8V]L$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T], M3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`V."4[ M($9/3E0M4TE:13H@,3!P="<^4F5S96%R8V@-"F%N9"!D979E;&]P;65N=#PO M=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3(E.R!&3TY4+5-)6D4Z M(#$P<'0G/@T*,C0T+#$T,SPO=&0^#0H\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`Q<'0@$$P M.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX-"B8C M>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@ M6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4TE:13H@,3!P="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/@T*,2PP-C`L-S`U/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G M/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q M,'!T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE65E"!B96YE9FET2!D:69F97)E;F-E65A"!A;6]U;G1S+B!!('9A;'5A=&EO;B!A;&QO=V%N8V4@:7,-"F5S M=&%B;&ES:&5D('=H96X@;F5C97-S87)Y('1O(')E9'5C92!D969E'!E8W1E9"!T;R!B92!R96%L M:7IE9"X@5V4@86QS;R!R96-O9VYI>F4@82!T87@@8F5N969I=`T*9G)O;2!U M;F-E#(P,4,[ M;6]R92!L:6ME;'D@=&AA;@T*;F]T)B-X,C`Q1#L@=&AA="!T:&4@<&]S:71I M;VX@:7,@"!E>'!E;G-E('=A M2X@3F\@:6YC;VUE#0IT87@@97AP96YS92!W M87,@"!E>'!E;G-E(&EN(#(P M,3(-"G)E"!P=7)P;W-E M2P@=VAI8V@@8V%N;F]T(&]F9G-E="!D M969E0T* M:7,@:6YC;'5D960@:6X@;W5R(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@8F%L M86YC92!S:&5E="!I;B!O=&AE<@T*;F]N8W5R&-L=61I;F<@=6YV M97-T960@2!T:&4@=V5I9VAT960@879E2!S=&]C:R!M971H;V0N M)B-X03`[)B-X03`[/"]P/@T*/'`@$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE&EM M871E;'D@,3$N-B!M:6QL:6]N(&%N9`T*87!P2`Q,"XY(&UI M;&QI;VX@<&]T96YT:6%L(&1I;'5T:79E('-H87)E2P-"F)E8V%U M$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&ET('!R:6-E*2!I;B!T:&4-"G!R M:6YC:7!A;"!OF5S('1H92!I;G!U=',@=7-E9"!T;R!M96%S=7)E(&9A:7(-"G9A M;'5E+B8C>$$P.R8C>$$P.U1H:7,@:&EE&EM:7IEF5S('1H92!U M6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO=&0^#0H\=&0@#(P,C([/"]T9#X-"CQT9#Y,979E;"`Q("8C M>#(P,30[(%%U;W1E9"!P6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE$$P.SPO=&0^#0H\=&0@#(P,C([/"]T9#X-"CQT9#Y,979E;"`R("8C>#(P,30[($]B6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO=&0^#0H\=&0@#(P,C([/"]T9#X-"CQT9#Y,979E;"`S("8C M>#(P,30[(%5N;V)S97)V86)L92!I;G!U=',@=&AA="!A$$P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE28C>#(P,3D[2!I2!I;G!U="!T:&%T(&ES#0IS:6=N:69I8V%N="!T;R!T M:&4@9F%I6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!B87-E9"!O;B!T M:&4@:6YP=71S('5S960@=&\@9&5T97)M:6YE('1H92!F86ER('9A;'5E(&%T M#0IT:&4@;65A$$P.R8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D]. M5"U325I%.B`Q,'!T)SX-"D1E$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G M(&-O;'-P86X],T0R/E5N6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@$$P.V%S)B-X03`[;V8\8G(@+SX-"DIU;F4@,S`L)B-X03`[/&)R M("\^#0HR,#$R/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`T-B4[($9/3E0M M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@ M,B4[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P M="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!724142#H@,30E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[ M($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)U=)1%1(.B`R)3L@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U3 M25I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=) M1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO=&0^#0H\=&0@ M$$P.SPO M=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)#PO=&0^#0H\ M=&0@$$P.SPO=&0^#0H\+W1R/@T*/"]T M86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE"!M;VYT:',-"F5N9&5D($IU;F4@,S`L(#(P,3$Z)B-X03`[/"]P/@T*/'`@ M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)T-/3$]2.B!B;&%C:R<^,C`Q,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@$$P.RA'86EN6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@ M$$P.V%S)B-X03`[;V8\8G(@+SX-"DIU;F4@,S`L)B-X03`[ M/&)R("\^#0HR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T* M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T M>6QE/3-$)U=)1%1(.B`R."4[($9/3E0M4TE:13H@,3!P="<^)B-X03`[/"]T M9#X-"CQT9"!S='EL93TS1"=724142#H@,B4[($9/3E0M4TE:13H@,3!P="<^ M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!7 M24142#H@,24[($9/3E0M4TE:13H@,3!P="<^#0HF(WA!,#L\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,30E.R!&3TY4 M+5-)6D4Z(#$P<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^#0HF M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`R)3L@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO M=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\=&0@$$P.SPO=&0^#0H\ M=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C@L,S8R+#DY M-3PO=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C8V."PV-#`\ M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/C4L.#4T+#DT.3PO=&0^ M#0H\=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E)SXF(WA!,#L\ M+V9O;G0^/"]P/@T*/'`@$$P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE'!E8W1E9"!T97)M+`T*86YT:6-I<&%T960@=F]L871I;&ET M>2!A;F0@97AP96-T960@9&EV:61E;F1S+B8C>$$P.R8C>$$P.T-H86YG97,- M"FEN(&%N>2!O9B!T:&4@87-S=6UP=&EO;G,@#(P,3D[(&9A:7(-"G9A M;'5E.R!I;F-R96%S97,@:6X@97AP96-T960@=&5R;2P@86YT:6-I<&%T960@ M=F]L871I;&ET>2!A;F0-"F5X<&5C=&5D(&1I=FED96YD2!R M97-U;'0@:6X-"F1E8W)E87-E"UM M;VYT:"!P97)I;V0@96YD960@2G5N90T*,S`L(#(P,3(@:7,@9'5E('!R:6UA M2!T;R!T:&4@8VAA;F=E(&EN('1H92!C;&]S:6YG('!R:6-E(&]F(&]U M<@T*"UM;VYT:"!P97)I;V0-"F5N9&5D($IU;F4@,S`L(#(P,3$@:7,@ M9'5E('!R:6UA2!T;R!T:&4@8VAA;F=E(&EN('1H92!C;&]S:6YG#0IP M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,4,[4TE'028C>#(P,40[*2!I;B!T M:&4@1&5L87=A$$P.R8C>$$P.U1H M92!C;VUP;&%I;G0@86QL96=E9"P@86UO;F<@;W1H97(@=&AI;F=S+`T*=&AA M="!W92!H879E('1H92!R:6=H="!T;R!L:6-E;G-E(&5X8VQU#(P M,3D[$$P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!E$$P.S4P)2!O M9B!A;&P@;F5T('!R;V9I=',-"G)E;&%T960@=&\@=&AE('-A;&4@;V8@4U0M M,C0V/&D^/'-U<#XF(WA!13L\+W-U<#X\+VD^86YD(')E;&%T960-"G!R;V1U M8W1S(&9O$%%.SPO2=S(&9E97,-"F%N9"!E>'!E&EM871E;'D@)#(N M-`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`Q,"P@86QT:&]U9V@@=&AE M(')E;&%T960-"G=A#(P,4,[<&EG9WDM8F%C:R8C>#(P,40[ M(&)A$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE'1I;F=U:7-H960@:6X@,C`Q,"P@:68@ M869T97(@=&AE(#)N9"!C;VYS96-U=&EV92!B=7-I;F5S2!T;PT*96%C M:"!S96QL:6YG('-T;V-K:&]L9&5R(&$@;VYE+71I;64@<&%Y;65N="!O9B`Q M+C`E(&]F('1H90T*86=G2!O9B!A($UA:6YT96YA;F-E($9A M:6QU2!P87EM96YT2!O9B!A#0I-86EN=&5N86YC92!&86EL M=7)E+"!I;B!E86-H(&-A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,3D[($5Q=6ET M>3PO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C>#(P,3D[#(P,4,[ M,C`P-R!0;&%N)B-X,C`Q1#LI('=H:6-H('!R;W9I9&5S(&9O#(P,40[*28C>$$P.R8C>$$P.W1O($-O;7!A;GD@;V9F:6-E$$P M.R8C>$$P.R8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE$$P.R8C>$$P.TEN(#(P,#@L('1H92!#;VUP M86YY)B-X,C`Q.3MS('-H87)E:&]L9&5RF5D(&9O65A2`X+C(-"FUI;&QI;VX@2`Q+C8@;6EL;&EO;B!S:&%R97,@87)E(&%V M86EL86)L92!T;R!B92!I$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE2`R,#`Y('!R:79A=&4@<&QA8V5M M96YT+"!W92!I'!I$$P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE28C>#(P,3D[7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A#(P,4,[3&]A;B!!9W)E96UE;G0F(W@R,#%$.RD@=VET M:"!'96YE2!B96-O M;64@<&%R='D@=&\@=&AE(&%G$$P.R!/;B!-87)C:"`S,"P@,C`Q,BP@=&AE('1E2!D2`D,"XQ(&UI;&QI;VX@=V%S M(&%V86EL86)L92!U;F1E0T*,C`Q,BXF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M&5D(&EN=&5R97-T(')A=&4@;VX@=&AE('1E$$P.R!";W1H('1H92!T97)M(&QO86X@86YD('1H92!R979O;'9I;F<@ M;&EN92!O9B!C2!B92!E>'1E M;F1E9"!T;R`Q,@T*;6]N=&AS(&EF(&-E2!A;6]R=&EZ92!O=F5R M(&ET$$P.SPO<#X- M"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M$$P.R8C>$$P.SPO<#X-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`T M,R4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE$$P.SPO=&0^ M#0H\=&0@$$P.SPO=&0^#0H\=&0@6QE/3-$)U=)1%1(.B`U)2<^)B-X03`[/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$U)2<^+3PO M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H M:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9#XF(WA!,#L\+W1D M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXY,#DL,#DV/"]T M9#X-"CPO='(^#0H\='(@$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9#XD/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^.3`Y+#`Y-CPO M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H M:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@$$P.SPO=&0^#0H\ M=&0@$$P M.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H="<^#0HV.#$L.#`X/"]T9#X-"CPO='(^#0H\='(@ M$$P.SPO=&0^#0H\=&0@6UE;G0@<')E;6EU;2!E<75A;"!T;R`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`D,C$V+#`P,"!O9B!R96QA=&5D(&5X<&5N M'!E;G-EF5D('1O(&EN=&5R97-T(&5X<&5N6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE&EM871E;'D@ M)#8N-2!M:6QL:6]N(&%N9"!N970@<')O8V5E9',@;V8-"F%P<')O>&EM871E M;'D@)#4N."!M:6QL:6]N+CPO<#X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.T]N($IU;'D@,S$L(#(P,3(L('1H92!$;T0@97AE7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE2UO=VYE9"!S=6)S:61I87)I97,@4&AA#(P,40[+"`F(W@R,#%#.W=E)B-X,C`Q1#LL#0HF(W@R,#%#.W5S)B-X M,C`Q1#LL("8C>#(P,4,[;W5R)B-X,C`Q1#L@;W(@=&AE#0HF(W@R,#%#.T-O M;7!A;GDN)B-X,C`Q1#LF(WA!,#LF(WA!,#M!;&P@$$P.R8C>$$P.T]U M2!A8V-E<'1E9`T*86-C;W5N=&EN9R!P2!O8V-U$$P M.R8C>$$P.R!#97)T86EN(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T90T*9&ES M8VQO2!I;F-L=61E9"!I;B!T:&4@9FEN86YC:6%L('-T M871E;65N=',@<')E<&%R960-"FEN(&%C8V]R9&%N8V4@=VET:"!5+E,N($=! M05`@:&%V92!B965N(&-O;F1E;G-E9"!O&-H86YG92!#;VUM M:7-S:6]N+B8C>$$P.U=E(&)E;&EE=F4@=&AA="!T:&4-"F1I&-H86YG92!#;VUM:7-S:6]N+B!792!C=7)R M96YT;'D@;W!E65A#(P,3D[6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E$$P.R8C>$$P.T%C='5A;"!R97-U M;'1S(&-O=6QD(&1I9F9E<@T*9G)O;2!T:&]S92!E6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE XML 16 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2012

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Foreign Currency Translation

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost which approximates market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit & Term Loan

Significant Customers and Accounts Receivable

Revenue Recognition

Share-Based Compensation

Share-based compensation expense for the three months ended June 30, 2012 and 2011 was:

	2012		2011

Research and development	$	127,076	$	216,997
General and administrative		384,965		327,703
Total share-based compensation expense	$	512,041	$	544,700

Share-based compensation expense for the six months ended June 30, 2012 and 2011 was:

	2012		2011

Research and development	$	244,143	$	458,431
General and administrative		816,562		796,894
Total share-based compensation expense	$	1,060,705	$	1,255,325

Income Taxes

Basic and Diluted Net Loss Per Share

Basic loss per share is computed by dividing consolidated net loss by the weighted average number of shares of common stock outstanding during the quarter, excluding unvested restricted stock.

Recent Accounting Pronouncements

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

ZIP 17 0001144204-12-043389-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-043389-xbrl.zip M4$L#!!0````(`,^$!T'X-Q<=%G@``+MS`P`0`!P`<&EP+3(P,3(P-C,P+GAM M;%54"0`#QGPA4,9$5!U>`L``00E#@``!#D!``#<75MSHTB6?I^(^0]:/TSL M1G3:>25)3U=-`(*>BNTJ>USNN>R+`TMIFQD$7D`N>W[]G@1=$$(VDH5*M3W1 M4UT2H/.=//<$_GY3\^3>/"DLSQ*DP\GY!2?#'0R2L=1_7K@)Z2P>"A*![/S\Z^??MV MJL?W88;2\H&GHW1R-D!H_F-_K>@\'PRL4R)/K=I75^DT&9\/ZA]YF0X+N'PP M!D+.!Q03BK"-L+PF\IS;YU3]3_WJ]/$EB^X?BL%_COX++L8"P1UD!>!/`&=T M.G#B>'!E+LT'5SK7V9,>G\Z>]'R;Q0-@:9)_.*F!,A^?IMG]&3R7G44SGIQ4 M5YZ;;^-7KH>?_I=AVN)Z\\'*]=]8>3512IV5W\XOC?*44R)?(Z:Z8O'L/&I[ M,EQ*SO[^^=>OHP<]"5$3P0BX7V0OBSO+G\CUZ/0^?3J;?7E6+0!!C,QO&^NH M_1;XHN7R*'G2>=%^1_5=RTU)FB3323L#QD5V5KP\ZC.X",%5.HM&B_O>OFGU MAL?H<>6&QX,&GV=+:IU57ZY<6K1>*JI+BQ.0\L&@E//X/"^EX4K?#4JA.SES/MY!^+OKU5F%"G[S M_#(MP$I%8>RE(+7AJ/AK&$_U8`1_T\_%E2%-I_'-I6])1KA`B%""T5]`/\C- MU^OA#;XIJ88OX3\%MBR+/0M+4:9.!M,DJIXP4[J;W[X.3P9C/8HF80RKBL3) M(!K#U^,;(ABGXL9R;=\AW$=,60)Q7Q+D>K:'"`M\C+$CL6`W!'[\AIQ\%!*; M?WX^VXQCB7/^\<6CL9'^L\Y&D;'+1P\4GWRDH@9T`Y`**1B2!1WT+*83;B M"KO(M1R%'-M7TE:^@JMNZ$V)39Q\Y#:SA++YSV?=0%2`9\;CO':E%SY&11A7 M-\P=5I!FP;289OI3GD]+![T5#[`$'C"S\(():3T+(B01VW($5%L-+<=%CNL& MP!'E()L2"UF>X]EVX`IN^^;'RD5G\T7?&6*#0V'^X"1C\X?_O]/H*8Q!7W*G M\,(L>P%^[J+WQ%BK%%5U(BR@(+\2$%V5"!BWS/MVPZE,2EGI$(6IH!&TR^(C4FO(%HHXI4 M@F/D9&L+N(2MA)1@`4%OV;:PR9!+0;PA&#[?1]RA$CG44VBH.+-AL3;.HB'3NA7&LQ^[+[+I\=F%^W%RA8!Z` M)Y2](0O=\79@WMS57$(0J!=?]L6QFB&Y>=393?DC=0;2W=G'@'VG`K_!O#?P MUD.+A3R6UU;B>*FS4CI[YLNZ9+V#,63.F+=AK0K,$#*#)\@^GW00)>![(`XS MF7!6IL#YKU%X&\6E_`5AE)6V>1CEHSC-ISLS2&!PQ.I98*F$?2,(!GTP?V,6 MW\$?8=\7GN=Z$*Q8+O@CUT;.$')B-22,"Y=R2;P;9GC$(?"TP=ISM92?]\#_ MGF:+8M;PWYT,E0TK0(B@R&$9D>1T40CHS^O#@34UIY3R+#9J8#PG32S\*V ML*D+;9_+2>$.ARZFR*("6$&I0*X[I(B[MCOT`Z4LXB[\MFI$]9UPOLV:S^%S M-)E.W#3+TF]P!V0(\$WQ\ETX9.W.(9/6XPXLVH2WP:DTN;_6V62H;XMW\OQ,G6#/O;\.SBO0RTX]A-`:-TDFN(3.Z*!YTYN2Y+G)OFF7@ MA[9FP*ZYG<_PD!+'@@`#$\1M&Y(:`4$'LRWE\D`HR2`HN8&*UZ\+,9P"I49PP:#-8^C"]AE3\ELS)& M+=`\MG6DMG%>R@)M)34]?!O(*O":&'])D]%QZJ."V,.H8RVN;:5[LXG]'!:S M\.T*]/BE#'XO[B!*@8CXT83$_]!A=OV0Z>UCD)WK3)Y/N(<54J[C(!X0AAQL MV<\ M.D^B^,,):*O>G5=TL84PAUD*_4,:`_6Y**]=6!BP<4'TK$'["PTI4W&U2VC=Q/P("6$=+%];(ZHLZ@N"*!G" M&GF4(Y=P!]'`8S;U+.$);Y%ZX5.3%;?+\]M@&@O\D&;%QIO_"O\?WL:Z5V:P MW9E!##,@DJLM_-9X5OGA3Q[C]$7KKSI[@BRLK(FX9JBQJ8T8\@@7R*`'% M4<$0*44XHH[DX/$8)\$R;Z'-Q*4W!C1BAM%H.IG&P/\JW9_H!'A`]P?*, MTHG^-+HY1K2RSPN?\(9_W.:%\;6?M'%Q=UU^'QLEHD:SXLQ M4W;-]?:`^XWM`&=:@$[L102[[0]VY(XHN=-,"E\A?Q6G&YE*TGS7%,1,1T]& MM;TTK]*LHK74#$KL=^F"4@JWG-:`_U732*C@XM@[`0$24)%;9= M6].WD33$MTP*CPT=(:;L8F,IK+J\EK2NTO];\UB MOD+^1H/I).,?($NC;2OX%HH]5GW[+S186Q5V0?LT6)YQM;&H3<"<_Y)!Y'

]8RX[-2;.B M`I'24K2^:;=#<])>FG-Z#MZL3L';]^_&V9$-W8O@/6]K;U]W_)8>H:%C^ZBH M?DLW.K1CC9FE"2@%6`36ZL%:X^6YG;S23SKIS]2AM=X$ZH(S8M0'*#Q`W",V MUW5WO&2GLF6FW9ZS;Z,LPN MLJ^%"8_+"W=L]GH5XH;VKK62<%>TO*R!`@&M>#J=E"M+IGK"C=Y@F`ZTM*3I2LR3+3-YF!--F:K3!(LU[VGZ(-)Z:X!,++K"HFZ=7,31; M*%+0N.+E,@;/#.&;"=T>9_738T-K@_Q2`;?4>RW08% M;978^@7'*ZC$5/L5N!V^86>N*9^F8-,?F\,V;&AB.NBA*PM/#S M1)DVGZV0]#J\00\YO$'>,;QA6-;6_[9H?#-;;LOMRXL[/X[NH]M85SL'\U+M M>ZM;JPV!K^S1KL67G1K>JD$?$Y_8HA*3O6)^)ROGQ;8?B9EEL&?C=S!S,^JW MNU&K3A;S\'?WH[9P['`=N_1FL?GX>COJ9L#?;4YBR;I]SDE0E^.`^PQ)FRAC M]C&"6%LB15W,?7!KE`^K_E7V:CSVH\U)S'FIF#3MOY)@:UMW$7B.<+B/D>=Y M/N+2=Q!X#QLI+"SI!M2B0UH;^9542M%3@>D@EF0_U`6NDM/]_Z@JCV`1/ M09K]8GYS5UYT/G^@YL1MC3%R/Z8?<[>]D.Q&][MZ\>R,LRIEX%A:VA=PFL^G4RCOO1<6GJT%E M)T2'/2_$)K0Z*.80YX70:D/R^,\+P157^MJ2K^(`7&[)VX)1^:XM^0/F:G@N M+8>?:9\'S#8#%52]Y&K[GTTD.\M1I[)EF?;;#`M;U.OKAYE-[!W;%K.)>Q_8 MZQU<-;!G"RH4J:G_]QC8ZQVK.ODH&*MWH728UWMW"V#OL,J>*E`]8N,M!K6^ M_YQ(_[)=SHD0+.H-YC_0G,@Z@_;7G4:/9DZD?_V`6(]3#O]N/2<"H5\!F3O( M2B^GP?6-W%HOQF^)J+>QF9YENQR;H4S/]F]QJ:H99MH)5/?#43/]K M:?9+J(V9J*]FOU,SO8,R]6Q,S=FUWW]JIG_YI&TKN-W4S'%%!)WJ/6Q9[P'? M*.4QC&#T'`A8G0*!MA&,=S?.]V^'3)1CE?<N^-S\6C>A@1AUK(`V9T_Q";O>[>`)UP'A,9#V'Z3#70UW]^2EI)/8' M!-IM4[0L1R!+,*P^%T/@T*D&#K95,8)7LM3"LN3>P_5['^Z66N:XC)1AUQY(0.'M#Y#@D M0.[0-MTC4MK*`7S,+*"@M(%O(X(UASW2>IP'63J9-FL.C[@)A8UHVUTY;"^-MH;V^UAE!AS?9$L_5C- M?8&87&:Z.*BD=[55YK4+!%39KH5L7>&\Y9WF-:^=-K0.YJ&HJ:\2P@E3K[FH M%C"-4QEGA=AY#F:ZP480_@VC>%IL4\OI@KSK^S>ZBH'1>'-D9^V,Q=?A-*-7 M,(T0M)6;NLG8F:19$?W[T%K>$2PO>U`867F)QD;Z5X&"[)NZ'EC#IVAL&K=_ MR\W)I8O0[9C->KG(C-G@V&K["-T1=>+$I_+0S2/GA$G*$<.0Z+S)AQ8\3;-G M+C"&L8H)YL>V'I_1$D$L4$9)1QM M3L9,4R57F-;#G-=!O!7=S)HRY\7TUN;,XQ,$8G(;8A&RZ_FM6I-ZFKCRS;=[@Y2ZD&>C=H M#4D'QSHV7T!@LQS;]Y]'\12L9^5[)X_3HI25B[MFU6S;=ZEMP:WUMJ#`E2`8 MCD2N\!CBKN5D?0X99%E'.)2AL%WA2#]@2'*A M$`\<&T'B`@I`.`D4%LR5M))]AOE^AMY;\3;V!.[N]`@R&M"C!_,X,PQ^D;37 M78[/CYB!1B19_:3';0`U-X!SN.]*1Y/;:9:;#+IW[5FWD,RVB(,=!S'B#R'+ MM2AR72M`GA"6:W'F8Y=7^]M\;99K`_GM@<'16@:U,318P6,ZF.3VS)AQMA2LP/].@)9(M_9)"Q'PLKVS-\`8&4? M3(IUE`;1O)VNXE*?H%>$:M%',#_\X>*NUM(*:S0_VN?X),L,>@K;'']K+T2K M,YPE$[PXS<$)5RV\YCBC79'><`6DXF?S$B&(^M^U5=SI2-'R@$,6! M-2R'S!3+0U2%Z5JTI.SP4NS=\D8R/^9$V)R1]V6.!^('P8SVET<;?H#AD,H, MI;V/'[\EF0YC,Q+=UG6RLPGX'L>9\-E1<&BMH>8-D$O#\`D(B\*XU@T[;W?] MX1AA7M8-3.`S[[(9685^K*/SZRPT^?C7E\EMNL71)<2F*^=)-_JX_2#PJ&\! MQ<:R*^PBUW(4NWI?;A4GQ)9QL MM3;[(A74[_+/SM5GY_K/_A?_I\&G+UY%=QN!2_(=\-ICX[F#.-QBSOQUNI6C M?.[X/N+&<*)4W^!E&L,P],R7V: M;3'QN#_V\I./$!;JV*3+>CPHZ:GS=X7`)?7#=%3VR%7OT*YBGP`^V\J.[8'5 M0/Y?:$7O1I(V45V]7^+P-)>']I)6JAT:M"U)GXW7+,5ESSS?AGH3`L#3D0D57Z.MHCXJ-UIKO5CS=&'EO-/= M<6R1$NS\7K)RI.?4`KS=T+QV+&3]M>?#J7DA^O9Y\P8.[.FE[M7;`@#[IG,@ M-T%XZS2L+VE1&VNZ!K!NO-4Y9Z_+,`]<X^.,X>AKDQ4NL/YP$%U^NSP<$/Q:#ZV@"0?D7_6UPE4["Y*?J@Y\& M7P'@W/S'P=;/>S_VGOWYK:1HV_T M?U7I.Z#\[+YE5Q%:W`B2ZSRNXG7CQ&OYV-[7)^>?%$2"%+(DP`"D9.ZG/WV9 M&0Q`D*(NI"F;J4HB2\!@IJ>GIZ^_QJ&N\`/XHH%$ M-Y#HYV=%JALO\9E\K.YK>IXV1/VR]_J5<7L=#:^-.>=89,8X27'T\[,)RD)$ M>$K&1J2&#N*1$2>Q^=\E&(GC"*9"$S02#C#4^)_G9SA3F:5NI(1Z73-`E,/P M,\*)14D'OTJ50TX,%*";+L/OG)_ISU\E\1(S.5X.D^DTQ,2/<+I2.T\+Y%<+ MJ],80_VT2"2E86EC$/&I^%PXFT^351AF%U6OY=B(TU4MWP"B=2#!TK)UVFVA M%E%S`P7.S[1YCB(@YB+AB1KPAPBTBCD8)2*3.5M.%WAS71SBA%7]M)_/MA=` MSF`!I("_U(S;$(E%H+R&6ZM;5@TT&(-U`Z3TD%R9@HH157/$(:7PG9_=1HMK MR5M`OZO0F+#;%Q@1CE9Q/VO(\-,EX9O!QF:PH_)5F(YQ'8P,V.U)1+P`8X6Q M,0M&H1@J@,,4)2FP+PQ5R4IO8_Q6<]NIQT653SW,0AJBM(CU.6.Z#$\ZA!E] MC6;+F1%3*@'0Y_Q,D"K(D0GQM$<2NCFG!,XPD\^H]E'!JN5<%3F7`\1301$%/G$4QC'Y[G9R?I91)PH MKFT!W(G\L3>I2!I?:OQ2TH-42(A:0[#8#S)=YWOFRA!J+;EL95;!;?G'$MB1 MCM^"OK0#0="8WB-92AXBTY`I$SP/=@]IU9O.+5&HZX) M^$WB$J>CB7X0T2BB!,,9Q&_X^D_8[0:5$!Z2SH(V&Q(X(?:X@*=CXQ]!O`Q2 M6%"3#G:]^O1/L\1(-#A,&!=&DARP;8$V2-9&H[GA_H)3OC!^PE8C^81K0JR6 M)OH[I@=+^=,XB`KP[)3L*G8MT`WD]@@,8V,L1E3?PAN.L\<8O8#GC MO[;A1V^P])\4R>1N-]#C\TE<0C)Q+0_S#.^!9/)!-396>>>88'/(]>T4\>=& MW8[M>WJUU*;9EPLE"`8#$TXF,=W<'Y)I-%P]N5^GU6E8_?Z@9S9[;1_VIVF; MG;[3PM*=?JO1[_N6[Q^97T>[V27(B4:G0]SG\O,E`;S/KWY!(Y9J#E&<+5,P MO'CIXS29*4]7:4+TNU$T'H>$;K98S4GTD?0EN!6P@HT@3]+)?@6VRA;F?`I\ M.`[9<4RP+#7Z`VJ9>0X;&VQL`8^CKR"(Y\K;3"]57M#$[#2#+,H6^,HL2*,I MFO["JC:RY94<`Y1P'#Y"IR@8=P8HT&C(@8A/)R'JR(1Z!E^&&9/(YRP"O%9@ MO#&Z3T-0MN-P3,X-S-ZZ#@.TG&!4IN>4OA`4JCA18'.="NB)(W@Y#D?2Q,FI M]XQO]O,S<70R@U`6*C>=S):4C]9?3``D,65KGY^%Z$.15N^0!+#:CA$YKMET M9`>\W"`T2&9\):,12"89"#;B)_PXF`=`ZTK.P1M5>YTO\,K70;'-[:.1<;6" M5=`9&(9BPODF_EKUJ6@L5L7/"!8@7Q)]!BU1&)T/4QIE?YI7F+""9A_,,,%' MD:FR.5PAXRA_4;HZQ#27\R26LYG-IZ'D6[*DU5ADRL7YMS-]3V[%G_!H$GYS M80ZI_%0-&7F\3-$4AM5DPS2Z0LJ$T^06F"'!W]^"?E,K.`WPDW*=:IN)40R= M45@94ULC)RKW`EC&F,"ABB4OP'XLR2N"CIEDCG`9Z,4KNA=G5$EH,%T%CV[E ML("MCGF`?\;))Z"'*89!X93\!Z4+#T1GGGE'4EU0$5UW./0XY6I310@:3XZ" M"Y3;.Q*>"5TR',#-O^]/_('F/1]2Q5-R6X!<\@)*\[NWICTX%WI.#=1TY;M; M_S/Y6?!DU(B=`BEI4U%ER7ZN45YH6;BORA(JR-2T\&#\>G[V,M)1_FB8Z!P90G!)OL+P*UPGKW$&A8&E MMQP8BTYRD`'O7\']%V2HSL-$:,4OHQOM);@1T:#EJVF,WC"P+3(#+*@PR]`F MAJ^+E3`CJFEHG&C\7EPZ7<&PQ>CGUL8'V0>WJ)+/8Y@O-8;6G$CT.G#"K\9+ M^Y41+7`E:#3!E;DD!04I`Q(A(G&#VHI.0ICK+`P7)7)QE,,(XVM\B'9:3N&& M6R2(V,[)DBHX^-#<#U&'R0=B]]M)]990GKNU)8>-#'A4ICQ,`RFNK M9-@K#KWP@1'R^&5^IDAV&W,P"F-,DM-(*C>8V/45N]R%#U4[1!?&6R1787:C M$/Z$<:4%7UA@X^8<4O"2YZ>/+SDAS>5NJ5'S!6AGE)SWPR25=$4_=9*"S3W% M-H@K25@\%$(XBV[E&S\CY0HO@N$GF'[54B+("HL1US!JEB!7RUFNHH"&=Y4@S\D=*ZH_K#_A3F$\-)B$9C(V M-66*KRN\@D2,@4ZZ\CAIVF/`A1S(7)-EQ,_AW33%>.Z"XKG;#9O/N\Q#.RT1 MN3ZUA*6D>[0KU)D])6>GRTS)9+O6+7!D=%,;A:7A:_(VSP+_@QU6@2BH8`U>MP$&-D%0RX71_4,+ MTF>9Q!J?RH@;L8=@-!*P.9-=&.W\XJP)XR[#`W.3`'.,Z+OL0N!;LZ3V_84K MY`)>9#;QTB*!62SA.,]"CF2%7W'2%6HCR6-2XL:H%JDC?7YV%4SI$&;7J"P$ MFCP70\!L26"#S(CYSF=0`F6\LY7/]^,T1R.X,+[PY]-1."J%!'^R6QA@7F9D M'^"]\9-U45?AO(I9X._@VX60(VU;#_8)(ZWG9ZY-O[:?L;]@7_D$62[4BH)] M@\#6K5&-T6M*^`D&5H8![W$&)Y<1.*6M1J(Q`4O=347608S^-LU91O(*='(KF7ZEC'"T+.J]>E]9PKPNAH MI<9_5W1UY MO#,&M<<&`X>)SV&#`=]N6/9.\'U[[B]PF)`K]A>`%]QR\^4#M![6'WS]@('"JE3S@"L7@^I/Z:]P`8< MV_U$VRV[W^R[K;KI-@:NZ35MVVS7?=?L.^U!"Z$&7:=S9-%V%>Q&"K%%A3\9 M&K&^AQ2Z?'5#7%VH0>N@"IHM6(?G\)%(^]+N=?0YI'^&H(:3S[=22?J2>V3) MSWL=35"7G4;P+53-B$@M=CRT70L=%"A87%(X`\=O8YUFQ^[;IF=UX">KTS";C58+KCZGYWKM(Y,46F(,41"95:?A M]R`F+I=DY6*=1\9`AKG#8"R;C[&TX*/,<1J.*"FK''VY'X`19VV,[(G<8.N:R6TL(G/1*`I2//W:.^=G7;`.1X'VKO97XX]_&N\P?1XC_WI] M#B="I,)%AX[%B+Q:>M6.-HY>NE,K/'1;_%NQ[F>9;7X1K$K]CX:L;M*?$>&8 M"_W!ZF1?H'5^+#E-:,@OGY\M5>?/A+.%]0X"./2,Q3X*-H/B4[G'@) M@9)@*&K?F1DO=>K]&NO+'T^1V8ZSA_.S.E9?\ MU0OE`#:D_Q<+(S+FA1%"F2"YT*6N#7R'-*'2*PQ-X#,;XR)T#*+9I@4C_1(8 M2!(Q(H<:!3XP$">".O)E^AP&`9+A$"DK/"'CY72*X3TL2Z>BCLK9&%U1RQ/% M%$E=2)?'.$D6,97ECO).E+S]-!M&#I7,7DD+>9PJW:=X!@P\`MKYR_<-UI"` M<*13IN<[152%/12%,NE2!-^!%I/E5)`/N4UF3PD_#'TLQSVE5R3&(8:69U&6 M%>7)%YS25*0:<*1)IT0FJS]'AA31F*HRPI2[!2=08-QL07NM"(OQ/3H)(G(/ MGYV&A$.CLL38(U'!O;B55?Q&7O1@5%F,Q(%S?0S5?I/EDA@#J($IZUEA6_&4 MMF,,31D?V4&)"P"K;097L?E/Q6?(6L+5)L]33D9YL&K`(5/A1V9:[K`;&`42 M/7-1:LPYM1:GAK>K#,<963CA+`G)RM()+YS6LG5PP#T[5(T:'O=*FN8,"7(N M+TC"PK>$-C-/411#(PV*%0IS3:W:0<=_C$*[V7_P"4P%'/0)&OHO'& M;WC6!M?!'>O9?]>^`WD`;6KBTFC6M:ZJ1]*U[T!\@$CN#;]NZ:T-OFW3O@?# MKCRL:9\KF_996K.#>S7MJVBE_/1&L-?WFX-&"_M`.SW3<]IUL]-R7;/7MZQN MO>_5>^W&D1G!)=`1US`-))7!.'R_`V<1Q8RPKP/L3-3/L'$57H`AP&X%*WE@9+ZD6+UKP MF*]4XK4PD."FA1%FZ*(+1C0R<7(MC4<>1XVR M,FV>?(#F%.-Z^I^O(U!BTN'U2E@)!'L`0\ODS"B>+^&SF);$6;CT$1IAF^/R M\W64Y6-S6;<:4^2!)5>83H9"$O5Q^@RN#HMJUIY=QOG38DZ;[2YV=])2,T8^ MV;@&R7ZH*X/1R9G+V:_?X'@M:&GB,U_>]C[_'8>U?K[')XQA.)UF\P!C%W35 MX;_G#/A`_PZFH+_][PO,O`M339`M4OGA_]O_^/EMM_W.;+][^QNL=& MY0DVYU]?5%21+49;7G*MXDM8U5KU&N$1$;_:FCO(>VW\/\MD(5-$,W:-<#XH MG3:N#X@05@530.!P\,E)BAE=:Q_\99'J_\#M.#'`D3"`4V2`R[(L$!E[(,%B MX[\Z=R@_$EF0@IMJG-D"=T[A6>*;#&3/-$@U<7M^ILO;-6Y[73&(8CX#;ZKU M(8W2B))Q20(+9XOXS&L:@ITD0B?!2,,@KH)&F:7"6<0':UPBQT]92X MCN"V"4[\_YSXWRWR_Q_KMV'.%=ERC@J#V'U@L@7S1YS(_1?9PBN1*BS?T[SB M(A]"QX3JNI(17,\U`UU8Z$@(-9^JR`)/ILDD MDL4L\A0MPN%U'/UW*70?4A#TJ5=J"L?&ZT^5"QN+VZWHZM&UU.)?6/W3BGIR M'>C\+%?78.-4$24^!5N"':;Y;:KKL)@(DS.5G9 MI?@%E6A25IPHJ@$E=A0"#U$F*J8YBH`A^@4WB6O%W=7:\08\F*D8CZ/[^G@H MW7-:R,'38$1:L2Q#F,K#&J;49I-=@H7#+4PFM$+0 MR4TIMPAD,RP@&`EY58?Z%J0M;%PHPF%$Q0K3-%BLP&P$`:4Q"N=14 M?$;F)N:"P*ZA#WG'@UDXE26S)L_H+;$F1X"*+#H2CFO*P"5VI+KN338H<5N< M8,5+;-Z?#O+0;;,8GZ]'@VS.O.95Z#'"$*&\_&PYFV'D$3-SR;^AG/[Z-@M1 M)F_\LM@1R<3;4J5__:;DW*S`=2X_]OH?S>[ENW?M#Y_ZOU)^03#/PB?4[791 MYJZ2Q2*95>IS8HJ=R\^?+W^')Z?!\$_#AEE1K(KG:7YZ^__U>;)BC!X%]N8J M5:5:[:MZ=R=]\:Y)?>[_OY_EVEBG79\HTAK(%J/?E_-L*.:9?RL^`B&K?:Q]J,B6MY0)9\"QC["[+M?^KWX18JCXFP+S.(\W<(+6OR# M3KV04I[_<_4)OX]5YSQF#'UGIN%X\=J0`G3#J&N"^.YQ"<$Y']A[NI&?5S4W"!F.NWN/W_[>/G'^QXJ-I.Y=6<>KT&___JM7$/4;0^ MYWLJ9GD47E<=B_)7J_>70)/[N(>JUU(>ZJ?[\4;5$':MV?1K?GW;I;+;9/9[ M,1^.('ZCUJR[)W+P$$[-JGNUNE7?)T&.QIFX+I%NKZ,%&%F/_?;G`JC3O0W< MD@NY$D!W-ZOW_&R]A-;>Q>K=&VE.YO"]S>$/[5[O[?O?U.`P[".$T#>W>7:P MD?%?8V!@.6?!@C17EE.6;=$:\2GEVCP$^3:.]O`S\+3[M.-I*&X@/%?<@7>; M-")J-K'5@W$P"AW_N:AR@[S$/-#LU;=GV*.ATE-[3![$G-_"C>(T3VZ4D^%_ MHN:)FB=JGIQ2/ZQ3JEES?:?6:NW5Z?"<".+[S9KO62=R\!`OW9K=\&M^TW_T M;+:IW<=/B'JM6?=J+:_U[;US^_,/E4S_#1^J6D7!%_`L,V/V-*QHUWA^5@&B M-ZJ\<`1X_6R>1I1`-0;#JM9LM4!*V]6]P(H-O88R174L0`^QADE^J-2XJX23 MSS`[^=/%_,314K87$06ZW"DL#A?H8%U,*5OK_&P<(IX/7YQ;'4FU`N=H+5`9 MYRTK*!&($51R%T\I/_I$#35<-819RD%$!(3#KNPJ.5-4`5ZK- M&7L89U[#1%&N\,)?W218^3^5&=;JT5&$!?KQ:$.7(W:<,S8!]366"=?+F6@U M7(+KKI@CO$VU!YSNB3#H!,0@JNK(F4XVM\WK+IJ8#RAE2-?&.2QXJQ%RN&1 M[%9@\AQ%1,8A,OT8%Y)VZ2P(%K`UPUQ($+.JEIE`Q)_L"T?KIBF0M'/8%!$28HQ4 M^\)M42N6PL,%^%66W3^YF\@"4D:CB_$@LE0&K>Y'%M%P5V:[KY/%NW#<+62Q M.4'48KHX%RUO[>'"['8`B-A:S5TL_.Z%>1_Y=CQJSS#%_Z]#(\#M6.7NO7AC M^XY;;^9+W3+_XD+?APL$Q?L@D%@Z*[B(1F]CU9[RF%$RJ;K?;MF.VVCE2]]] M13M1XFTLVDL?,R4<:PWS8_?EE-$N)$(C(ZR^Q0@"EM(<'=LW7[QI-'5HATU3 MWPSN\C&@VFV:K-VB8\)N.V72CM\E\>0SF`@][,=]?'ONO'CCU+><]>J%E"!M MA]?A:(GX3_VO>#B647:-I^-RC,\^.;!-W6KW.O5ZV^Q9O0$LK0V'UVJT3+O> M]EOM=A]VNW=DP#9@1;&J%%(774(JS?NQH05Y87Q0*"RJO:.PQKB!UC0)&,HN M$^2F*D:%T_$=E(\=8N:'7D-5[IOG/F4I_T,S%DJY&EL=XH]_H,J++<`'RC-1 M!V$/^1GWSW+1IN?2D/]"0,%'4.!14Q`4$@+BX;'0_QD.Q^/A\%XA4!6L?E@` M128-R5AO_6>9\+(1C% M+FS++]AAZ">=Y],/MHT3[DVXG%W.S_RF76M:S2,^;/EL#Z2>5#*T<^'4@9JC M9`FZW'VWI&*(S3OBU,`6JX$Q=K_@_;I/>D>3["Y$V@\($QZ->J+O@3![P1RF M]D!M!KTX.J/6QC9/CM=L%+UX#UE/>]D M#OT3E['QC^5T)=L4.-S?O9?TC/!KF`XIR0*M?1&R9Z!R;"L<4A.1\3(>&3@U M:NV"!CXBKPZY#R\V&2ZT?C&R5;8(9ZH<["I*YFDR8M#]]XTX M3&]"(YC@?LS"$0'S<4)'*A!JJ,_U)`UF-='0.N^E:D38R)#[;-P&J4`2I""9 M<6?<\Q?D*#T+V[ZT%;I`\?;%M`!:OEUURVU=7SRE:^QEAPQ369=%@MP M5U^J[(4.(9SQ<_!ZF/T>Q8A)O)(A*/A@<11TTB]6OQ-HX%NM*=K1>=OICG8= MO]5LN046/11)-KFP\SQMK5*NO5!!_L]X3)[\XK=;K@OT\>$T-SNF-VC89KO; M;IAUMPOGNVU9]:9U9!?_">QKLX?W5-W\F+3K;UZ*>`+[.H%]G<"^3K5K!YSQ MB9HG:AX7-4]UE4=;+G8"^SJ!?9W`OO9>L7@"^SJ9PR>PKQ/8UPGLZP3V=0+[ M.H%];;(R3V!?)\/_1,T3-4_4/#FE?ERGU`GLZP3V=0+[>A9@7]ORA>^7_U+, MHOD89B&VYVO'HQXZMI(YIMH<;<6O\^)-RW<\2T^2V[J$G9`=GD>)?^/%&\=M MMNJ^>R>VPYU%_9A2_E8AP(CB-"P5?L3"2ZMR8*/Z==MT[%[;]+J.9W9LKVTZ M@Z[;=+I^O5OOPJKJ+]Y\J*B=-53I;"22Q,PDGJZ4H]481VFV@&,EW*T23P;Q MHJX0X&K![E>XJ6U')B)%XQPU+(E'$>-2P=:@+_"*S^:VV MTT+.V^O:@UZ]=63);#P8)5DS=0Q*+B1A&2G/Y+/, M5M_3L%\0&HSSA[G3.Y-M@60SEIF$@*+&J(6^J"MN]QH,KQG9#`Y:`78.P?8F M<212VN$8(-X?C@MG,0['E$R?%K$#U5F?S9,4`S*C:#P.,3L7_G@5+F[#4(1E M9,-6O;\RM1/&X0DA;:V-WH?V]?G8'-29&%B/%!E M!7<54'$^75+[Y%D4PP_81SP-J:NMF@5($4STOC#:E';)B%,!AK8(N!#[5L,\ MX&J/,E`$0/X!P>(0R)#!'VC8ME>%"F$<-U$<0!?D-#QB/`1^D[ MO3"^`&VF6:*32M_7\[-QFLS@RI-RE8^O`0M*8;#(;)EAI_AGK]R1Y"]N+'Z$+ED!CN,9+L$ MEIB3M,0W%_H:Y)U"O`)J0C`5/'E^MFDIB)M)()Q)C'<"L)RV50(I#\EU?B;A M,[DY/!>.P#Q5.C0QQ'R9PMC,NQ)`4IP_N2L4A-2/$%%$0`02V0."`.2?ARKQ MNHBE]VQE(,OT\S.-OE1Y0I+H*QT_X)V?;!_HDBPSPOU$?#@=)%`P@#9;O&$.)O#HHNW#:4!KA9R-:Y MO"N(NP6/AR!%(J$"!0Q;=0H^7Q,L:M7G8!69 M`'9ETFU!B"Q"M.*S6.%!;;R'5,BQ*,CY,A^N6TR;E*A2!8T$C.I+_,NCLX)` M:;;K==MKZ;A/:_,N01T%$1@&_XRPUN+@.&X[FCBM%V\\RVOHN$9KLUZW8_:D M$CO-7MUK.%USX/@P9ZO3-UO];L/L#1J->KUK]SK]SO&JQ!_#FV1Z@R?T7113 M0DL7#B-^?$97AU[A MMW]'+P>GIH-6F!GS(&4M`14#]66:6Y1E2P+9K<1+AMLL,?(/\0`@OB.RM_D[ M<'$Y`F&V"/=+%ZH"P,:K$`9/)ZP\8EH/KHD@L:*1B:8V?Z0F5!>^-/A"NEJP MDH3:CM#V4/23=B5`S'@&Q4'PWJ?_BC>_[CJ_A(NZT MDN+JVV!M#E$7^X18RQTTN%"S!.V"!-?AO<1NN]WU[89GMGM^'?2C;M-L-?R& M:<'G&KVZW6RY6'/I(!BJ;S6L>K[^W=92/C-\#%$+.;X]=MT7;QINR[9UYL\G M7*J6K5SUY5S40,.I0?_$38CLD+$@>2I%JE?O^_UNJV6ZEC4PO4$'E-IN:V"V M'-"DFMVN9TGXUF-4I(AP)E'.T$EW4IJV^AFE!4SWFG*7%34)0G`WV8]#\!29 M,4&M@E0)&&(VGR:K$'V3!&NAP./)#R/WP9@CQVYMWJ%E=:<*^U@,-;FSCT`4@W(FYI%"TQ63V_@,])1 MN6-3$C$-QN=02T(52ZTI5WX>VICD\]J[]*SJ%X/=5X`F$VFGCX/A(L'?%EJ. M3*.QRJ]G@I$S5W\D;\9!I>8;,_&%=HO;LG'"1;65/TCJ+NP.:J/"CZ0[0!%O MH+AYL&?HU].83NU@C#4%BS3`V#&L+2:_)+PLMS9GXQ*X2WG'#;GASU::@)4C MEEHXV95TTV@K@F[DHD/VV^2;4WV2V.8(IL/E5/B)I&N>9,CYV;9]Q4'`%@(M M/8R%AYP]:$I((4)".@XCZEF$9DG`#GU$N"GX'FWG9WKS"OB]U,GI_$Q-"BP$ M.`4$VZ.->W&`W3C`)S[=M<\R^,$.V+7-K>B"A;O[ZS>@R;,N@OD^"OB?MN;^ M>!?YA"@4C\^(_[;I:QMRKLI$VS%Q]?!KN6OB^_CZMTJH%4+1WU0[(?.P.%`T MRE.QMBS]FR18WS,A4(ZV:9+G9[;3J%F-^R5)/N,$]2>GGV/[M5:K<3#Z[1%> M>;^QS9/>D>6O,_'MJ3<@FK8]&HM_]ASTY\I;4%B-:R] MHB]\R[J/\C0_$QJI9I56F_,'XP_G8A.T]#86>0"$]58$ZTW?J=M.S?*V::E' M>_".G+">!Z=NK^4E1P/Q\;A/]*@C*8=%-_@.M*2MVU`YCNUF'<'8A5LS*SF2 M43&-DUC^PAA%:4A.2OK++!B%\.Q[AS?P6&H M2N^6A`B;QPP01+N4%>AWA*[P#./?E) MGY>SZ^0G/?E)3W[2DY_TY"=%/Q_8/[9W/Z_#R4^:+]6K-VN>>S_#_.0G_=Y] M>4W;K]7]8P>6?9ZT;;3\6K-5U3+RY"?]X=UY=LWRK5ICOYB]/RIID` M0WXZ7^E=Y:T%=Z)5:WG-Y^$I+:\KAZ-<]Y.Z(".W^4D+#I]-3M.'S[J:/N=G M>K[QO3O?W3][OYC^#Z_-(NZB!<]SEZY)&`^C,.M%&:8X+].G;Y%5[[I8O=`U MO>X`_P?;N+6[/;->=WJ^77>:'<\^LLQ_'.H*?WA/O3$]PS0TVA'S%ZA'^W6U M7R?G(1)-3C<-]?<_W1#&+@SQF<$N4BFR23"P>#07YR?%6I'\:FUJE%J;AI.,5B">?1+JAD] M/^M>8WEENMJ8.:]-8CH-)^&HD-Z/I8_Q!%$!*)N>0CLW7.Y!%SM*71!#Y-H. MOPZGRXP@%71W!UMULR#],Z2J4'J/X3&*"\%\^5&ZG"!(P8C``>"SGSZ;CN5@&NAVZCDOS_X]!_:%M?PA8E-U&*@:97A>\@Y,LR MQ9I6(DU@S,)T@@$E50BJHT!@96\4"LB/6ZP^X#H."E\1J(3E[[1Q62)WC\?B M$SX.B-%@'G$X21910,@S!#>!A254V,KUJ@10DBV'V#I!;&=Q(?)!,;?RJKZ+ M//>W,;!;.%_0<17Z!A>EX&$2I=9!#`I'%!-0C2@*8T#'&&.A5 M&@:(WZ<#DE&G7$032JZF0@"3\K(4T=WE_#J9$N@&%2#!%O/VS--D!I-(TA7& M.)/Y?$O]#DU9U,%045#^Y\+13:F]K(8,7K=^I@J(Z93BJ?!-Q*0I0**2GA9, MJ5+BX:<3;U@Q*#4VQE;)+!1LBX.K6H,/T=Z8JK&P=3,:KV(&5$P.0N/\+$$0 M$:(\O`TD_@IA\H]$,*B(3-<*L;OP4IKBUW@<2)1A,7]_UF.)G2^C0YX!^-R#5!1X6)42$"+H@;V=Z\"I$ M68X08>/E5*+OR">Y#(]A&!`.66@,A:W)OX?9$(ME*D&+^!#"$X5;&PL0Q983 M/BR1YZ^JL-GO%2B``47RMU,8,PAF.1&N?"*<-!( MO\&EK\(%OBZ1E>*5.%W&:!FR!*&MB6*>@&+X**,KX2`5?@>X=:6AI';G-^2) MF'29KKC-8,-+>M=W8"KM9>8*!%7(1HG@E<0$0V(B7J`)$ETI"BQK%50A@LP0 M/E>*9_SJ/R*3*5`-S8WE'(_A$C&`KE9"_HY)/Y>[=7[6IC^WT;9=D4#HM#_V MVG0MH*@0"DY-&U8((\1=97P7`0E('^(YXIG1ZS#I(($"'"`DHP)/Q)7"-^!U M"?BHT/CI5&W$(BB!-6ZDJ,7W0&,(40_0#WEXG0KL91G-I?N$C_UA.44^R6EB`?H,6 M%!A=PU!"]\$QQ1LR`HV-L"V%2U5>21(_J5)1_T)'6$$-"[?`XC;!:T>;?[:` ML11T\B!)X>8QW7P5G\+A,F7P'C(@^E^YY1U[M#*IBO&8`HF`8C\"<6&Z4I"4 MVG*,S:N1VJ8^2W1\JFG2T:?2:U`,I@%NC`(]8K!1D!?"_!$H$`BF'&;NLZ/WO)^)(KX?S(B M#1!`DDC@""%C)>W1DB&#FB?T2J-)!N8=XUVM3>O\[!;86/Z>OQ=^Q?MUR?"O MC#1I@6B>(A[FY%K02QA2"J^+D:A!TBZ`?&2:/F.Y*;0R8+$0CBCN=X%!A$-) M.2,RWAEUN&L"6(28%BG,>U$RO_\,P[G@%1WX>1D03B;B M$L5UX%;+[A32'ALNEH8["3+Q-! M-NF%@LTC'YE1L5+"HT;<14RPF`5?H]ERIIU4<:S)2,SAQX-R\04(J60Y'2&! M2FX<#?;X&1^_[\,T'BC_9"4KY'Q.;K\2L\^"/T/"Y]S([10'ASV?J[X9!^+U M$-Y9`3/"'8JLGHNS\@$X/ZM+2([C[#F>)/,CB,%6=G'6X<)H@49BO;[X+QFH)!&:?#&$:L.EJ/G=' M\.\7@"\&[[^(DJ,V5QR]7V(.,UG58#_IB3Y6%+*V-`,]*X@O<66(X=!LX_/N#&YHLWMN_7W:8. MW[IU#6M=C/@YQ/,\/G1R0F5U/=?W7+O0J2B?=&D]29Q()%9^YFC[3]D.K,UQ MK%9+;\*T:?[%98*!#MP>=PF[?KCZ#`99%A"8,(H$^B>[B[,](9KW!VW/;?;; M9LOK-DS/:C3-=AO6V/1Z7;?3AF4Z[I&EX_!@Y.@2Y#,D_0R-8M]#H@J%`\?+ M>"CPLX=RG2($>`O7/]SZR6W,ER81`_U$T2@*T@A]!`+A%B_:;A`'HT!A*_X! MYP'^\$_@T%$RHX8HUV&4&O@&W''R6Y7NJ'9E7QTY+3$3,!>TJ9`?9R'V1WK? MQ!P^H8$`E@X6!Z:90N_37"0I/2``P<-X)+46U?]G*SJF:,,A`Z+4A@,LDK4Y MR4B7+.@U9$%O:1XBLH:ZT2A/2-QM+AJ+%GSF%"8%)6*VE/1!I4E9\(4^,YKJ ME^G1-2`8:(V+#0D\N7`Q*(4(;7/L%B/V1F_!05202*&!;.*$X2]\80?=YL&" MK011K!H:2AS)3PR-69W]*`"=,0]R_%&5DG^@S>@BGPJ/3Z5'I]*CW_@TN,31.,) MHO%4>OS4Y;$GB,8]TO8$T7@J/3Y!-!Z:L">(Q@>4'9\@&D\0C2>(QEVJ1(\5 MH?"')\`)HO'D)SWY24]^TI.?].0G_8']I">(QA-$X\E/^M2^O!-$X_YH>X)H M//E)3Q"-WX*TWQJBL0(G;U\I9*5,M>K1L,1R0K5/G57^B*CL;Z,GC!'[LM_( MH?LOT!NVFV?2=OMFT/7O0LNINI^%P^AJ6-7O- MN^`''[K>(BV_?=;^KJG?WGK:_D[I^GVJI`&6%'FE'X-%>!EW@^P:*T'@__K_ M748WP90R0X^N6,%IOGAC>D"5?-7W65#IX$1PQ,;1$-BA/1QB15(43R@I-`J? M/E^SWN[9L)B^V;,\-_AFN*Q\0%D&_#2=Y/I3Y6@P.,C M%!E<"(PZ+P<^%/I)H4J;LK7)^1SPOG-,Y0-(W5D;?AV'#`A)OF<$7N%J`9.K M!0JI^=H[YV=<)J"]J_W5^..?QKMHADG[-7(4N%J)0G?781IB_GI6 MJ!/7QM&+?&N%AVZ+?SLOE`LOL\TO)LNT4'[.COGB^P)!YT)_L+*\`<$AM(.% MA8OID%\^/UMHR>Q$H*M@RB!<>7%^.(UR;$;:6;&?5(Q;\4FL7KQK_S?@9LQ3 M+!(0)0-#Q*"B&DL"-IBP*0X;!']!O$*TR',Q(8I!L4).F['@($2.!3 M@*7M6C%%C=Z-,EHC%BXD*=QX&"!<4. MOZPPHJAR5@72QLOI%`&?LB',$*.RE;,QN@(C,XK'N+=<31-CD#A9Q'1/CE0) MK=A^FDVAQ*6:%O(X$?Q&^3SA&3#P"&CG+]\W6$,"PI%Q*C5$!,3K39=#`5&5 M+J<*5&:R%&4PQ&W#-+K"'5_Q":&/%1%[C`K`'HU"7W!*TR@DV%U9S913(I/@ M@2-#BFBL.AJ%_UUBC9$H-1?UVXJP6#%-)R$<$7`7?'8:!H1X@E@Z^#C7959P MKX[=I?-;BHP0T$;`X_\1)6XY3E&W,,9`C?%)&P.H\9X*U?5MQ5/:CF/$3/U( M]5A41T9`2*`F_E/Q&6$-N1N(6<3%$ ML'03O%T5K$<6"K1,RF92 M"94\6RH/K1F:3$95=2@A#Q8;WI`%GX3;)>Z/2FVHIJI:JZ:3@CR,EV(QPAF* M0*05I9O&ELK--D,QRPML2.`1HPAHD0J$P\5UDFG$^XY@/4_EUJ=RZU.Y]9&4 M6S^?$[7O^QT]BYR0@3\9FI/Q>Y!'^>K(D`PUGS!A^B[D*4(X8&G%YBFU>+-C M(XWS,WAK66W6?0G95";(-#"BK^$D@HB;1O"MD8!%S'$209=*HPFAO<,'I"), MLD%+]D8^1PV7`>6&M`AM[I7S.,0U=L";\F-XDTQO4%*]`VT?*=0%BS):L,<* M_VM\AL-NO$N"[^+FW-.P[8RMUV66L:!$>\_@QC@E%-]I@GB(1=A>D8=R?M9' M/V4:#4%*S".,E7>3=)X([;G@X_JM+Y\I^+CPV[]S]A?&%BZ,=D8-69CW42.6 M7Z:Y"0!8;N\U7\)["&^60\?"C/,/\0!P449T*_!WP-!S'`9^1?>302=8H;DI MZ-;;`/30ZR"=L*&'&;="=YD'T+4@A9Q`X$J*-N'6 MQL.09U!\-$)7$SO19G@!_X7*PXV`?<,K3"H+I2U!PY=O;@6'BBX6W$607K,0 ME.?1A2%,?7@2A1K9]LM4.#=!4L5AP5&`<&[Y%U`HTM2,.V96FA0;,CE(:WE2 M&[F;8MEOW_?ZR-.M^>)).T_L74CIH:,N*$:@LXFZD[8,*'RDGB\48O\.I!0% M6>;8B2E=@7*O5IRRRZL3P;_173DUVJ,;9/^1(;,^.9>MIW6J:B^!-U(TK`L" MA-#Q"[*#FZ:0X=U#]7(AP$AQ.`;;?XD/Z(/TDEYI"&E%O`_$^7X;@Y6Y6"X$ MMNO?0P1Y+D[E_=N_%QWU*+7@!!0J@VADW:-,$DYU,R('?=%'!`K\*!3=@+C[ M#$$0@U6"KK+\]^=G*BXB$'%G0'L4Y%DRQ9`16>;RZ;S13D8>*K$YU&*GP15"0?-UK5UL.&,)YCS,'7IH MY^)U1MDCV-@"+K+K,!BQ03#)4VR-8H:M,;L2&I$?/Y%*X+Y"?\.+82 M"S=X(:Y#_741`*UZ'=4KZ0G@4!!%UD.,0"G_O5CEKU6?BA2<+STC6$`T-0I) MPY0PYG`FHNQ/4=XVBZ8(@1\+-REV*L``@GI1VG-BFM0Z1LQF-I^&DF\9+%>. M1==(G'\[T_=$!H_RCG'Z'%+YJ1HR\GB9$@#Z*`^2P4U\"\Q`P.BW<*_4UD#( M2W#M@E$,G5%J7$,JMT9.5.X%L(PQ@4,52UZ`_6`]-L!0&CF@N-$._)T"9KA/ MK#8JO]K='!9D3,9``#YSK6U>^@J?HNX]/!"=>>8=275!1:GACU/A>)*$H/'D M*+A`N;VY^RF7#-_!/:MA]BN>DMN2!P0D,W(8/W]0HFC79((!TG3]SQ1+Y(YZ M2+Q`2MJTH#,6NIMJ]U590@69FA8>C%_/SUY&KW)"%98BW9?7&.D=O39>1OJC M<2*/2Y$M]280Y7XD14J%7^$Z>8TS*`PL$WZP&5J6]Q]<<1\ZG`BM^&5TH[V$ M3NE%$//5-!YC1!:MUD*FA5@),Z*:AEZX_WMQZ=)G)1*9Y/@1=Z.4\CEO"HG! MZ2A/4P!.^-5X:;]"X&X$[,96D3&VTEN$PL\E6EZ@MJ*3$.-CF(51))<(*84G#;4_H7I"M^Z3=(_ M@0J8U["2A,5#(80S-MFA"..&SZ@^%;0(D4U']*N6$D%66(RXAE&SQ"26?%^! MB?*#?^"0Y#/U.PX2:CI781>0>,`^*[K8T>5REJLHH.%=)*ZH_H%`([ MA<75P20TD[&I*5-\755F(9643RVA;[*,^+DQ19M0S8!#E]_N&Q/1[IZ'=EHB M$>#+BJHF*!@3$%1@>[S6KU;6-"77QB/56C=/3BRU#%YS_8FF#2.I-V5.O:[(@TN)$IHLY$?I1RT#8`.UQT@O ME"&P-5$Z7,Z0F884LEF)NS'"\`Z(>^[YADS$32LT4!2,X6+4&86=R+3+$[_T M)(XT).06#!Y/<]`*T)?G"8-8@(2E\!'\>L6/9]A30^3-D->8;""T9BDT)/YFQ)`T#WN,L]ZW*/'^2Q=+[*G(>-Z<,5PLAG+Y4,W,)+DX! MST'Z[$;L$!#Y8?0Q>3XJ;Z=`LZ[5L=(71RD@@A7A+J4,O;5%ECW,%.?;0H@- MF2CX>5:;28Z*'K9%C93DWR9'$BVIL&A:@_2L"<6TZ%VK@4CD<-1B-<>``AQ/ MV:(I4E.BD5W+]"WN\28G-5P-IP=*'MN?PS>(@^GJKU!T=\+\A'7_*[*3\G6A MU4OB[A;Y%G/K<'%$(=Y-0MBZ\'*1"R_`+VRRGZ:R5F`N:V9JW!0V(UX7BY/)W\8D[YQ- MB\-#(E>G.QAT)!)U>UP8Z^O+HJ\PCXUP?+NMSKZPU&+D\M1Z=U_=^5EY><9] M5G>80,TA([%4ND^ELH9>3OL]!%WW*&-D+[]*SRA^4D9XO74=@ MI%.@+6._CNHH/XW&RL)C@LGXN7KD)D'/%1MSXLG*:+?(X<%MV3CAHJ^,/TA6 M&.P.>NV$]-0;WF->74EME$&`-8Q!%+4&AO!D8K08/'&M9V?Z4WLH5RZI]',%).ZCK!Y-66N:.-^ M%Y&<4[>B$PKG"87SA,)Y0N$\H7!.?F04SE.WHE.WHA,*YU,C19ZZ%>V1MJ=N M12<4SE.WHD,3]M2M:,=/G+H5Y0&?4[>B4[>BY]VLYXO*3GORD M)S_IR4_Z`_M)3]V*3MV*3G[2I_;EG;H5[8^VIVY%)S_IJ5O1MR#MM^Y6]#Q] MI1N]!^N>4L>R:BVO^3P\I>5UG9]M]I.Z(".W^4D+#I]-3M.'S[J:/HB(G.<; M'\H_>,`\>0$L^SGX^GT@>>]IV"^A:O)!+C]1KKM`LFDYVH2Y70`57G'V:3"\ MKLF"4(42SBGD>E&O,5ZB?QO'53A%!I92%3"*1>8ML'^2(MR#Q'3"*K.K<'$; MAJ5>#++LAU!6,&T;AP^R'.^X&BO\PAC04JE%A4QMSU0UBW"UQQHQN!D"U=2^ M%/-_I27ZQCDN#.:/4TN!'",0WZ>4797].U8P$`M$W4F# M,HTD8I"LOM-3E:^H>GG*9;!?L(=*5HA*Z/LJ\,V7,"%N5D#D$QU0<).QL&TL MX#1T#+I9`J281G\2YL0UTC1.%CHJ75ZN+(?#(;)EAI\A-[#:$62O13B\CB-" MS)[!#B/9L'/.'-M=K0A46U^#`G*DFK\P#J:")['M2O52"(NC4)JK;95039%< M`@8,:T8(&9.*E7&>>4,49`A18DV\*PLEQ/F3NT*%`_H1(HH(.!#NXT(PT/RS M^!)=QOFWGG%&/\MTT"QR^E+R?;GRS"\4-V/AF:,*[<:RV1,'.ZE<]0XE12]5 MNS#>)V*;U^>A2N&`5:@2VGB[QA#B;X[$8`I'"LU0DW<%<;>`LR>1((U)DHQN M82U!;:0\/>J9G2M34"\)-!26>67<<6I7C.W7""NQHBDI0:[]M]ED((LKB&V M@X`B4@'_LKGQC/F-8&R$(B0;"HAS++'WA$:CNG<9"&ECCI`G$2X)X;>9/1$1 M#^BTRR[B4<\_=7XF*IIWV+Y\NU3!7@0";L@0`0@PE6-%R3FJ':$P:I MJM6_&F5%3Y$5(_57].E],80TYV)=0NPK3 MW#:5-?!(!IEN$J'`9+4=&<,TV!\?%UQ4$;Y!YA]6CGV!@M)7HH3IKE M\09THK;(G5HO1;0O?!W:H)P095MY0E35.15S56W*J-U,H1V?I)4P+R51U46@ M$3:^G[ZGH1L4,`I`..44CU+66,@BO*7N3HA:I!-2!U;8OY)0^M:!D*$1\[W4 M3#A-XF0IH`V_"\?+EY#X$%B036Z\E>"0:6O^A!<1I?[],1\QPM]UFBPGUWF? MA,5.[3LK.[,1(#IWB6!U.^_:B/T81;T\5Y2C?$?;`&]G.CP!-E^!I<"0ZG:, M!;!V56/.1.M;JBS=-;7F%[B_\5]:B_>=.G,7NWG_D8678]5M[ZFZ=OO6P&K` M7TVKX31-K]ONFNU6KV_Z;K/EU"VWT;.$^S:?6I!>&I!>&PM"->/>?'(%H_S M93H)XN@OVN.$2O\HQV/]!;LEV/5HC7OT-I3I%;"XJD$0L^RZW['[9E>O]LP MO;;5,CN=IF.Z5K_5V[\$P!`5JR*8. MN:S&R7`I'+LB/0UY'YX?<5<4/)M+]-_.R&8)='@F9:\1D44BOZ/_'DSL2L!WHC]N(];W)*D3PZB!& MQ3).&#>;`9SQ<^(*KT[%!'PRPN;B.TA$AFF[U+Q[YF?N[`H%! M\+5;UG!S'&H!<*4!KVG-,I!YM98H:4!]>KB[94W\OSF-XC\%&"1U!!.MQK/7ZG@]S_0[=;BIFFW'[`Q\^&??L_VZU^HY[>J;ZMNIKBI/45?"QG>7XX\:@'-?)#X\6$M:QA&_%66)Y]B- M?__QJ?<"I,(0]FF:_>\+LU[6I-RF;[>M=MMT[3X8_ET?-*F./S"[];K?\3VW M;W6\?[NH2=D6_2=?[,;Y%Y?Y5J0+[7UQ:UIBM]YIVVV_:UK]CF-ZKF>;+;L% M/_F.-6C5&UYKT("UM6!MMN-^2P_DM M*M.BC^X7,(3?)?$$FU'W2*<_V))]>^"T^U8/-&&W:7J-AFLV;:MEPK\Z;LOU MK4'=!L78K;]XX[>:#?]OOSQX51I1D-4)9UF'66[G'84ZJ_R1#XS'WD8$@(_J MIOV$HNL/6&WV&^<"OXT_<'7^XVG'LDP7;RQ!LSTN.B.9'=MKF\Z@ZS:=KE_OUKM`!>_%&QBC M;EHMIL6.L\R7Q=$P+?Y1B(7MR6AT^GV[ZUFNV6_`B0!Q,(#='7AFN]GN]WK= MEM]V_>,U&D\!Q!\\@'CO7:A:%XKX`'-0+N$E0X^E.W MIV$O0>9P'B7!!RF^10.Z=(PVI,TY*#E2SK*>N([/:T> MT#/>7W'X098=][%W%-RR1I?=J>=GW23%6@DZP86&[K_UY4.%\:A!+CMP2WC/0LON8&;?#ML(;QJ*LD3:EA:J;UTRM^@C9#?@,O MH8(W;+V?V(7QAQHI[SN]6..I8F=.ZMR&M!LEMW&>2Z^F@C5&A>4R>S3K/^/O M<@[8W%.*;\VF57IA6QLJZC>GK8_!DFKKVV:K;:-"AIL@FE(E2TY37/OY67Z@ M%I+VP%]!!/II!>6UU089@8EA/SRNY<'K&2MY1),J#/'-L9^5Z"M2;#P,STX)%2B#'U0MO]NY_`A7A^C8-IXF M24I'T[ZH_USCGO?UG\LLKZ0D57?H4[C%4+D/[^H"MI-HO>]R4;^-M\_/9@%5 M%0*+?`KG"^I#B)^MZP-_D"VXUZ@+=BQ>.3PUDPK39&'>.$IAMK8E''"R(D9T MIP1-DCUR<#RPDD=XZ2*8F"@4TYI(YVWHA4^P=$'2+&;AXL+XI%VU:]<+E?PL MJ3P"V_U1YK3I MN30D^H\>0X%'34%02`B(70FT#CSP/\/A>#P%?/0SN2H+V23"I^L^[ M`!$^X*,/?Z7^P*65P+?$,.;#MV=W+*S''#Q!_BHLM:>1"/<"+Z/IM*Q6S6JM M=\'8"V,_`>VJ4)V>+>WNC\"V798]&%T(3%0P#-'Y=X=@%+NP#>%GAZ&?=)Y/ M/]@]\)+N)ES.+J#.-^U:TVH>\6'+9WL@]60#_I23`U#==TLJAMB\(TZM;ED( M/+1]3_:$,_5\+8>W8W*84,7*JLHBI5PD$9/98IO.4W1T"B>I,K2,F0@C4EB' M?,=HB"57TV@B`>7QNX&<@7"BAK-H.EB\TI"?6`WYOIK,MT\&`[3I<@Z%G4S(S*21=\& M'%!V>LU]B4ML[?J77&".VB,=`V2<7S_K3JB7V.)<[`#Y)(K>Q:(S@F'2%QAP MH'ZH5\2,E2X^K=P!_1+3:0EV2;GSS\^&079=T_V!C+.38N@0L:1B3B'G>@CC MRW4T#46^/G\W=]2`X(.WXV1!N:[AG&8RC68<%XW2X7*&DQIR#O\--VKFUZ<8 M/\$3)+];0Q@B&H^?1'\R_&T8AB/R?2XSY5`^/\.<*@Q=!-.0L7XJ!GS&3$)N MQ1([8-@4?0:H_H,3<\;KS.1.!J#MF:JB)RF46772Z MSYVYG5Q4+MUE5=+)4!#:=4YP'%P&`(4'AAQ1G59*5X&V+&E9?\25AGKH#^;U6__\3.X61A."3&SM^G*0IJ3=!'_2 M8:8T:,SW%56!N6P5S*'=[QOU@&=\^O9E%6P08^7(]*U,M=(/G"QFH"QY5>+@ M^;5ZT],2WK6H=C&^6LB$IZI+S#3'RDH8!O1]/O@_V1>^G6>4U_3[0-W?R!4J M^SN1<4(ZO*Q>J\(+4@6GH,F)!(E,U/:)VW4<1"F!4*I2]_S-12E7@F;GMVK- MAL_!OQR##B$4"11Q&2^DL32$@:C`HS`\I8H@2R/*)5]0,A(V4OER2DDL=,DJ M:?]8+!"L)Z4]'QYO3[.$9)119LEEQJE(#,,GZ%G%HZQCK54\_(2M;PFL>*Q: MG$D(`A'!5_]FPTYA^LG2V[6M2>[8%4H3^:YDT-N8HN"4LF#7C`]8-MY&0[V< M*!9K6B/MGU0/T)0-*=53KY:]O<[%Q\@H9!@!">U:L][`?B9K-302[)E3L)0` MRB6'>U&WM%H4W$IUFA&'6[W"N3-!;N"#=',;=LUSUK\JB@TY7T$-A]4I,U+_ M4'QQ@H)VVY-T,]:$V_E9>8Z8*CH5+HPQE>C'8+6G5+(N)083!O$E,U*/9!@_ MRCA+P:Z3?/+7`#+!2`4"3U*X3-$/(PS"M?JAGWPM18WTN'!A:(^OG:[Z15,E M?Y5YKY@3>X_D5BTC5OWQH-LPF[;O MFO5.K]FQZAV_Y;>.+"M62T'7"&4H2M%NMF5>UT?EMJ"->N;YZ.0-XJ+1E5`, M:,5"D>Q$"1Y'!+AHCV[PV(R,CP7HBIZ&--%>@C).YG5!X+T5J&]87 MIP29(&Q^NFESMYCT-Q&JB=RI_P_WU[_7*+:=,`*O?;39A.--Q![[I]9R.V6X-.F:_V_>;3J]A=YSNOVV8 MR+^=%V_L"U=4+*VMI5BSV)["[J-*5UWE]MB6 MZSSD%.Q$#P?I8;]X`Q=NW7<>1@]BG2"[1F4#3"Z]V.UQY8I`@I93][[">AK- MYK_KEM>J-X`@GE5WU^K8_)X#K%,W>Y[?-4&?')B=OM[ M_\']77#\MFF7X`9CV<+@-]"P$9?D,N[!+-Y@5?6&WP*V;[3JL$;; MLCT\!`W7]QZPZ4['LP9>WS4;3;ME>LVF97;:[8;9-Z[?Q?+G(L`IH*A+!*.7WX;1HV*T6[K=KZR(`[(=P MJ\#K=UOU3KO;-;L-WS,]R\=E>_!3UVIV!G9KT$45$I?MO7AC75A"Y-^QCB(# ME![^H,*KCUMRT[.=!K&XXSSYDNEXN[1D[7!O7\T_4G7W1=W%[WWNG[ZGL(1;4S">A:M>W\#JLW&EO5NNU@%';/ M:]3M+@)0]ONFUW8:9MOIMLQ>"^$9/!N_Q+(-]-EZ4^!1/&"%.6E^0\_%?I3[ M;T8<$/Q^72/.O=>H<4Z88M)?,(%G@6XPR#AB&(/P'KJ.I$1+7'V6T[+7*7'G M00%]ONZZ@[HY:")&`ZKYS6[=-YVV9_>ZG9[=;KA*\;$NZI(WMJPA7ZGZR\>0 MT&N2&"GU";2EK$.U?#UL8!M=43!@D*0=4""&UTA!C@\_-34V\87_<*J`S/0L M2V.,QZY94XJ392II.@COHR,^CAIKIV1W:KAH&FG$*"\A7UQYV3:C?:@V>WQ M;ML(6:)Q_GV65RT.UU_CIS^&HY!!M9^:+&4!N<8=NY.#=4:[0D+>O:QOR"0[ M.$O6F:1=;_6LEN^8W2ZH5M[``ANQW^Z9O8'5[[6L7M\?M)\WDVPS(->89'=R M/`V3/,)MZ/H>R4G;^59N0Y?=ADYCJ]OPT[6&S[<>/6&O79Z@=M;/;\-$^]T!G#CM=IF MT[%]T^^V86V#3MUKDK?+*=YX6^99`N-G1)YXP@T("85WYX6T;$W%WQ="G?-O M_\4;TP5RN8X&OU M_LA=(8YN@;`^WW.:3:^`H5B<='E)LWD:7L-:HYN0EPXJ^^7X<_#U<*OSW4ZG MW6CX9J_M-TRO"Q9HNVV#4M%K^H[G-AK-5AM6!^JTZ7B.V_0A4#$_ M"9F`SX*$&3VZ139?O'%+@*C5,R^=8D;?0AJ,L"4SL#PQ_[%>.2"S7`^,\(8F MLNY80\456R'D\/0/DC2,)G&7<]'US"08F_[%:,=ME5=ZM+(==6#XAUVZF)]\ MX>73HD9,DUE7M>B^5!B*[*3BY^#U,/L]BBG%1K(G?+`X"F>)_4YE:CE/'Y_& M9_-UZC9\V]5/X<$H4MP*F=6$`CQ/:3K68PWL6F^!FM5JYJ3;NH(-%D%?IN\> MVP+K+]ZT,'SN5YD#!X[$I[/=\=##HML]GU^[#2#AAX@X$-_VPVFDX7 MC!TI>>J>U]!AQQ^2O_)%M)]H<_>)]]1\XG),(USF%<%/KG+M!#V]JTAH@(GN M^Z[MMOR<&@];69$Z('Z/V/BUZU6BL##GTG*>C\GKH$GH-JR&MK#=K-T'PX\+ MGP@ACF?W1UE_%* M`T^[W"?OPW!/?GE@&P8G;\-PN"X,!SH*V(2A;C?<77HP'$6[@4,2COO*-N.XV4P!6-@'%)KQ_LEUVPB[YU)`KWVP&KT!PVSX]M-TZNW>F9G MX/IFLV%UVCV_U^O[?3Y)UH7M/)*ZNZ[[@+K8HY.+=]+,R.&.F@`1\ONE8WK<(2!QFD1B0J-NM M@T'J;AXU&/+;@91>/%27WF/"4Y]6/(QAQ(([%\@;';5JMXPE& MW+WR)PU&V"H8X7S38,1A-MQ[\0:9O/EM8A&'66/SQ1NOJ8OA0\K996S!'[(8,2!KA6Z33W+LZWO*!9Q&-IA7E7+;OKU M^L%C$8=98!VNH`986(4#>>!8Q"-7NIO%2[$(^(IG'WDLXC%M,'>5"!B+:+I. MO:4KV$\1BVB#')$-=T5+L"C,^J)9,(L:;#M.]+T(\JE/N+KYK9OMF_6!!'*5F"$)W!"[HT7$+ MYH_YMKN6U;$V]:+?X6PV&$RB1&/A4\[,*;X M%3YG/Y2LVVMI=Q)OHE3X@_,O^W>_I_F4#TH`)KZ@`JWCP52@H6`P+/A>K,2_ MX-^,6#Z.$#=R>`T"Y7]?7"\6\U]_^>7V]O8B"X<7D^3FE^[;?X),@@^YCF]C M$GS^6CY4%DY0^+SYV]>K=#J*?@V_SJ?1,%K\SJ!QHVB&;KHD_M\7RB6",JS] M-O)&_^CWX&LV6,W[G;[]4#O7F;[_(;XE5_5)8UM_F^=W!,UL$Z:*'L@[I M8UHNZ#(PAOJM>C`$^S1_S#=="X<>:0^!4-8NIE_$WCQJHXI2X"@WZI-HSP(V MZ2X'0(@6,F+++([,GW56'\-YDB[>17%I_^]P?O^(?,&7Y0_.%UN]IS\05^R= M#YX==;;D_?S@9^;;R5+;M#S3NI,O[(/SQ4F6?D-9>FQ<<5RR]`BHLQ6AX:@. M#7E&U(%YL(_DPS2(WP_\V$U M8?OOY@!X#"Y4O'3WP@%;0$F.B@-&8?3KNW`23/LTFWP'M6X2>Y1EUDY[!8_M MY5*![OAG%OE6>V89^OPS1LCQ?AGDW&8]NS M0@N@H]HS93."^@'F(358'7"75RP?`N@M^.4%;D@9?LJ5CH6Z6*'1W3G/(;CB"_X7@9XY3@\&V3Q8Z. M+4Y!P6>R5\>5C7(4Y"FD<)U4\&>N@N\*8H326>29BL!.\G=[XI-O?H@.N6;K M=#:^A[-A'8A/CNEL['O-IXJ0PU6$Y-N:%WKLBY55=!.A-NN8^-&L-XYO6R7: M#J*5]*)L.$VR)6P=&"SC$/$]"<9$TWCSEL4W8?HNNDJ>.,-`.WG*_[7W+3J= MO,.=O`-N*_8A;'$%P9&=/!7VG099=CD6]_9E^A'A'LL%`T^=W/BM]\)_OGOQ MY$EPWV8O3DKX,U;"#\@G<"$"9S3@_YLJMZ[I6_:Q2M,-676?PCA*4@*%A9NS M\)!,N'NR7)KM^7T?PYMD>A/%$_VQ[XQ3?CC>>`8;A#$7S_U:]UJ^=:3!.$W( MOXN"*]H!NI+SOY/\*/S^;G8\ MZCSQ(B.X!V6$DY+Q?)6,@W#*D8G)_:[YE)?U79AJ]KZOTU/E]5%NQDG9/M;- M.:9;9-]KMAI6TW)/\8T#1Q8;)H+-N?M4B)K6D07)'5KS7J.I#9%`XOL^R%:_ MY;A':BE^6EYEX7^7\%(?V&SQ>377V!)QH;`?\#[5\<8]X]K8&H&!_+76"/*] M61A@0/B-^-NO\+>__2)_R8/A^Z611#.4\B#\ZQW>+_>RI5B,&FX4WI<&BR3?NETFSZ2I?I^&[85Q,@,UF?X'7_KEWID2(&GW M);-I)R%)A[G)DB'9=J=?.L(61+=&HI)-0G_]/?(+QF#9,N"53??+9@&]/,_Q MD73.T9'\X>?7F6LM,!>$T8M6[Z3;LC"UF4/H]*+UZ;%]^=@?#%H___3M-Q_^ MU6Y;-]>_7(ZL(74)Q=:@?8\]3EZMSS9V,4<>MI[0*Z-LMK3ZR+5]%WG0K'5' MZ)]C)/#WEOS7L>"KSU>C.^OTI&=9SYXW/^]T7EY>3K`S1;S-@L9/;#;K6.UV MW/&O(<1SZ\U)[^W)F[5?1LRG#GR_]E6?X[!G!S"=6Z?=WFF[^Z[=??O4>WO^ MP[OSL^[OZZ79?,G)]-FS_FW_!PIW?VQ#C5Z*Z_?6@-HGUJ7K6B-95%@C+#!? M8.OW_?"7X-2PMR+H)6[I@=B$8#H*4L(3^U MXV)M^54;)'S6.WD53NLGV>$'SEP\PA,KP'#N+>?XHB7(;.[B5O3=,\>3B]:< MS*6T3[MOSKJR^G?7S/9GF'KQ7T2=&^H1;SF@$\9G`?B6)9O_-!JD6,R?D?S] M&4?:XT6ZV)&%.UKM=O8$/X**?SQZH'6RB^'DEE!X8@2Y#TP0V4/?14*0"<'. M+APT6_Z"+!X0QSL]CA+-0Q,>L9%[<%XPI-D,7[H>YA2>_P+O262[O4,C'@(* MWF>S.<<`1T`789][`EVC\?22>;UWV(@;4(1S;WI[`M]O;%_$U$;;+A,_Q MHS^;(;X<3A[)E((VVHAZE[8-JXT'B^,#CNNKI'B/Y60Z/*G2S1#^'(P=:,B->V!4%G0G&`5BIU0R_ MTKT=4&$]9O_YS%P'C-V;OWPP3JJ87C0[.:!RA@L\G3YQ!(/=ELU7HISZ_1R0 MG.^ZR\L9XQ[Y&SM/F,_N&-J72':;AYP9QP+_Y8..WRPJFBGTNCB(@?&1>5@\ ML94=N3(0Q)!/$25_!WW!2!:P=CK!!QC9#QP\./`#Y,E0O# M9A>1?$%T%4LSUQZI2$::?=:">?R%"0FL^JZ%))[0V#4CAZCGBJ6P,H.245C5 M`,CORB3/*AZR3H<5<\ZQ_RI?$4KV7?58W[(49=G*A:#?;<7\K_'8@\<08EBS M*2N70)F.ZR.#*N:#\MU7/28VS-JJQH"RFXB?G>ROR.V5%$\HBZDC0\SAM[*O M0T?*0Q2=#1B58].,@`M@L*=4KBW M5!>^D"US'SM1,$VN(F%P-^PA%>M*(2M7MQS0@PG8GTFUPHXJ7GW'A+AE'(.E M&(*VPSDCU,5+YW^^"!;7CQCTYPF]JI_.P7LR(K&5R_V`B#.@?30G'G*ED<%H ML,JJ!%!SU$>=+,)(#IT'!1*^N$5;)B,HEL%G,!-9KS$%T M>09**CE53'`88>%Q M8H,[M(\55K85,TP]1"BXP(A3`"+6/,%K/"$V43TSC8HF^&BOSC59CS_1<5V/%8"T@=:U2B(V2FCVRM33P\B^M/.)MM M^:-Q9TSE"EJ,@]"#U.LWW6[+>L$ROSCX#)_FG#`.3^.B==JR?`'@V#STS.O* M+G_"2\B^/0:R"BLA8?GN&%@F_E)"['W3B&V8#^O\-%>UA'SOB,CGA(42PJ=' M1#AWC4DHGQT192VS.J'^PQ%1+VV[)F+XL3EBR(@:K0LA*\RQXMEKD*87\,QS M?Q.^#5+OHN>J"*XD7(]'APO#SPGI!MG1NL%4Q6A>9]T@@WH7UEFE5N1/&V2@ MJ&/.*2=1D4Z0/._NL5`NF;:02*!!9KC>0\\,[R=\&Z3D>F-Z>_LS(=L@SUF/ MK$XV1D*_0?ZU)OTJTG>2!:!!LZ&>O'1"T0G]7:;"NF;OI0]]FX>Z?:S;2*;( M*EJQP#0G4V2CF)E,$1C9\&RCHTS10;;H3%DF[+P:1C)$8.C)V6A($[=C0(7' M@X18`1/0`X?QJ4H@U*YNA!LH/$>N%+,S(Y0`K`#@ZFAW-J6"6B:8K*T:,,&& MIR5\F"N'84GL)Z$Y6#!P.*>T&!2'%`8S5C(#8IT*^&$?(^]9P:_ M+'"XXJAR<;XD`G,2!MS18[X"+9@H-T%5IKG%&TA7J1 M5=)8SE19%2FH9"A+!X,;(OYY*T3_J+R;F1P4%.$&6:G8M.R77.^18M+FKO*'&QD[E1)[AM& MNR*1ZIB>=Y'YT&(UJ9$:6%O7< M,&DCL[%RG+_TMM]F++N1J96:;#-T09%CIKNL&=T-4=X5:^;X[":,@J/]>36^ M!M!R0R0E-FS#.UI@3MOE]H6*.C,Z56@H:LIG3FM%(V?'DI2K4K']+">C,^WV MY=:UN7?A`0QU&8FP.48"7^/PKVK.+=.$F?WJ"0;5_#+:J!&_%:SQ:[\LAKX&L10WL029-W_E\B]U=P,JXR"9O`N MP[<$3%;CM,^$)_8E=VF"V<:R\%:*`C48#![@T%1JW,7:"K?:!$+Y\ MRQ[XW\G)#.CP-\0YVG8Z2EH,X^4:.$P$\F"B#"4`E8C6V"^!)6Z9O[8 MF_AN["EESR%:-8W<(B7?UW:U^;XVA<05A,U"1@#(M M^$:>6*](0)D3=W*JKT$9#_L*J%S<-Q%1@P99>3=^XUZU0ANND:>G]Q2+TDM2 MG*6N>^[@P92DI+G8R*/4NTFKO,NWWT'K1@EG9Q^KD9>QE`\]9DT^.F$.Q9U, MS9R.=.53QG]KY/U-Y4.[QY;GLYL$2CG+CTCF^S.E# M:4M^TL6>><>-E(TJ>-7(LYS[#IN"/+=FGC#;2R99NX*-O+Y[/S'H)00ISJ(= M]?RAF5*B.)KV#Q.-7I:1XMSW/TQ66_F#33W+?6BIE,K9V^\:ZR^?WY^\N/A1 M2IM*KB0YOFX<6R[0>;"6)`5R^6'TZ&/K^3 M9VS/UA7)..05P'L8"/`Y?`E\/9]^SFOJ:XIX^\[-F@)=A5;73CG55:BWONLN M(^<;.W(;ZHZA&N#:?'EZK<2G?N?[D$\1C<(8,*8$K`!.'.(`PTK(5['+CVN7 MIR:5$_;)J^)KQS!WI6L\[OB+IN)_"EV9VJ%?K8R)CM=967+AUE7&.2MZ,V:6 MK?5=EFT$=)FZ$>V$>>MGFX\-?%U5?]-:T)#VAXZ$(-T?^/!_4$L#!!0````( M`,^$!T%;[EB%/"0```"&`@`4`!P`<&EP+3(P,3(P-C,P7V1E9BYX;6Q55`D` M`\9\(5#&?"%0=7@+``$$)0X```0Y`0``[3W9Q[@LA^V:ZZ6#%B&9.Q2I!DF555^_"1[B(0`$2%``6:R'LBWAR$P< M>2=^^>O;RIUL$`X/DYGG.AZ:W!Y_0B%VWB;_G",782M$DV?KS??\U79RA1:.YX0P MZN3.\?[S8@7HSQ/ROSV!C_YY\7@W>?_N;#)Y#^.@2(RN>V0:0/DS>GYZ] M/S[]Z?CTQ^>S'S]\]].'\]-_%UO[ZRUVEJ_AY+_G_P.-3[\_AAYG)53_/+GU MYN\F4]>=/)*FP>01!0AOD/TN' M_?$/DZ3QA[?`*77X[I_DK6EG'CA>$EC_?SSSR?Q MM\76`(<=[IH7P?K^)/DR:1TX'X)XSCM_'A-2`)T)LP7YZSAK=DP^.H;U.#][ M]Q;81W\A$_Z"?1<]HL4DAOA#N%VCCT>!LUJ[Z"C][!6CQ<>CM;,F:_/^](?S M4]+]3U?^/%HA+\Q^6IY][85.N+WU%CY>Q<`?3+&\6!]'#[X[6%^,H)YJX?1!@] M1:N5A;>SQ9.S]&`WSBTOG,[GP)M"X*0/ONO,'11,;3O>LY;;]GY2,K%"]`%: M%'-WLC%@5\037+^17QOM-]&A.UC!RU?+6R+8)#>6@_]NN1&"/1_A.[1![OF= M8[TX+M`2!8K637@Z=:CN9OJ$+/(W.1Y=[$V)>=0A![MDY83)5![LF?@<@$C; MS?&3GDWAA@W]^7]>?=<&T?CZ]PB$DRZN%\%)%&[.A,%[RV=LP6&?D^$[V9SB M\RA$+G+=[73EX]#YBNQGA%=WOM46$?J8*F_&EP#]'L$>O]YT=%.(3:%$P+CW M0Q0\^SLY*<=_P$G^P&#O@=Z`/FS((3FG7-.'"L6E"D@-"US$UN?)(1S02G-,(S+,/=%!@-[<1E'BV7EP]=$AG[I@*.S$H M/X5='0#^5#KQ[&*112;L&&>._-F[/A,5L;:K,\"<)L7/PG-1%!EF_,Q!0.SWW\>H M6ZY[-$D'+B*RZ^5XX8GMK$[2-B>D0X?PP%3$&NE[QS9:6)$;RD&WW_TPL/HK MR_$:@YKT[A+2>(;C%5J]("P)9JEKAS"^PA!X'KV@XQUEY""E#9#":^_D/OQ:/_[D\[AN8PP<>+H-3FAX,V64?VYJ2W.QQ\SS`L!ZSXZ^ZAB2\THG`3:8L"3OG[ M`\&SO00"8&)9M-';W]"6!==>NX/!!WJ=[\6*3>S\"F912$(_2$P.&UA>IT-! M?I5*,PP8KXKB2O?0W#@NPI=P[I8^9J]RN=6A8'M$2R>`W>6%]]:*>32JS;J' M[@XM+3>9>_KFT"[@:HON80)-CNSBI^WJQ7TCX+[*\$F%$VI4^[ZR8^MA'^>'1V>OKN%/Y!ZUBJ_4`4561_/`IQA/(/ M?2\$)WZ0K.E04@C84*?.J MC"#O3L\(.7J-646JSE%[WWO4&`)0CN+Y8%#HUGA M'3EJ/_0>-;H@D6/XXT`PW!/72*H_O$#P['0B"?,4M MQU>3@$.UDU:QIJKL&9I[VD&^276MX9XEO8H00Z,IKURFN,KB\\M)V4#5@2.5I$+ZV^S(O#O M_""X\3%REEX"]#SQ@KI)G)C]?U$0APO<(]@_S]8;>W64SZ2%8KL@P@?+L6^] M2VOMA)9;N*59!*COJ`6?($!A=>-6OM0'U_2%B*%SYI$O-]('9\W-5&JC'4HA MHE;;ZH#ZPG%=%,<@$1`>T1PYFS3"@PHYN[T.Z$EF$`FA@A\D>&1CN7%057AI M8;P%X2T.,F-@(M97"U;Y?<5%H-I,!ZQ7"`/I2!I<@<_>^]Z<>UKK>@W%[]&< MKK_ZOOW%<:MF\[VOA^59:$XOMH1(:Z$90KAV]L,?Z\&F=S,1EQKV)]Q=,VY\ MD8/2T`QXQ:EO@@1RYWM+DOQ$@D!K"$YIJ1OB6E;':*P#[E@I3$3/6K#I;;5! M+2-<<#KH@/\!HS5HHZEU(C-.B.@T(CWU8.2O$0ZW#R[)TDGBMM>IU8")"J>+ M#AP>$5QYSCQ$=AL=0G84/9B&(,0B^]K"'@`2%*Q$I-;/W&&MF4!''?CL3*E[ M1OT*_)2&6N&E!=,Q&NF!4U`B-40&E98Z#9,S/WLO)5M*D!M3&`CP>AS>U<:W M(A(W38UES&2/MSAR?&9HLLM;'$>&X&BRIUL"V%L:&H;86 MD1(4TG8XOSSK.;[FQ8PK67>& M?3?'V[PP\'"!9:8ZDK-T>P%MQ9!D^*AS['4Q)OW M\DSK_17EV[CL)1A@FJD<0:J&KOQ"-E<)W1OF)R1W(Q,(F$&)B@YZ=/M.5OIA%!9O70P<&F2$F M8QT75N#,`;`KQXU"ILY6U\LH34-/9C9,3`Q^,R^/E[CU`I!.XC<=[E'X@%'( M+-(BW%T+;G"18,LEV]=>P:U$#%\$P-V#H'24:GKIP*1@F(4K/GEC)X*-/5N3 M]\[A3`87:.'CU(#[;+VAX)/CQ??W+4B6P,-(,']YE,3`]PF!E`+?;%!BU&6I M=(>$0!^%`>YTF2]@%RR8R62LUGH@3\C+W]755GH@S=8XH5\&$Q-D1O/1'I,0 M"&[7_$`QB%ANHP5*D.&22\);)J#P=RJ[O5'0UZ3GU??3DGV>@91%%#&@WV]G M!+0U-&>WUPI][1FEM=16FT#VN-9TTI0-CT!;)@D:5^3]\S6MN' MDQG^#^0L7T'YFVY@PR[1?43L1;-%K!\6+#UB"F;#P?I@E#?`)"]@TA/FST4+ M'UL0[4.::4.4*UI"'U)^&F%:Q\7ZD._3"'%Q4TX?4G\:D4!HV"O) MJ#PIIP\)/U+XUEKS^I#F(X4QUVK?AY0>*6PINJGV*/DQ)D"U:[7J,QM.``!G MLP_'_4\U:@S']2\@=&CW_RM#]J!.)9.?O&I"-HJGJ`\5P`2/0=FQT(>R7V*( MU481]*$(F!BJ3!F="1KG^IH,M/HE@&6O+P*GV-D!>@*)3_K_*WM!QX=:WU-8_E6'$SJ3L^> MDZ*#NTR[.66TF!U(%>N])4G!N1J.X8DK96LW.8TJV8)4>KUQ_2_!+:C-&,'N MTR`)Y#=^\.P_(KCOYHZ+2E?$LT\@?<#^Q@&\+[:?X9J\]79FVRGPD4U2K*?F M3<8_I5H_2KQ0+NO-GB M^FW^:GE+]`@7X\RC;R$&2E)##,5.-"9F\7%[@O6>+4JOCNR>'*G%C-M94Q)1 MZ=J\]2IE2ADHU?V9LD]0^BB_75F>9(BC4R@2\T&7T[ M.P,234U+:^45U32VXT=T`+/QJ\O8DQ_(('R38)L6ZTD;P&S\FJTG;R"#\*68 M4>3PI`U@-G[-UM,T>U/7OO2UDTQ]^L/Y:3PQ>2?@WH\5Z>I=Q7I#5*B+#N(E ME9C_YI"P0FYM`$I#/?!N8W5Z5WL6)%\_8`J1S.8Z87_VIW/0FC%BOOU9@XW` M``JV.`P^1\B.HTQ)S3$@'RC_A5I=,.$_+(RM?0N4='%3=A3=F#Z"3IB=\?)K@#3 M/YSPE<,*FX^C+RZD2U]^]GR8\%77A["BK@DF[WCK0_C1H:@FEJML<,[/N<`>P)EJF#UE\AR(6S<[4A]0_>9=M)7-5P*'?A_HX MJNE`=9#VH4J.:D*(>PU-PA7N*0 M`N;H/I0@4D0-II]'>XDB+3M"TLRM_>7?SHDD[Z'JPT/UZC>.D">H#T_9JR&- M3'!63A5SY?+FP3NTVU;$,ZV]7,GAJ"+C:.M%'5LE9)&)A^M%S=O&\5(B:C04IIY^Y"J\:^LEHC#E5S-6`E1TGX2#-G"KF&:5E8@4SL;:A@W9' MAG--9!@K42BO1-'BWC370M`*>ZZPDF-OKFV@%?9<;2>_`,R5S`6K1DHE/^=X MFRMZ"Q8ED2HRD.-MKG#=!N^]DA$YPN8JY(*\3C18+$?97#F8C[*8!)3CJ4FR M-:7BCI8%E`M=I+URDR2)RA9#.W1YH2LG(-)CA-%3M%I9>#M;/#E+SUDX9$]YJVTX"<($<6NH0`5@V*1CL;-`3FDKR=$408X2>JAG;G)H\E-1@@0X*`FLKPWZR0D++;<*^*0&T_/9: M".H'(?$O.:N7"`?D?N._X<=NK[-\$?]Y^&HK+<5]5FO7WR(X;GCCS!$]V@Z8 M)E%UD#W]8F$[>/;)[5SXGA#_W@__A4)B=8-;["O[5?;.YAL4]9*3=^/C]"/2 M[NS0)*4#,99GTOU>N"E%*JBLY\X!/F*3`8FY>ALM>>;I@PX[^]M38F-DYIPSV^N`_I$L-$9,T4")FYS>6@V/#U#0(HE6L MV`93SXLL%YCW`CD@S<>&2\H%W/V MCX/5/H.LEX!'+/U,K;'3Z520@V=0V;,0%A$3Z]@UB+0T8\%.W8=4HX45N3N9 MMVS%J[>&5!ZS;7&7Z[=JHWA9/ MD82+^%14I3YD3*F0&C-'$E?/U9Y'MQ<`(\\/=S%``BQJ@`$RS0@FH*%K?Z9' M.=("'@>3BTRT6^D]4[_)E2':H]0FYRJ8=VNT6U#FYRP0<- M6TQ(93>Y[D.[W=6AW]+D8A"&$HWAKC0Y0:L=)>LKK1B8?-4.946!/]KSL&K# MZ^3LE-CA3J>;*1; MH\FD7>5#C"#[%>YL;+FD6*:]`@9`HMJ)7)7>7MPX!;&^_8\N4Q8H@D`P(-+* M%=H@UX^+)(C06:2GEMB&^2NR(U(#0LT!O=CF1Y03E=7YM$.@);

"=S'3J! MNB,9IV0X[&91!NBC.N"BB,KL)GL_#B-%5>(XZKF/R0[!PY-,4#32[U`<;H0+ M+[3K4-*'M-FZP>8SB>:FXT/1I_#'0!9F[4!V>*7 M<3F2X-;;Q1K,%K,(WQ$QX[Q8B%E+^FOV>$I:9X%DK>]>42D`MX,]1Y"A/;4: M)UZZTC..?Q[<8UV_%Z:,7@$[+(9924 M0-XC,]<2+S?&-X%E*S=""SSWF0_O8#%:*T@3,/F!G3C.7[K=1,'&NIQ2T769=3%[K MT9M9$)TR\FSCS2/FY*+TT8I%:8GCXVS/O$>28HEA&UY8@1-\]OR7`"Y`HAW$ M\DWVO)D3'_(J3F)^EL[F':FI<%XUM26I#(/EWA?HT!5(K)IWG,9:$G@H]J>" MQ'&/P@>,@'DS-HUP]_Z[YZA+_T#$G&DLYC!9X'Z;P\NA+&:X>_9Y'P_]MEEI MBWC:K"G:'@:\\5$JI(4B\.]]@/*(Z@()/5 M[O#3;(W59WJ\]%N$(:EU=;U4`K4WG+QU'^A;DK`BW"R#LB^07OA<=0F M?3:`4HD0._]O`$VF,EQMH6K29VC`5L'WFO3?'*'&_$,$J]*9N-C>DXK'*+EH MDH]I"#080#]^*6A<,RBO1^\QT!1)W/5C9-1K(58,_(4#ZC8(#(2!D]*.3Y8+ M>Q0!4R>!F2%V7J+X*Q]7&2SE&FD]I`JT_!`%#]:6L-7I5)T]T633`6-W1J]VET@'U[U5.[1[<#JNQ;2/6'F'1[UD74 M7>V9?EWL?SD;A?X'D8:6D"`6.25O_&6+=A7#I$DDX`1`=4:!OL0Q"5B7LT.] M[V8Q^56DI@@6G5?ZGT`2.\=]>JU7Z?/#?3EE#1\@-O#9-JYY32B86-?[?8)5 M@47,<27#3ID0^G>C6"7>5F@V.78:"XV2`+I7WP5X`_+&%TAP1J<7<@R_[/8Z M3-=4:+@&=UZ/WF.@R8%`A>CZ#;10)T!QW.CNRR#]5FI[U0UE#,[92^7YDXZ7 MENLB^V+;!GV)4;50`K1SWXNON$MK[826&Y>2#LA[#7B#R$NF-Q$1>6^#("(U M6EBX2X\SS-BU&VXEM\&H6O()Y_W8M>ZFZ>/E-K8SDN,5T# MTXL?HN^8:'O3J3AD>TK/GK&^>%PXK3L!AI5&P&JI"HA;C_AFG`TBI_OY"_R^ M_3?"_A/:((_)A$5[J@)REA20++A.GQ%>L0!CM%8`3"K@7K^M'1QO[2LKI"T: MO9U>.TZM9EV;5=DSBXXJA/MB4A50W4MV_1G%%FFPVT(6O8(289+7XEOPIG:H MP61+W('(;!)5*;NDCT0U_>KL5/G:4554S-+NY:)&0@K(S25,:5+M0`,?!4G3 MPC)I>B"D[.9@"?*FASQ*KG0'1@K3PQ\U46C?,&%Z!*7LI='6L6-Z-*4*>M0Z M]_3'4RJ[1QDV".WA)$*I(C5VKYYG00E@)V">P>$&R=\BO&/%+*=3WT^'GZ`P;35XN&ESL("A6 M:V,"4<;@&^.#;Y@%IE*--:8W44SCY];CFYKB^*CIH#D>*-$9$ICJHWY*K540 M$R.X^V^L>=T#`8R&6HA7!(57](C24#^\_+A%6M,>PJR)0UVAES"O.1I7]7U: M8V39,^_O%G:(+/BX[QR5[:T?LTNX5K<@Q%&K!PEUT8_#K1O4L_^%+!H+%NVIYPPL$`9&D.B7Z-(/PN!7[`?L(\!J M/[B`Y.-O:%C['_)7DX!14KJ5R[SM(!/>G" M(?:?Z7Q.B!D\HCER-HQ88K7CZT+XL_?2,M-22 M^O9Z*KM[2V*<(>HW"^!B$]TPYLSC`EG$-';CO"&[J#4(8"$PB-H"WAN$[YP7 MG_TB!;MM3TIWTR>64#SO$:U0O.P("H!^1!O?W<"F*!Y4)MUXK57D8B'/\7'L M>D1VY3H/R]H@GY;^E46ZB:E%,&H?R]OJPLX<`;D4I8[W55 M]Q++H*P)RBF&]PF017M(HU@6I4JDS4@'$DR791J$2F&<5-^]23CR$F0;HVC& M0@KDC')"*W8UF!EA.?FM9%X>@0Q^,D+;#N=S_1N7E5A:YW//GX=F>Z+U[]W: M5,_V:)I^2,7"!3(\*V)??CIU5<]4B1@M5_W)]N%T%G/B4-QJJYL'\JAW?(CCH6P0U MCNE2W?U:MYI)6/.>'U"(M.E'5-8GNN,^%5M??D#-R_!MBB/7[ITS6TWU?/8* M94@YA.OV\'"+9C0G4\DQ:')5#*4[@>V%-[E@AE(24`+,3"Z%(8U[!W%?)E?` M.!Q]>&%B)M?$4'IZ>"$N)M?$4,(H1*(SM)?-Z(((37S9VHN/=4$(X23%/A3` M;(D].PE0?WE,Q?Q"..\KQWQ`@B0O1S)'>$!B8TV^5([S0,3%VBRW'.,!"(`[ M7Z>R0FAG`Q#Z1/.=U[N4PI$7 M<6A^N''A1GC5R7 M^)9P2,JK9Q[UYH58]1?$49,&=?T6@BH%J_I*3O)L04[V'NNN9#SQ^XS5,_J9 MVWJQS>RFTY<@?JU!`&I*)]UXI``YY)V-U"X(F@?H&-[<69,RS,04?.-'U2RK M=F/U`NLX.E<5VLE@_<#[BZ\,:QC*<)P3'[!-S*0WP/\LEU+S3MFP6E)W=S7F M:9R(5_U`I.>A0\B$.'#)VRN"_H"#R:0)5L?E]`=&#"W@6ND@>)&2_R5!NH.1MC63$Y$G$S/=5KN'N998+&GX.K1G?P]T9//OIT[*6^Q1:(4J,-WAI><[76"$&K`+?=>SDA5W/ M?L`H("E@Y$]B`MWKG"O73:-$.,HAJ M]=_]AEKAY>J\Y4:CUM)2:V'ND1(_K*S,D#45(8*HOX:T*SCBTC'UF/;6ULZ6 M*)Z8+"<(KAV#QXAU'GGZR--'GCX8GBYZ M98R<.ON@.<=N?@_&I5=(?$DN&X*HV(I+M1I2!R^XM`)2>83\N/X]#NQO/6`SZ-EZ$T..V;S_:A?C\352.:W`1S"PX\B;)URW_F*1ZZ]C`SRB M#?(B!(#ZRT1J$=L)]?WTO.$&=QRI!VE?^JLUB(:)$6J=R@:P?8GC>8,>7"L[ M?RR5K,%(HS[/NKM&O3V=JJ5=FU>&1VJ M1U9[.)$RS%K(J'U(9!$C@J#VW(=D%3&$J8JU]CR5UN@U4MGU9V2J6E4!@;L/ M):D%>743>;P/A:C%T&=KUWTH-RV&8ZU=J@_%I>MO+$E+@/:ZTJ./I)F/)*9" M"P^)66914XQKRLM\K-:NOT7H">&-,T=T-C-U8UCB**24W7Z-ZZHZOAV7SZT- M@^ALOM%2-$9.C!:8P5A@.KR8M)MG1D&B*DCL7E_(M=CA14.V<*ARR<-PFG+[ MC/+/R,%'#CYR\"XM[/Q+:^3"_>+"HQ9O,!?;"X]\>^3;(]_N/=^6OC1&OFT:N,WFS]\2%SLDG,QC MP`"9V7[DP2,/UL&#V1MXY+ILKOO+"9GBQ0H0_/'_4$L#!!0````(`,^$!T'& M9!C0H$\``,7Y`P`4`!P`<&EP+3(P,3(P-C,P7VQA8BYX;6Q55`D``\9$5#& M?"%0=7@+``$$)0X```0Y`0``W%U;<^,X=G[?JOT/B)-*9JHL6Z2N[IG>+=GM MGG+*/7;9GLDD7:DNBH0L[%*D`E!N:W]]<`!2O(@74"())0\S+4O`N>%\!P?W MG__ZOG+1&Z:,^-[',^.B?X:P9_L.\5X_GOWVW)L]W]S=G?WU+W_^T\__U.NA MVT^_S)[0@^<2#Z.[WA<<4/*._K"QBZD58/1BO?N>O]JB>VN.78;NB??WN<7P M.8+_.\CWT!_73_?(O#`06@;!^L/EY??OWR^P\VK1GB_H7MC^ZA+U>A'/WZ5T M']#XPIA&GD<'$^(+-OF+W^M->?O!B3#\/IAT'_ MOY*E_?66DM=E@'ZP?^2%^Z,>KV&DU#Q'=YY]@6:NBYZ@*$-/F&'ZAIV+D)(; M*HFX+3WV\2RAU_N74<&S/_$R<(?WAE)5?@^B(H;EW]\N7^V MEWAE]8C'`LNS4Q6!6%Y5X^KJZE+\*DLS\H$)*O>^+4RC("`J+`%_]:)B/?BJ MQRT\,"[>F7/V%V#X,_5=_(072,CP(=BN\<GNQT506'#+C>L]VI9:TG$!2>,2)U=2O'$ ME^"7*0'Q>X`]!RC+;Z%^B:$D>;"Q(`ID?3M%T`5K^S1794%K8;&Y(!B)#+YZ MB=U@IT1/>J\1*1]^_6UFV]SQ`_9H;:VYBV\VE&(OB#@)_3Z>512^W,D-Q5.2 M4\S\#;5Q+5,`E5H2?'/G4&'E\N(0:[#7^^WY#!'GXQEQOAFCP=`K3\!C#KYO52DSI=1:TLE39D;3GF51.Q**?ZS0 M)BQQ:?L\?*R#7JJA%M1?57I*Q-M74OZR%A[61#IY?SSH"Q?G7P!UNL'.[?L: M>PRSF><\!$M,0R[WQ)H3EP0$LTS3U*O;,``ZL2C=\NX:O5GN!B.+(7^!.&W>X[K09R"VQ#@0_2'\XL]=\BJD9(AX-O!W MD.4YD0>>HS6F@44\(!GXR/89=\]@:07(HIP8UW##VW'+*R./?Z:\!ORPH\7[ M7NYL`;7L8&.Y27[GR*?(LKFA-JZ0AN<=*"`K+/@O^(_?E\1>F/`N&7Z=8_X]#]X4NN3;=PNZ&J&$6_TZ")3>&SS.B+;:H%$U\!<4]GZ[`#&M(D,"F]M;FP8LLD.M[KYC^"*D% M\R-QF:ADO;Y2T6LA.VI=:P60.R]MW_/__PTL*'$MDZT`11A>6Y"!NEOD$&:[ M/C1HV`0I0VENZSL/68Y#@,EYILU%`P-G!R^PL#3%;]C;@/*V_^J1?V!I1&YZ MCW'KBR:V*&'`RME0T:`)92@6ZO!ON4#$Y^#XE*5,.(&=EMORX$$Q-*HPG;4C ML*:^L[&%@W*!WH!(W,Y1H:7%]EHY5.@"_8(];B[7W7(W\]"M%P`-*$`=MF^* M[TM>G021GS!P148<87#>;M"C<>GL#0O\%7>^.>;2<-O:2X+?1(M(WT M$$LZ_HJ7!R];<0%!_(@;5W6>,C\1OL^+K$!*:'KTRVSV>-%*$I*75+76ET0Y M%E!&$6G$:2-!/,JV4()\MYE7:YJ;2 M\M;88";L+D+1_-6:8HYRQN'-1]X MR+U^Q<'#XL5Z+T[9&^?4[3"J:?$5AROF<#S:Q8=(AB@L)*5`4@P$9;[:!'GSKNQUB2P7*[2RO>>`]_^>Y%'5E?L,NY42J/D[L.KJ_%@&H:1'4D$ M-"$I#JDB218)NIKB0:/ZFAE]UYQFCW@]6U+5"FEE_TPA5,T\>@`789^]^$\8 M3$!_!N++1^I_\;'#,[U%L:"=]Y#-&";R3$,SX=FO'13@R1$B13"?XCR((B8=#U5H[B>>#8"81BB=#7 M2*;_UA5#])K7S)I73'=$YO6X>5VP*_\6/MM@VTTX81)/7E@[$3[H#5/MH3H= MV%IJ,RVAT!7$L?.\M"B^AK572*5X'B6RI'`\6.2]:I6[#%=*$JDAQ#`X2,(` M%)%%@BX2A%&29KN6\*Q>HF M.QR7#-L7K_[;I8.)A"3_D$4B_^K;C$<3!R+*9]=ZS;3Q_N\=X&F/J6(J.YF8 M@Q`R46T$U;N%Q5'2FVK2M^WAA6X!3IROH);^PPN(0]P-[]#P,[8W5'1KM^]B MO<+YS%4!5&WD2D-N50K*VR.,X9[0*!>\,%RD'2#EVK)@^SZR:-DH7ZMQ3:\TE#*^FP_$T MZ;'ZYU4.UD)V#,_/MR_/^MVW=!IB7T5][ERQM315IG-GKK7GTACTK]*^W.KV M4;4H?(`&B6`<;?,YE:!R-&>Y9GG/)-7CRR(;7$)Y0YOGOD_ M^BZQ^0CA!;\'UV[QHO51)#O$U3%RJB[!F,98PD\P@W%YDIW85)=@B&*.*&*) MO@)3)+AJPFI7AC)C0_EI0^D$=A,(2>+_:&MJ"1/$=6'^7&[V?A);;F$+>=$` MO+A\EP`O$D+5*ML*ORN!2F M2LW1P$FD:XHM>_FPN(F/.\`^%R)6B6??+>H\BHWUF>:J5;7C/)PB+VCC2P@'IY$0#WD;59S3*$\'*1@:.&[KO\=^D#BD8"$ M=3&UX2.S7'%XZ?FE9P['W>ZV;\-B1L)B/#M(D$8Q;22((TF]^[WV;>@M8L_S MW2\S-,]UE_@L4=I=*IU#U\;\NA$BVI=?R[A:NOX-(QYF;&;_SX8PL>-/?*08 M?_)7%LG&%O5Z7:8"5<(H]IN#J1&E!"%%E"")(IKHJZ2J*V%O4ENS2-MS-74[ M2QA4_325."A9ZE1@]TX*\^V"TIHAQD50W2(]FDQ*@/452)T0FFHJ5HBA$L5T MXB;A:%5HB2RA`R.P!Y./G>&?6R[1&^_^^4AF%D0'X7^'<_`%K:I6MT/\*`FD M.$/:[X_#C8UBMS1,,XD/"<)H%J#=A0&"=BOHDFG;K>>4(:QQU8<[U>'PIMC5 MC&/"Y\@*$):GQ]?MY=22]'-@T:!3Y4?5RL_Q*_'$L?]V35`96QM7WBQ57F>< MK16LDE%7W48G%(.+4Y62"OJC;8U^W1P-JT*LSJRE&073<*JAH&94%20P%48Y M'?S(,?^=9U-L,?P)RW]K-74!">T8RY=+<40ZFDZG5:B3#%#$`44L].SO:,L( M8OM'1(")ZTC^[_1ZY>Y=C=@2\YT0AF'U;ENU6JY65S]JTP(I>FK_:M"OA*N@ M?`++W(TK7MYYGB`J\QU6`8XY-FI@T2W#Y0M<04:";>%*6WGYCI?72H51\Z)! MOV\8T=5^:>%BA;"&M/-R-.M$]5*%[P:TR^.`"[A]!Q0:A5I5SSN M[F*]2@ERT20K%GN1I$ MJ\:"$BP:A[30`Y7W4NL==S:AGQGKY\?Z^=7Z==:!5KE>JM,L-L MAF[TU%K3'$_&_4K\:%V];4C'*@R=P)*M@AM6XDCS,FVN3+?OL"&%X4=*;+S[ MD86_UNJ>JDCIQEZ%?*H[^L?#RDXMXH0$JT01MBNC:3-FVX812([L@2,SK('P MR:%7T?4K8:UBOI/!^Z]B!^/#(CY%?6/!AM3K[3'0KT%5=Q10%U5U+6\X-JH" M@F0*/R7N1)!\X5JPDXX.[1@L&2@8(HQMY"7=:Z[4$J;"Q64&3.ZU%+`)05Y(:Y,@KN=]#U&`Z-+#; MJW@3^(N/*WCB#!;G@CUQ;A'.8.6U046-KK%9+HZ:@TS'DVEX`"IY<,>3IP9W M%-%70;.=J:5"Z#:GH*%5P7)D-Z>E>8R6G:!=#7,[["N81DO*NY.+907[)-]N MVE!;F<.QED8LAP/C3FO@OP*N_11:5JVGKW8IG4'&XXF@P&V2X^Q^'0UWOQ*#)0 MUM71-Z.K0IAI75?%/K\9A:NC2:7"W7;_U?#W//OV\@1OB_N9>G0Z3@=J":=ZGWM_-(FA&KV9LWM(1S+9O54. MSW$AR0=%C/0E!:W9PTS80X[4:4A6=SYPD)]G4X+Z=M,,ZT>+/M#G`"[D%P>6 MHFN$JWVCL*8>Z!:)HYJT3HT\L'*J,+X`\1VNN]%O1 MT5,-D*SRT0(0EEJGH60\8@43=W=B8:\`0`H5-"3@Q=(H3LL,S>DP3KUCV(B] M())BRW@IR[F;42\G*G2G7F6:W8R.YIZ.X3*UMNTLZ@A+9M(5UM##3V=:U8,Y:?.IGF=:ICYQN2T=Z3'Z)?3@8;[.:Q2!35TI$7^ M5]"!YEKE)"`DH:W:KF%IG="1(JAN&C+-<3%L)*D3@4Q]O?9[&OD*#FE/K3=, MYW[KBAG%@:!8-VU!((V@T@"0,,5)@%]A[U59%9UAX(!]2,:H7QP+].^V:DC# M8NSXY2IJ`U#5+JLJPVB&4ND=7-EB>B!3YY(AF_D)&?W^>5_^MY]Q_H2&T_/!<'1^-1V*U1+^ISD8GQL3,]TKB1\3 M((-[J/Y]XV$TZ)\C\"-1X!.VL=C6/3#$M_S_G,0:PX.ZV-V>"#*+[VK*:PQ- M"%Q3O,0>XW:3[Q;_BH.'Q8OU7NQ'A36ZQ661&*IW+PPF\%']8 M($Y/TX4PS2@XWE<07O+6#)`JG\M@I=00C+YPO>7_&.4FX2]!?\ MKX6N![.+W3V>MMQ3MT&(/:SEJ]KRV%[N]2P%)36!+B.&ZN7U5X-I!GW^.GPL M/:34[:,$#:B3QJ,DM#MNJ^/ZE>-5$@"5JZ@7%+* MPY[P&_9*1G.98IUFC6G>RIF4,4J[/^R3$11T#>8.UT/X?(GTW:6!^>Z2SOUR M]-3CVXRGG$^8K.8;RF`S_.W[&OKPP@8J*M^IMQ<(H3CV'YI7NRR,B=%0DA8* MB>E"0`.ZF3O=:$A('H3V%PN&`[$3C#NTO)?/X1[H^FN1PF')2O,HJL(CTS@J MLU8CZ=V&RF=HL/,9[[WWEEND\X0NS5\U3QA-=INY.0'YS!!WDP4GT74*=[@" M1JQ`2`$!"1U)V^%*R(?H0O&-RP&"ZUQ]3P0C*^".ZN'MOS'1,@*R`%.N\'<2 MB/,CSN5RS-($+BEV2/#9LHDK;C,HGN'(+]@U1G.E4`OI5X/^ M=!0B59!!,1U-4Q]':V-HT*8K9.:JI`V7I?C8H;-8:RW):%*<;=E-EOL% MNTP_][@K#E.,T<3,<_VMWALKCU(GQ^W+U.DLBRQTI53ZF*^Z?M\OOXLRKZ@V M_Z]U,^-PFA_\M[KOG#Q2I7P4G,(5DR5N58R$1BZ59-B^>/7?+AU,)`SXAZSW M\Z^^W6PHY:G39\)LR_U//C"]]9Q/5I"=@2@MVH'WE_%7?%)F,AU$\5\20I(2 M`E+H%I;_.;%N$="46N8A:K6-`A7W`A14&J&!$JA;N^.Q30W1%.^.GXY&IASPO"PQXJP)Q8AG>3;Q7MDY6N%@Z8MG\*R53P/R M#]B6X^`%%C1W)4-F8O\.):_\:S?BP66"U^//Y;LS<.$761!;6$KP`R&0[PDQ MYI8+AQ$16V(<7*`[#UF.$[XDFZOC*_699.OA`*VI;V/L\.$^=VU!D(3'&[/W M&8HJ4&`A)O0Y.1IR4M$-`7:XFB^I(X2Y$_C&I`6#2#B[N>= MJR8(:QM['A#IH@%I72/IR-1!QCN/!51$Q6N+$?:\IMAR'KS?+4I@UNYI/WVI M6[O#?%Y1)-5W\\;#:0*6,6$D*"-)&CUX*"*.GCK/>EI4/03D.YSI@TZ%QR`> MGR'POD7Z4DWIT($>G!PGU#&8?G!&3X3.5M!+*_E`IHHV&*;E4'7`?G^8C[W= M4\>2WBF@[7`-)<0L$N[0AC422N:;0("+IX(`MN_RVM73@5F^+Q9C*\<\^@%U MY_%&QBP`C'_:4"Y>[FMD-2MK`UF11(K..!V95_EPBPB+K@U)TEJ>\VI/;U,^ MP!GJ"5T:#'0H?O/=-]#6A6NB8&0B9I9.!X=5+ER,R%*KZ4Y7C*`]:S0TKY;@(!"9LW186E3#C%F>'*H7B1AF>"?ZGOO+IY];7$TLF]XY M5J5\1+>N4N6LS;%ZF0?IU=5,31EVDM,RA59H"<.Y2Z`5A4\`QW76#JM@N;Y:I6C6LMC;G&ZEB-:XZJN&I3)4'[SRJX#KW;NYL*SVQ?<">$H; M5MHJVZFXIE;$%XJE^D:R.1WGPC_Q!C201H*V6-8!ZAJ#02,:YT6&?(UG;6I< M(TXTHG8FI8?63(^1S^.WL1U-,\0'@#8_FI1;3-=@^=%WB;VM>E`AKV3'P^,, M>^7KD8;]!+HDD1-X_>!(C:*#7>'$TGT(FG"[U;]:J_5/8L"/[CFN=`^-"UPL M.R;.,X<>5,C=#G(%&<-Y&O8+[#LH;,JB\ITBI$`(U3?6)]-!A)-PLT=("@E: M2!#3A94&=(OST\PF%KWHJ'"U-$;*S*`3*?*FCA?K/3QI=HT]O"#%BXOEM32@ MID`4U7N31H-I!COAQ3*<8G1T$H4T]4*H`47-E*)$*AI8[WJ/2"JZ8AZ>RFRB M$U7E1^NSI32@IM:!=,,T]E"B]5S]$5JD(4#UGZ\O<)D\;]=]NOX37E-L$S&; MP,<_,[G+-&]R0:5&IUY?*(9B'C*8F+O=F3$M,:)/4M,%AT;4,_?4@T&]U;9Z M"M?L-M5^U1I&=P;HC0B5,$M'AW+CZ(D4E+Q9<,ECN)?7 MB\GW6\\I!W4WAAJ"H6[E@8%K>6BA1:6?`XL&IZ#V"-2^QJ_$\RHT[RZN'1\4 MTH'O2$LVLB04R9#@5WA[0UGISI=^"D51?&'Q:MSO1\L]NRB4C#=:+G-H2*]L M=.U,KXIEG$:4,XN5T[=*4XFC>&6FW`AZ\YV$3+_Z\CQ?R5;]\EI:LI9<410[ MGL%P.BF%3DQ1UTBI,36S(")QUW,:G6RI)^;WH\5&::*KW'6^)6_7SL(SI-"5 M+WRZDJ.:.1/7"^9%Q..)=MWQ'BVQ\LVIP_#8<>+0:`^5/X?<0S%KE."-OD;< M.^[..[66D;%6^5O9>BQ5GB!T:BZS&^?J)/]H+#CMTI1FFJ+1P+L;"'W!%OPM M93HXY!Y`3ENPK2^K.A(&.6$V,=F2Y'C"`;9="V5#:Y%]3CJHMFNB_7#:L!-U M&T@/#S;[(?1`PS<;/*.])\E+*8X(GO7)Z0N>M655]_MA7O#,O0#DE&-GJP;: MBYWYYCGMT-FJA7)"9Z,NU''D/#C2Y$3.P^S>;.3?7$Q75><+-A@;_B35Q^5N(0"MIBCY)XJAXYN>KOA2!_ M@1(S\6PP[\%`FYJF8?`U,[#932H74*&B+2DKBJ?>3XYS$ M2+#H"1XHR62W3U][?M2X$;*1*F:@Q0**<:IQ,^SG3$?Z0KYR#:B;BI\K#"44,^K]K0%U(W%^/=J-94_8SJ=( M?&(+???K'<]/,?[C3)S*Q]=NQZC-*,%YQB9LFMOW6N87LZ$0'VO,3G$HM51< M8D4IXW:(0^E%X@[[,A?+OK"-!Y%XPL:*[MD/OKRXT65[N'LFGP['#T%V6+L] M;,_19]J0=5;(+#3TB6VI`OK'EBR;&_]&ZBO9L*R$"!\8>4$Q*8;G9T2K?N@#^^DVS-OC*%%]62EA*'BOGO.`Q),C#KFM:I% MC0.OT^'(0V2K:M0Z](&,$Q3?R?^=8/]1\)% MM^VJ&_!F;OS3U!.G1(DU9S_2/, MBHH(LRE%&Y0>8@0MQUQ]RN>TEL\F.G2&=PT1I4;LX>2KJ*5U7^W"JW[.,C)* M@QM[TNGJ"A)I$$'HL+8)<$AH+8_35!Z;EB\UI6N3KXINS]8?"5G-5V%_MFS9 M=$QS`[@.=^C;<%;;%ELTB&M#S:2#*/CTT8UH6;V8H(5E9]+6T;L; M`AK//R=8U4"V[BV+!9]J6#$LJ^HL1*,[08_Z/)Z``IP@/XQC="*RQW0,R`I0AJ99K`!EHJ(QH,RLX4W=6X`H:]\2[:'CS]V M+'V!MH3>!G=N3-M:`?UF+90WQ'BH#!M8=LES#;5 M'`B`7TY^>,'X.XY>O1T6DWCYPM"-SS@@/VT/W_`N/`;T0C9?[[&.1*I]N*%& ML>D&^F7=&"*;].A5C(]2!O(0^?K^6LX$]2LY&V(S@;?T@MLP'(%&';5&)3<" M/Q15&K97J36'-0R62SYM@&_W?MW>-WP*HX1*(VW2/?!@[\X)7DM@N(">;V:S M87PA9X@WTH1IQ3T>!0_B&C\8J_A]^4@5\/MWE=)/.EJ/^24,7G%,5MPW;VZT MCQ_#Q/6+?ZXZ,W80YPNJ+RT41B*L.]2-2PFHIL-2M>-L^8 MC%"!6S3]D[G?SI^D5Y_,'MFE?WNB3V94O0`ESQCQ-FY_2M^M=3Y6'+K:&(9/ M,F$)\!Z.'VD9.TG61/GOEM),2H,:Y]HY8E#)*(7R?;XQS_P1:7^RG,V;?=Z<.-\(V=1L.$+2LD@1@<1 M0D"VW$4>IZD\UFQ;94HE&Y>*;LW6PY>7,&!5G=AT$V_/24SO+7G!4?VM="_9 M18&&$V.WN%J7(<%H\F)?/`2-48$L&$!Z$M51B/K!4%:+X#&PS2LDU>G(%JRD M)QJ5/UN%2H--;6HIFS(H8#;XNW#O&')OSYZKN]U2^6S9Z"?/Q]$=6;`=PT@= MY)2?LFJQI:&-/_UL6C)<1@0)*E#FVUH4IY$H]FQ9:CQEDZ[*;,NRO^&C1R]9 M!\D7]T6YYKQ^S*IME\L;V<(^?DL]U*67:=VQN2>L8,=VN7*S3BNUE:C1Y@=(;0]96 M7V(Z$C%#0S&M;:2:&&1IW[-6.Q"XRBK)W;KDN]#M6(R37Z+P?"+,IOV]7/][ M0F8XRO:=>Z+;JK79G)W)6D1G5UX-LPNGDVD*X$)1PW1(Q,9$8E"4C8JR89$8 M=P1`MZDQIZRQ#PJ5?>BF,UM>HR^X%1U++U\#UO=<9*S+SE(:O0KB0]3\&%J] MLYPMJG[BHG(5(*?N6`K=$:,"BS'__;PQ'1R_.%59J] M^>'53_O:EV&`J>'(T$8GT[DC@V;A?QGMM%#Q[Y0\/#I[DKV"SUQ"C]G@SP$IW,2TY6C_]6]4&U]JY8',WG# MT9^Z`8Q"B/DLA\1O71S"'TO1#1_MYCZ M>7(O]'+Z@8Z/3I%'UM\G\M,3C_7C#^A,DTM=V@87>915^M(+MTUTH.;Z2J6P MVQ&Y1^5=>Q=.D6W0^"BER6H9V*\`W:.4S+E\Q80[8I%'UI\D_>*IA"?B:;SS M"U2)9T,XBZK.)IH!G;`Y7[S7R:_XY0E'==.'Y`V(R;K*ANE9R&Q9G:I3,(DV M.+]SBM`S=3<9*\M*3NZ#D'(4<[7:_J0SM4(C(X#0UPB?E-.ZV3MP,"HS8FAD MRZ7H`EL%4DX08$KJ74C)I'3*!02RWP3>\.T"V2OE\?:.A'#CPL![:&$,2UNL%QO M*NZAV%].,$5K;V5LL1*4,2HRQGT**K,FW:@"K20Q*KU?K]&?FFG+NM\:&O!2 MWS?HAP+UG\4MF>K>NYDO-*(!X==,&#/$RG0ZJRZLB_3EAU`C<31]*Z*R8"@. M\*&Y*JQ[D29F+_4(QAKMC-/^[RI\#=X M6E;MSEUG^;3^!2[MK%\A=8<"X'EBYG"K[-NI%3.4"Y`E:-4\/`;H-\A*FD^S M1KM*BQDP_ZH1XAN+I4<[1%I9?[+I00Z7.F:&)2VV@=/#1#[I0Q`G$0.?+@M% M\;3-8%S.@F&TN5@MQ=9`EEZ<$X)-..DNF--",&NALM[02D&Q1A,@&`DC[!V# M.[(ZQ\'N\ABY0>SN6-+U3;!G__79C!6;]9QH3\\FSMHR:5J<>;824Q8?"8FA M4'$L5A:_.-IX>EA8T9"CUA`G#HKIKL`HH;Z3.B'\PB]D34Y;C&R#>QQYKX2Y M5YR[K/@+3KY&.'%_*.S'^'6+J#?ER31KR]FDNUR4,._'L@U03KLP1\6L90LG M#P/H(81G^+WC;2Z(!O)L('J4M\_UX.7C#"+\*XZ>0OOB3Z_D?W&C?Y.O/*@& MF/3G#+T%H_][@(^NNN/:$`I8]_/];7GTIBZMZ,`;J0_67W]W?;P]?(W"$XZ2 MRU?R&1/:F>5$&:TU#NW+(+Y:QY'IWB+QU)0RO9$N:"-&'&74P9':E^CK M3/20E_;<>_$IC,DJBJ5%=/DG\DFO2&3TF/KH#)%E)($"I;ZD],IRDDA MYI8H@N+,S!Q+`#-0S`B1I4W!-7MW/"AKDK(ZGQ>[`CUS%S,2 M"*I3=\V5!0+',-R_>;[R2XL_VP15.J;I[<:)*+H5I>RC4("5X^:<;T0)ALE20YC0L M'Q$W9M#,73K+S<3A)\=L!+HF8$,@^CV1EPY"5PL[7I\V9J5XJ4]]2T>R>P%L M4$5,RR+HML'`ZSDMYEIQ/[7(?3WB6HF0%@,]>1&_3D-,;P&*K8J5 MEZ!5EK$O9#V2!VJP57P$`EV%\*OP!$X==/),7+3G7Y![(.:)O&R<"GWKP79KC14P MS2A`H[JE&$[QP_^:?L)?"Q_F4_KAM]EG!86]!((EX%^KH3?HOX4UP,\>`(&] M&-W\VZ^*DRIY'W!2;<7]U"+W!O!K(X)D4EW!HNO:RLO8*LD(L?WZ$.S"%TP/ M0NEJ]BXD(7]P]H+C]H2Y"N-;?`@CS)][='_@^%0_(7V.V2)#XIM2YL<6-Q$MBB6:4F2I>BNPJGRY`:V6Y6SAW+^ M$&<0I4\S%I'@$0DFV896A2#G%'%648'789P);:.IVQH?Z<=8TH]!L_U\JK@G MKFZ/ZS*A3$#NR`-XAN*FO^U/!N=\LPKF-T_T:&ZGRKQ2/6W=J558,+3YC3.? ME!Q07M#^=T$*Z$"Y!\&<%H+9Q;+2T*JXDVL"#B,$W^EQ]2T.\,'38Z3ZM'6, M5%@PO>RPG*U+&"&$LJ2+E!0D1#K)580(F=]$ZW&@Y,D>!%J;"V07ZDJ\5*$N M5P`HU,VNCRD?AP![JZM-D_5BLZF@?307N_H0SBD+-X:05FU@4G",Y98582C" M;HSO,?_W(;C9[<(SB5^_NA=-2YGZ]^SB1<^,8?+29C'-@<,H(4&2K#:1((I2 MJF#XZ4]8!J1,KI-:+HM@,K/'*U09J&1<\/J&=]A[;86PPJNC`%G.CW';PMG* M!&9UR6X15KQX!%7-5$ST%WI9C2XB\YX7Z@->!/LM\DSCM*]G^!8 M^%L3>VA"%AJO#7@U371?.S58IF.6"H32O5TV+,K&+?Y]1-/J0.H2LR[33+JZ MB]DY?H96H"HUFLT5?,X/$K&WIU[\A+7K]]H-24`ZB547!G.<[/) M6A=#YXA/R8]ADW8`#11NYL?T:GJ8R>W&,4XXV@LX_Z]Q`;W.MO60UBIP'.!E ME=&]_3T^X"C"^W2O2GB>&_:-C`W&B!@HJ$TX-+U4NM).^.E(2`R5;3/GLSX? M;C0A?=^Z84&^4(-D=M^Q&CQ)Z@C&A?LFL-#[`&.MCL,?_!803^SC?;YV,8>_ M[%U0M$L8,JVJ,I^L->`6A`LK\_'@N*/4#+:9@.[8%^D:@]4#4Z6F'C(PT_S4 MO$!-5I)3DHZG>=AR9J::$],.9TMG7D[-WKE1=*'17DTU(G:)C9C;_LR:9-#2 M*,1OAA&+%$D4Y85[NZG6_>AB6M1%H1Y97F/6?OIG/Y(Y/+GJK;2AX;&4T"E4 M2F@][$1Z:(T.8*9BGE:E+T%S_935Z;4TM.$^SWR]6`@8I"F-O124Z3!?MA9C M71)C%-D(4ILISWM5<2'-^RN)A6N^#'L$P+#IN(;FX$RGZRNKIF]#;=RTXY]O MS;CQ,V(KM$-(;SIQ4F,PZJ*ER"PZ$[>7@(W3I-WA\F;)MY=O=-6&"M1[.&3)F9C1DUI\M1'27&CWK=9S3IDW+,NK\CP/6.E>';@/(/1V/W#71 MW0#".[T);R<,;`CF/"ILHKL^W4YQ`&GWLKJGH5Q+E14SNUIL)@OGVIE<&=&0 M3%>H`R9.%A=G>(JDX%$9^RD>MQH_ MRWDP[>?IK+.-$D%(7'E[T,2C-@+K[H*5L<)OG\%&UWK[*D?:&OG;@R/&N[\= MP]>_>XP\AP;_^1H4_+<%/D3=IX\_<+3S8OPU\G;76R6&+UD`B!DGAFFJJ[5H M^QQ M/)$?KL%$?O6_G_'1]3\&B9=<)*M9V1,68"(9UM185K/TRB-['W$"(&NOCD(X M#808VL8UAD(-6B4I1+14GZD*E'3:."%RLIPXZ;IA\!30NOO\+9EG]^T?*?&Q M)&[6Y&".(9VRG.[)ZEL^A_Z>N!E^G;[^$\E?@[%U*2^F%]I6HC?(=8YTD61: M^P(<&)TEE:.%I4?%!<)_89U`Y`(#P$AKHPILJ54U1L#59"\;OSXB`#;,VYTN M1.:"`1#!TY:'$)Y'8P\WMP^?'QX?/GY'-U_NT??'[=T__GO[^?[CM^]_01__ MY[>'QW^-&96Z5.5&2@-&*6_5:(!'\2`,\M+13;M!9:VTBQA+:8!/;BUD*4QG M(J]W?$'@E2DI$%&4?ARV;SXG7;\`BH5FKGZ2`>W]FJ`@3T MVDN]P>F1,H+9(J`M`B*\]Y)/[HYR=[EYH7G+VW,2)R2F]H*C\KN:O&L51P8, MF1Y!S*<9I`+>+8/118(PXI11@304O'J6FB'M&WX-_5>:0^Q3^6G;%"[_.88I MM=_*8LOH,]73:(!8W6BN?1P:;L;Y,9/55-084B$,8C>Z3^'2K>F`K`[0%_<% M,KO'U,QJ`=-C#H^,_FT81>$;`>*M&^.OF'S5('&/Y+&/OG?TGGQ\RVZ>U)9` MZ9^^Y3RA7IDW,]KY=#:=\=Y'[AM9++,.7E$>IH1N@/XXN[YW\(CF M^`TUJ%2J05R;2+[J_WM`.7-QD7`X=ZX9X3TX=#7[YCB:]^'2LUNM[]*I]Z/& M'MRZ=37V[]C[T647UWX.WJ%SKW=UG=Q[S5<9RXJ6+X:D>?K&KP&O<(N\F.ZJ MK#8UWB-=),+DMP\AK:.9Y^KB8U$Y[H/YB'S6*(\8"R#R64,)J>H!RR>5`TTGS* MM+#3:`$2LG6V7H=@K2['`NAOF,[>-,KN`&D-$6!0JSDS/8>?S"=Z6&=#C!K8 M_2B"E^!]=3V?+K/X(M4]1ICW5TK"%-5C0W*]D==AN49]8T'SHZ8ROOIY8(P^ MFF^DT,HZ-;/L[XS)`(>[S>U3'32"^;\'^RR.U^MUV*C.Z6%BL1@>A[W)-<42JZ:[>->A'-*PL%M MZM9")]^@UD M?PG(\JN<&)K29"**I9>Q0(M'"9+P*=Z]213$1,J MXEXQ.4)`1'=52*$':#"D"/5P_`V?4H^S/61>Z"'X%W:C3\0N#+ZO.2T@0!DS M:%H1=3U?2B&7#X3RD>@V1>[>'P)$1T-T.'AH#J(9!EYB@XNQX+.QL:L0W$Q= M[P+CCV1TY9YA.V)C1CGCT#0ZFV5%)EK#G(WW3G#>6#<"Z/-W!?22Q7=">JZP M]P'UM[`W4R&D1@WSM]#T8&NQG'8&^5OX7B#>3"\"X+/W!?#/GGQSO4I[]T-1DYVG*"7\FHZDRVRXX;&#B`;E_Z:C\P\PNB]06>% M"<_@O!//H`5)2R^A5B*TQ_A"=&>\VU5X&`C=.0>F>T2+M7P!GE."AV`[J9Q, MJFR;ZP/R<1QGI7+2[;"Q`*]J:RHX72D$&B3YI9);@ELO.'[R?N!]L:^#P4X?\$#L5Q,,H%Q.T0$)1;2901APR-*T MN+&`T]S&5:`U5!X,F./X+@QHVT=,9F0B@DSZ$10J:6S.9=?T:&A"P"`%SKDQ+P$]$V3A"&K$F MK((X#=\H>7H4D0V`\A%@J@,/HX&ET,".M:$5&GBZH$,FN:N5W!;^FAMV$9P- MM3=NY-9DKK8@-$HD-\S[G$U7\Y:(!D]\'58IZ>[*>\6S+D6VI>)&A&_>EZS# MS"PC`(]G"5?&71M7*P,<9P.,=6;NJ`'US/P3K9V,O.!GY&4ZF-29N@&65 M'L>-X79SM([0*#'=N+G+VB3JEF%[K'-T3TIQ\L:B[Q'/+>;H.L6-"-_;$X[< M+G.TC``\GB5#2;V=KPOZWBW".>J=5\A M]4K$'FK\$*($^@8#$DO8G]__*LS M7Z(G-CC:%T9'Y#?HB8W/*D"F'/S-:A4BF_K*G",?$65#(CHF8H,B/BHJ#HO( MN(@/+'*OZ-#VJQK95!:O$//PRPT*,@N+>?7[F"G*W**@ZB;UY8Y$<:5>U-^' MFPT#&F5=GT>HBL\8O6+;3=;P8S;IKB?3C9.Z06)];)%1.8H;O`*-TK7U*.,4 M6$:]6^I14"<5E&U^5-(%P$JPF4(N!^`3.93)K/+&\2317IN*'"Q=0M?D0?:354'$D2<:?[^]I`=A'S'1U:D M0#6#*9^W&32HF#`][%JMTX(]G!+=.\N/O00QH!"A#]F<@FP429EL,2<&&A[4 M65PI+-!J`P(P&2=I?*("2O4YBP"I#&Y:@7LIRB;G;!& M'EL84!I1T?;EHH_"YFM6F.KG(3'0<(VUFZ>*PU-2U" MP#O//#F*SR'_&/Y):P^6_5U^Y[&)O`ZYEWT]WXC9/F8!490"4.$&$!%7G@ M)0E3+E#.!LKY0+]33A!C!6HN!-2H4]$HW?6Z/<=>@&'SK(:"8LGU#*%Y$+]% M=]%OXA@G<6W=0_FS-CV(C`'3PIM.Y@;8P0$G`U[SL+-(A;.0O+^'RX6CB-SC M`XYH*ZE=&,/VQ=&:6@E<2IV`(>0N?#E%^)F$VMXKSL.-3V&$O6/`>Y/L+H^1 M&\0T+8+Y`?8_GWN%_?\[QPD%_Q><;`^/[@^=.?0_F&V,]BZ!:0_MQ:($\A(? MQ5@=I:P@P0LJ,,.B@0([*.<'T51%$AL0E@#]!:AZ>9&!5'T[H;ZDH"XWHP_N M;@;#;<5?#?--QN;P!'-?<>2%>_+["+LQOL?\W[K-L>Z$1^+(S+@UG<:GV;9" MC=/*G0_B(R,Q-!)CP^_/655;(?K9E=3V$[WM\7.:'@*[K]<;G$Q]3@,U@_F7 MSY[[1)N:>MAPW2%_P;8_D')A:+#+]6I:Q'F!UCB6(9V%DZY%_)PJ.`RU5E>! MEUH?8+!IFBI<\Y)M^'3,K)V0D99%"%E/'3;"42]2:G(F1J_(<79.78%9]4\J!%V%1'-SWG7(NE,"5!K_53(EEW`1AX=)-&W$/Y*[N( MDO4/P&K`VT*%VIB*2%!(#V/]HB%/=AWFCNX/*K^;XG&K2)#S8'C:N9DZ4X&' MO!M5?FOK3K4]:BX4$^BTP+=]ZTRMC!"- M(B!Q\AC>[/XX>Q'^&M%Y++E\)5\DN0GV'\EO3R_JM4L#`@!8JN?*-/=R[:RO MT/48HI0X$M01(\^V5[,!@"'7KP88"+\2;I]=FBL5'N@E;2XZ/8O!.J%MX]'< MI&4(-=1;#]=6\AXZVT,UFYPGD7_#>_QR4EP-:4C`\L659MP97MMUUM,%O[E2 M:#-%K-'57CL@QO-*/J5'+V4$[(I&A'V^MDI"1,)XY!X.>$=`A>)GERC#[IV4 MX30UO=(4"0QDEU+X$"@?P_ZME.%TX'2Q%G;C`^JN2CL'(2ZKM-!HSTXM*V%Q M\^9&^\J,5?LXH,.ZYL6TF,EL[K&J>`U*"C%:P_8],O`" M[86JN`!+0IDZ@/:274<5N60C@+(<.A(<2^3O`\0DAGZY(9-;@-7@K3QC&[37 M#!A^_?EZEMZ=+U``@F@7$::9",B&#'I$=A'$N?H68/A367V&.ZF4?>`M9!7B M7%_4?OL_KG^^/CC5/&@;>5(N3$.O]6:>PD^0R6HD(D;(+@0[RS*U+HL>BIT% M66",7E5B68&H%B@93M4J`-FIC_#)]?:B=DZP+V21WVG3BTS>M+DW M7\^.X;G0:K,1F_*<9E8-BN[`EZY!W$$F'_4LL5.46-QY9QL&O!!;FLB37I(` MW8HWM]G2'KRAOOJ8,Z-PA_$^ID55'^+X3"L2T>*I+R]A\#T)=_\FH__3C2*W M6C>E\>NVY]<&O)DZ]LUDF)%WLUR5*]8WM<_Q^J>&2FCKHNA6_;C=5$-% M9)T^U-Z*F<%[\$P%I+=Q3D)S,*L9&9^?P^#XB*.7>_RD7LS4OFAU+5/'C>GU M@JR+NQJDE"RB=!$E#+64Z5/@FK`AOV.Q5PAL;R%C:J[E=8R1LJ#Q)U*>/H41 M6VAI.M%KK,&$"A`R#5@SO;FPV*QD,,V2`FG7%K[Q(&O/#H_9GE617^(8"SH; M&+,*JJ8Z@L9M5F@VWAZ^8=H%AJ:NR5I`F"&X&3T@+#=BTC2U53'YYF/1Z3&B?T-Z``Y`-JV#*T:L>9KF6HI]0IWH=+ZN\#YSWJ0!*%BXS$D6;X-S=R M%:I-U`B$8SE'U=T]HU?L(E7)A^%.S7PRG6;05(+0_MY4WR(Z)1%+^/I`TT*! M059K@5>HTNNDGVWP5R_FM86^X5U(FXR0*/T^/#\EA[-_L]O1;';%09W1F_:W MO4W8,K,I9SE=I-O=-]DM!NK)Q8'PB=?428^,V<%<^IZ^TJP89S0MV_GE/?RVNZH@_?J!CN8&XJI$\ MNPER3V2:^N&]N/110M^+6%IUA%W?^P_KPL(R3M!/C$?^(M4#"V`)N2>BI=#W MV?]_MK[KW[<-"-?)Z3*O*2BS'0I!&PGB(%O\?4O-O.FMNV>[A9E)`V[D-_%5 MA0U\8[U`!";?Z`+PYH>GVE#(_VXQY,@&-6VRMA%)Z>Q-]#M]%ZB>6"O>'1/> M;44*%9,HA@5E\<`L5IJ`+GO"MM4V2'2>;];SA5.R6Y!4[8[\%VWW/J2=X."M MMYJIK1*RARB6N'42G`0XQ.4'Y,<=WSS[&OK>[J*JD]_\? M;#W?I'$MIRZB21H+TJG!M,`=."`G+RJ$S?FOC:X&XP'3@F M.H"*^%KA6L1]S54&,I?B&!-M/)/@]!Z_8C]D*WQ]B3[].S;G6QTCIA6B-Z+' MIZ#&5E<%>K#U^7J3T2G)R`OM9_1`YVL3$RS-X+4J&1V2]-&JP9MC0563:WR3 MY6JU,<,6=.#;K\A5J-V_`ZAI0F9#]0#!KG!R2SBD_]"MZE?7IQ/M37+G1M&% M3,"RRY-MJ=B%8Q/63,\)-^M)!LU2%@1%*/NA,`:Z29`8!>("HP5=.%>ZH#D0 MP%!M8]=7L&VLK3%"6/[;NBFU/1D.^`]Q_=*"`>+"8+[?/+F977NL<';^>ILBH, M7K3J`.JX,>]T)$Y`4I)(T$0%HBBE"@7B/J5E4"W*ME?+9@^;IF991J"17F!P M]HJ#,Z8GE\?`HWO$^OUL\_>LHJR&&=.ZU;-\LXA11`62\#NU@XCK*,2%19FA M499!9J*57HZ#7D/_E>#X,\'T]G`7X;V7*`MFZ9ZV?M2C9,6P,.MR,EV)@YV4 M%J+$V)541@ZFHE9/DDWA)*LYGNE%/$\/].< MY'LWE&SZ%44(=HB;';_!A0;S/,+*89D:M1&97T4L) MEE#*$V),(<85*K*%BCRGA#MQ?$N>.3-63:XYCT[I3T'JKT_M>G MBMX_%!4?*A7_`3V9:MZ^WQS6=.55.R8WFB;B.2RDG\I4>5[=D_):&*K/F2N1DIEF<-ZF0%07V>V"OQJ M%39"))I'%MJWQX/(AKO"R\5FT0"5(YJ\^Q*>P?/3F18WN'D)HX3%+*S^YN?0 M!3W0;FBZ#1#9]^%V/IQBQJ:E:(_LDM/M)7\D+<''NLK1@B)?W!?9AO00(U@^ M1.^9?3/[7LP6J[20?Q'?2QGA?1Q9E1Y$>1ER;UEU:@^HRHJ? M?">JU*8)`.K3@=&GC02%@3RB2&H8XJ.-:Q[@*=7#VFLZQON="[@`AI!S-NO5 MP+.!)@_^/KHC:1[2#`R^,ON/= M.2(88WFEG]P=32.[T/T#NGT@OY#8\&7;\8DQ9V8VLYI,%^LT\&"D44I;I$@+ MZOFNR\#W"I6AQ""23T9^+N;M'%Z) MPFB["-$2='P1;`^8K`]^NZK_/;NP5]?S:9(8\TF(/S1_C7>*Z8Y8FF_FD9Q MBYX2>)2J9<\P=G*FRSHWQ(=A%;6S@5B2HNCL-*90LS>=%(XXS$[E84-*(Z.O MCQOKU0>#\S!*:'X*O0]&?`YES3WB6^Q&K/1_Y-&E]@/Q2<32$LFA=P="5E'> ME#O3C(SU)$LSH?6>6`83NR29CX+289`8!XF!``X\[6B$03P3UQ/B0AU9=K?V M,KY;J:Z/M9]W#+R#MW-+O>.H!_%P_-D+\$."7Z37)LU>M+T>,^+*<&I9KYQ) MNK+*R9;:!J:$T>^4-&*T+>>5]B[O=!3RZM^8Q.+.D8,EZD3)ZL-*Z@A00X)>K`U ML_N2DN&MB6S6T&5BA"50U:H$%$NJ%;CF00C4-%QT35:+V?(:*G!KRG[$<9J) M8QT1TM5AC>B@MK\]T!:0G_SP+;YYBI/(W2G3-W6O0.!!PH=A.$/6THMK9-"> M2+0Q**-'G&Q*$1HE'86\PDO80$CKV-&8HA1%*M4`X^F3%[C!SG/]KV',.M*9 MXTK]*@R^E/P8NNS%9N5(<):118+NF/#6B]!5W#46&@!_M::KP*%>9Z\X_:TQ-(VHP*#4A#73*S[S]48"6$Z+=Q`OCB'^,"+T M]JV,*I"WR3..VN@!`-!-;%^!;6.%@L)<6Y*]_!`$2)L4'=\L-K/*L@VTGGIK M*:Y7:R.HD"XU&*GI`V_#T]3"Y]#?DZ_S\8^SERCS]*H/6K7PZ]%-=[C6>6B8 MDT"2IL2^@O"2I'L&;W*ELJ&+Q5_',9?&Z@I M7P`%0Z.(@]X\S%)/JZ`80935AWC.M7@"(?\U+HCHPR.M)OI([ZB,H-JDKGO: M=D*'FA7#(K+KQ5*4&Y2!8.@-;&4*1S^"J=$-MC/?HW05<)M*9R5-HQY367Y& MC3K&,2E^"1-\[\4[/XS/47V7>>/W0:=,!5/&G8*794ZEX$GS>;9)JYTRRZZT2LX%)F>PND'JN!Q3?@Z#([_; M5M8`J(\P1V?)9QCJJ"\?DA8#N0L#MK`_NS[5H^H#*IZ&\!5R5LSL9S:9SHN! M0%9+IT"-V9-]W]!=K"F06/7P[RX;@[R0RF4E,!*%/-9PKD=0"=L:!8`LM<]/ M,?[C3)#V\=4D/U3UN,V%M(('TP3_Z43<*\H((49I#"FC/+HK;(JG M`1&1LF#:JGZ9G>Q?6Q"E!'MAK;MD#D79^0%NOG%,%0@#9]TUK_H3D7T?9X2$![0CBKB0!7A MY0/!PK&1/9?!::Z^/G;."\/]TZ6E5),'UBSA(;@+@P#OZ*#_]))G>C`A2K') M=D5;T;&]V]Z&2<,2O1,G:YM7--0W/DS:@8*6BMYE(Z$W,A3RR5A_I5N_:$]& ML[M-/[0^JCXK'0;Q<6A9YWPD1(ZU@&\O@E,2`0JA MQ3D">!S>21BGD3"VPFJE$14#:+GB>/5,G\%KUU;];F#TJ@QHZVM5JDIXPI&\C_KI= M:^W$O6/&_=#6JC0+:JIR`4%B(++NB0_D0]P$^^\X>O5VA*="+9:'@$Q8S+_' M=$\VEO])>YS0ZQ`V(Z\>^3:MMC6?;#+X\<%9O91L^'+AH\(P;-L_5O\9]K@# M2I7<%S#-A&TT8RV('`"%I?BS;_U#N*K?@B?/]VE?'9[?&7_#.^R]:O)?=&]8 M="0:-@R/Q]?.++WT*VAE2<"XOFQRC2"N=+8`:V%X1;W4J M@8%/A%V?MHK_A:#X1X0K>AU"E3-3]Y95&&E9,9P7YK/52D!)T$.4 M(*(4T39`!9I0@.I-4.=*T)\HQ?AG)BML<75#]@K3 M0ZZ//TY>Q#;K[JL-_=3/6=XUE#)A>**Y<59I[9>4R@>4TT'W0W7=4VT?=A9E M6A#%BB3:;<3.XA3/FA'.Q=D#]0>LQ8;87%1+#C'KI-Q(]_WESUB<D`,3K':3J=%_#$",`AJB7_4YO\UZ*JI1!.`R%L04QB\$6074O:%\S> M0CW(LK]#0$P,;OYM%T6`O86`\&K#^]0>[_70:B.`4Q0`%$W7=EW"4DDT;M@I MLY_)L^3_Y'_D!Q(Y8_*?_P]02P,$%`````@`SX0'0>@G`L``00E#@`` M!#D!``#M75MSX[B5?D]5_H/6>=FMBMO=]F0FTS6=E'SK=<5MN61W;B]3M`C) MV%"D!B355O_Z!7@1+P)`@`0%"L(^;'HL7`X^'@#GCE_^^K;T1FN`0ACXGTX^ MO'M_,@+^+'"AO_AT\O7I=/QT=7=W\M>__/YWO_S7Z>GHYOKS>#J:^![TP>CN M]`N($'P;_7,&/("<"(R>G;?`#Y:;T2,"(?`C)\+CCNZA_Y\7)P1_')'_[X[P MG_YY.;T?G;_[,!J]1M'JX]G9MV_?W@%WX:#3(!G]W2Q8GHU.3_.9_Y[2^''T MX[L//[W[L?3+-(A]%_^]]*_0]N_/Y/I[C'A\IB_SBZ\V?O1F//&TU)TW`TQ0M$ M:^"^RT;RLD6.,*)^^.FDM*ZW%^2]"]#B#(]]<98W//G][T9IXX]O(:QT^':1 M-_]P]L\O]T^S5[!T3J$?1HX_JW0D@]&Z?OCYYY_/DE_3UB'\&":CW`>S!!H! M`D?,%N2_3O-FI^1/IQCABP_OWD+WY"]DPE]0X($IF(\2&CY&FQ7X=!+"YS>(E9)_]?QW=O_`A&FSM_'J!E0OS) MB`S_=7I76<7JU2&_OX*,>Z*,&<](XS.A<<\Z$C_%'7]]PFP/R!23^2WT\1># MCO<8A)#,<.4Y80CG$+AMUB`X\AY7\>@@T.IS2`R/AXC@S/&4KPMOZ6`)QEX$ MD(^__QIT7,CN>*HIGF`JT%6P7"&`R0GQ%.F<'0EG#JN:_BLG?+WU@F_AG>]" M!&911\)WQ^M*\34,9UX0Q@@\Q!?WT'F!'L82A(J^F_!TZI:ZG>D+<,A_D^W1!V]* MS*-N<9A+EC!*I_(QSR3[`(NI_6P_Z=D4,FP4S/[S&G@N%G9O?HNQ<-+'\2(X MB4+F3"]X?_&,'+S99V3X7IA3?!Z%BXL];S->!BB"WX'[#-#R/G"Z+H0^ILJ3 M\24$O\68QV_6/9T48E,H$3`>@@B$S\%6CMP*".$$+1P??D_FPCLYQ'>GF_P' MWMEE%;4DA!:=B[4\@[?HTL/;I@TD>Z2N9S2Y\DA/&`G..8B5YW_0@R\>'IPR&;N&86M&%3LPKXV`'\JG>OLXR.+3-CSFCGR7^\W@N3_U'4F1 MM.T=!/%I>U[_-7B)\&=(:2C)E+TC(#/Q<##HXSR0G[[O/5$3:_O:`\QILO6M M2O(A\:]4%HH;`]\E-N;TKV0RU:;RA`Q,"":J,K=''`P!JJ*<39UX$4(P>[<( MUF?*/T]1%\R'S(?P!_^G7,9[:)=/?>LXB'\YS7H#WZ63W][/>Z;F* M$3%&WV+.<[Q_`0?=^.XU_EX4TIA-Y:CNMMH7;5.P@.2Z\J,'9\G<&O5F_5-W#Q:.E\X]?H.T`[C>HG^: ML`!-N/AILWP)/`I%U=^W])1ES3&JTN:@63X0_N>.H%F-&\E:G*T2M_[I[!5Z M6QEUCH)E"Q$E)R:@G8.C`&$E,HEKPO]W,L(+F0,LFKGWZ9J9A"941EC_!$E+ MTA,&")/PZ>3\9!2'>)'!*K5F:X%)]+K/8:E>9@4J'XX:E9J&4)9DB3#-(9*C'7 M.SXJ\;[M36:=`(Z7L8>_O\O*F[@/PO`V0``N_)3H6>J[]M*=ZOY?'"9!'@\` M\\^S\\;^.LIGTH+8-O3ST8'NG7_EK&#D>*6[E@5`A@8R5B/75LJKBO.(NH-Y,!ZW7`&'H2/)B MZ9Y]"/P9=[U\]!X'[#>XT!X/9GLQR3[?%B2XBT%IHIQ,?.;M!J M,]GT;D-<2\/U)]Q=\]KX(@>EX3#H%4=_"!+(?>`O2,H:"=UM`)S24C?%C5<= MH[$.NA.E,!4]&\FFM]5&M8QPP>F@@_Y'!%98&\VL$[EQ0D2G$>FI9T7!"J!H M\^B1W*HTVGZ560V82^%TT;&&*E$19B@7OC(!\3$I:L M1-=@#F>0]NCP6_%MH\1UU6#O,S7Z1!P8OGA@:OB) M.#X,,=S4J!-Q8`J;EZE!)K*G2]<0DB!RO$-`@F&X*`,B**9O\3HW*V)4&B^. M8Z?`R*SP46F,N.)*@9+)%[D`2D(&C`(MDZ]U`;2D#0L%B"J!XK0OVG!TB:W-*1&A7GU4Y&AZG%@]KA(Y+Q9VH]H9:(]9%5:FI%HG80BP1.FEJ@J!UB7.M! MJUI%,M+YDQB!7A"4L\OD"G4Q)=O3K(Q*&V=_X''V-J9A`&HS MUSHE="V;KRE*0K5[WYNO&K:"*!`D,!HA?K,U:5LP9@:P`VT`"L M6>]/C6UC#]/L)U%.>A3\;03[&OB.%>06P5Q(NW1".,.$74,OCI@J?%,O4]3@#D6/\,3$:CWQBYC!.Q]?34D) MU?`!1(\(1,SZA\+=M:P-'R3(\0C[NDOH)Q7+"8%9F`QK20V]=*RDY%W`-T7Z MZ&B,&7NR`BC9D^$EF`_ MK$'JF6!9'/9)@3Z$MW=,@_6"U5H?Y1CQC$$O,?_.F14F6*WU4)XR!G\_UEOI MH33GSA2_G"8FR8SFUM"9`H3OA>(H8(!8;:.%2BQ]IL>;OTA)X7,JN_V@J&\X MVYK[:2E)E9.4Q[@RJ-]M-PAJ&S!GM]=*?>,>I;745K!,=KLV=-)4(@LX:$9R M6*^QNN@%21$/_C+X?:P;RYS22O\``)O-$LRW95<54 MXY:#Z;2+-)I;VG=`8;T^Y%*/D M5#KS,0LG1Y5),#4)):8G?;<"3=P>:7K^=ROXA-BMC;-U^#E;C3I7K60,3]#N MEO4]?-Z2PJK1C&YZKK<46EQ76[>\;L.0HIATNF50#O^,$@V:J7N6;4!:`W?9 M<#2FX:Y;AI$I>TI`FCJ::#0N4'MU->\O4VGXD%,\N&*%K0]8KQ;KBO4/>^JE_/![0NN@@DM3S&$'H2]M,S4BZYLZF7+3W0JO3`?([/ M\LG\YFWVZO@+,,4'_L2GLQ!C25)#F&*0MD4)^&M[PM][,J\\W;Q]M[EQ9=S. MFM+0*\?FG5][MH6QI.9^PUI-X_/J0ET'LR;R;$SUQ8;$WK"5T"IOQXBO5V;8 M86"Q)2TKA-Y<`4)T@&&L[S%]4C87$:A/RPJO56BP8:P[?W"X\ARSX#)I?746 MRB"5^IG$EYI8)_+6GDQ3/[-:?&7UD^UA%AU@V.MKJOD@/]"`UIN&E';XGK0! MAKV^=M^3-]"`UDLQ#\FMDS;`L-?7[GL.S8[6=]#."J93O__QXGTR,7G[\"%( M%.GZ6;7S:D9&AU`7'>"ES_#\#9+@>6YU*4I#/?1N$G5Z6]L62[Y!R!0BF*P6P.TP2QU'<0OT3SVP;;'G7HUA,Y0$GY^X+K+%ZL#:5&4C`01*Q=I866'NYE>1+('`*6BT4PM.VE3>>N5<%N'N52D M&`$GD^GU.14AR?3\BM7O/.!+0STK2GK-M@B?V[W.-)E*.,L+/`TM\*^<884< MV@6L9M8S4`.K3'QJ@6@;`__P\]/;QS[2KB:1P!ZQ$G_F75:RD,H$.1C_7HH2 M2&7BF,7>5C%NWTN:*%F58\[-K'>B!K1^[,<%]F:6T5:#O8SQI$#43$.2LB-` M.)F@0+2-Z6BXAZI,/'RN+[4,X-E">&&6]:TY.*\=T]&VLYE&ID[(<26I`CDS MG8Z=D./JGL5N-=-L)%@S7ZJ21X&9F;J,8-$\J6H[!69F:BM=,-NIO%2`U<*D MLTJ^`*8'14<#V:_G9=!:J'8I:#>^:P)DPB'B!61F:F1\N,1DX@(C,W4LD=P- M6^NSGA=B:WT.MM:G)ESDTG)HKV:G15SV5_!;1U'4:QC.O"",$7B*ETL';2;S M)[CPX1S.B,L@C93"Y_!CX,$9451<%Z9$E\#44CT5D^62-Z#@&CR!68P2/0KK M"UZ,T4A?Q%NNXA0UK$C4'N$:+\G"&$E9:L8>3L5-2N$?@0X*4LYJPWYQ(H+E M)M5)**EE_/9:``W"B(1[P.5+C$)RQ&X?4Z;CR6ROLSCI]GE:*LWU5@H^O))C MA5,71.WX6FJ5+E=>L`'X?$%K.`/T%!0L#1,C&W#'WQSDAL]$[2[_3KCM(8C^ M!2+B%,+K_P[JVZK_^8Q"+SUJ;@.4_8FT^[!O2.E$V&JSJ1 M>P_QQ>F2`8EG:)&(ON$70%[1I!R@O-8Z/NT7YPTNXR657GH;+66SLD=)MUZC M)[#('DBF4LQNKX/Z*?G0'%FP^%T;==SO7VZAA<)*T.^NU$S_*W])789441." M>F>5SH3+3=$D"]E++K);!Z+$TCL.PWB9Z+'AV/=CQ\/7UAQ`++@G3AO*T=/_ MG,,I;2.PJDFZD,])F/.=3]6->II$)P,5G)^$>G_%4DY*'O&0,A7$7J=3`0=/ M"=DQ>I<7)M:Q;Q)IM78$.^DT]C6;/B M`+1N6>,'#.YQA^_*PR-BZ]Z&]5JX*(;&'!W+3%)'WSYCQ36'0).#^:4N>.2* MMXX@9R\9',OP5)&('XHJV%EMM"7/EU.30IO<=R`O$%2HTL$9Y&>6J*A9J_`C4D),C7;\W)3;%!.!&/OTYJ` M)?<]K5[F&D`XBXQ<4K%P]P.^J6IMS[)2Q?XB*!N;ZE_I808V9*Z>T;XGF4K:,]."V^VWZB"S'9VQ?&^H[F^K&6NIW_NW4BYJ M'I&].P_ROTJ*[(5W_C8@:C*?Q.B>2'D7Y:=\M-0PR%]WS8I"D62#[3.O)>*V MM!<+9&BYG8;44\=A4!C\>MY3C0A1/I2K#"$]JK7];I&Z=#SR+,O3*P#19Q3$ M*^@OM@RSK2QUY:3Q?$W.C<[#ZL5B0R.;9TX3ZJIY3=M__B_$ZB96[S?)QN!8 M604[:UW7G;^*\3&6;'&N!9W70^L*O@"'G&+I"SX[,'-=8G)C:%GE[IW#8SA& M:P67T!T)"G2\TFV8PT2Y6SB-K2LK_53/R/%#+"V3%R%3B1R?<]OGYRHRQC.F M):3_Q.5NI5/HP.BKCX#C$06D>.F]X"G6)FCJI6,EV2L$W`.VVF8`KJ"NPF99 M^123#4RWRZB2%JMY8EU4GDY.GX,IV*T2]Z;+T-2LLSYYN/&@-S6K;*@'0Z4L M?9L>X-Y[N+*<[#V.,^^S01-X>(UFN#3-7)\%W]_AO&ML9N*1QXP?J12%"DS M\8C@C&8YWVVCPH&\U01+6A^SXC6OM5)OMC@C";FQ6PQG_=`EQ+UL5XX<:1$-J*Y'K4!6]SUFHBO@N421JF*Y+M7 M05(Q#?B*WD6FZI67"#BSU\F<3$:TKS@I>II1D51"9;Z5)-Q5A0VX&+@&#,O\ MT=1#*5$[GXMG)Q+JIH2\&*7?`;BW8"?NE]I$J:%:EIV%S-6M!SUDHS45Z"0^ MXQ9_0:9!J-Y"U:3/N`';#+73Y/!-:!O.D!TC,T_3-M`2T& MT+^^C#2N(X#7P\178JE;*E$]@SF,I@#+$>3,(L6=GQP/?U^`SS$27QHA^!(G M/P6H?N]2MF#G(54L*XA`^.ALR&T[7BP0WH`1P#HD9MR5XTW!*GM,(*M3O;L& MJ?XJ3.P`S8B,M\#;:7?"=)XI<$'ZC@?-_BXW@&*2M]\\N\\;"-QIKM])L<^* MB/:IXFXU`]-GN[B'>[6-%BKS@-7+.,22=1CFKXWQ2CQR^^@R*PCJ/T<7:R^) MC2!C&&W+:P&7C.!JM'6O!7:4]P'.CQP:<=N)N3906?O1UO//E?A,#7YOBY:X M==-DKU8;Y+HKI2:[Z]L@NFN.-35D1\79)J*`FYK=W'K/REE<3'X,4YT38E=@ M8<@WIJI8`_;6ZHF*DS?CLW6IFI'\N*"C>@CR_;;K:#+U5K`>II2S>%4MH%FR?(E1M2"!U;S`3XZ'*V<%(\=+"OZ' MY&TBM`;DK??;F`AF=V$8DU(YK+5+CZ.VXKG8^296YUQR+#,#[2:_-O@((G ML`8^\R82[:F*R$E:>[#DTGT&:,DBC-%:`3&9N'KSMH(H8>UKK'I3R*"WTVDD M:-0P&_.,C\5>+:#-5DRR$XJER5!KM2PT)6'65&.U$A4L!XUY*YBZYZR?L<1& M/2D^6^92KV+8K]%"(ZML=A'IRU1_CJ!07A%,Y"UU)H='"J+7*$:;'`@IR6$] MF!=,#HK4A.ZN.<+DN$K90[*K8\?D&$L56#8Z!DV.LI2XD>9 MJR>`B8"5RNC\/`&(>M$0C4[<$P65=Z#M,QE-\U,%Z7L._B)Y"@)K!T13&$R` M5![:-I[A+Q0F-"7_1(!?;*2YGPZO'(TJ=K`7J_5@@H9LH-3@`Z68M5'F-*:ZJ#Y&KQ$1U@[G=%#R MJE)E]`071G`>LVE/9###Y3B-E9,2?B&)7^2@PLSS)?"CU['O_@LXM/M#M*<> MMDN5HU29`%=!&(6?41"RN8[57NWK6<*ZC=CK6?+#&14Y\MSKF1^'S5QX"$>-I@!X(:D`D?NS"2YQEOY%6_S7">@AXI+ MCJ&`\,H-N-TMEYLIV>4`3TY^8!S[XGU5$EH>G'D1\%IWW]?07^.Q4Y9-_UUG MUO2OF`SR/X31\F]6499KA`MV.OP<`D5E;*%/MD95S4G$TN;W,,7Z#F95G%+# MK.8*MAQM[,L`H>!;^I@0*!>"N?'@`F+5YA(2X\=X-B-@AE,P`W#-")-6.[ZN M!7_U7WI>,F>&H7#H/3%H(WX-Z:9N@UD+(\5`K,]05I$5&-@RUY6SPK]$&XE% M,8<8RAJG@#`.V3D=5LD99"CKI.69-+?74UH>:U@`+8G"RR*XW$0WC<5Q>XGU M;_SM;^$;<,N"K<`J!`916T-\#=`]?`G8#TJPVQY(]7#ZQ!*ZT0.@V0-D1U!` M]!2L`V^-F:*\49FX\5JK2,P"/@Q0XJD";NW,P,Q\'S@^VPDBT5E/VF2`(N:6 MS"WO`EN[Q4`*/DT.(1/^6@,54[[B%8SG>!WL2>M-%$Q++)V\+/WJ[XHFY#^% M4V^A:E).88#J[SHSQ(3C-$3J-9V;E>\@&/U1CH<3@-/4R,%F'W4E<)#J&3XN M;.@;C!674.PRLP+F9;"1$6&V>%V8Q4LB[MGBJ6ZV_]34O2;F-\X1JLDCQ28S M+]1=#A1:*OB%>1EYDJ!02]U>F)>$)P[+KAY1X&)>^IR*$(5*H6FVP<_D\UG: M\9QS&]<1?!2(L3W@E!<:ZK;"XGHS*\_-EJ6HEREO<"0WG4%5E]XQHD5S:F[O MO)JYKMA69N7?ML6':_8NQ`.S"@M)>96KCTV4W6:FEK]H#X^4?]O4RAA*X:,$ M2IE:\T(:MQYBGTPM=;$_;'EA5J86OU"ZXWG!,J86OU!R(8O$B)A:'Z,U@&V\ M\:8636L-HG`>HNE%3#LBQ\X1-+7$::M[63B_K4#-*BB-J9L%6%8=$4G@*O"R M:DASREZ!UI$K%LHJ?Q2('KDR(9K#5@!FE0>!(@L%7%95:$I`+["R&@&_=$[A M?SAR#4"D2%(!UI%+_9WJ>I5@/'(UH&4%@`*_(]<,6B7W%.@=CYYPW(5II9#A MQ:(;6Y>V%4*TQH:7FI7"B1]MG6-T?O08243TY:!='#5HCQX)X$`1>:PDCT23*_'<5'V-.H58I35^UT.NJJ8F4?GF+8+^`N_T5W*7 M3.;D;MD1BVLYR?P^MB+485:?N-SD/C;&SA+LI'L=&4&0/.J5^7+"R?P107\& M5R01@K@-;X.XG@?=;:R#6'62+J1JV>E@A['N;X&R5>.A!K[F-+;*)2ZF6WP1 M.AZE#JRR8;44U]B^8D*[B7CUB41Z#B"52TC>J00XB2!BNB5&2)1AQ=71;C]3 M`Q%M=E)=\Q,2@UBLT^XX-CZOHD],2]>Z\0D6>\`Q%0N-3[GH'\E4K3`^OZ(3 MD.9G2$C(IT?K-I/$2%#&.QZSZU/\$H+?8CS1S9H<10H>VF,\\94^]>!'_0T=7DNE;W\((2UDC)8;R13;]%"LNO0JK@'>CQ%TO)R5 MDOAFRE=D--1B_JBR49.UGME\`+1S;36TID.@&<_'>0.!U7H@E'.KXK/;ZS>* MM3J&*S8R*NN9*F=9&T]=X&PX-8MP78;T8;K!1A0@UI5INB&&=W4=KQK7`$KC M'6I\]&-+A#0IM]'R5'^E>FZD?)IM"B$.46-1H/=AEKIY1H*JHUTT+G]J@VA<[OMK&XXA)N5 MN2W*HH?Z@\9XE9*Z?8]766+"P6-$\\5_YNE)A6;OAKMA";5/<.'#.9PY?I15 M'R05I/!9-(.XAQ55ARRJ"GX[AI@CUMF*E5:LM&+E(.XU,;%2]%"PPJ(5%JVP M:(5%]<)B_H?V0F/[*RZI(TOB:$N,Y+N=!*5.0^JXYJ^M?Q6$4+/&>YA/79@0M"=P.(G74 MP[R@F!CD3;U,"3YLC^MM@`#^Y%\]5.X1A*_CV)^EMV[SP2+77P<#3,$:^#'`A`;X MW"-\*<8)S?VT*/SDC"./>;A7P7(%\,Y+#/6K3#;`[$M"FM;@T7/R_<>R"K08 MR9IDK$E&3UV,KR%)L`DCB)4'P.*`6B-K.AJ`EBMF.NJF/!V-08F+87V+&!_& M*H1*!^G7]#1B,0`%=7K34X7%P**:"HS/$N9"T\J`86K!$CEN$E!=3'\A3=#S MU$8K,OU=-#'HV/81TU\_$\.GT2II^EMGS:>[I`W)]&?.K/O7NG^M^U>'^SGZ'X#927NERNO&`#P!-`:S@#=-EM["6T)$'HF?S[/7EK"`9N\I15 M8Y!A;_-9([@U@MNXQ$'YTIJ0'?*%Y2BDWXB2@YB2$&J8 M2&W%2BM66K&R98J&Y#%JA4DK3%IAT@J34A&8$0;J-?#PZD.2!Q9M2%M;6]S* M5T$PA'-D550)``/&?"%0QGPA4'5X"P`!!"4.```$.0$` M`.T=77/;-O*],_T/.+U<.E-95MPDC<=N1_[J:,:)/++3]OK2@X MC,]..U]NNX/;\^&P\^LOWW]W\J]NEUQ>_#88DQ'W&`3:^)F\/^H3,E5H<]WKW]_<'X,ZH[`I# M[L`1?H]TN\E0OT=,'9/W!_T/!^]3/6,1.#\@\.&[+F+T,]+]2(;<.2`#SR-C M#1J0,00@E^`>Q)0"(R)!!?+@M).2ZO[H0,A9#^GV>W]^NHY4T?G^.Q+!'C], MI,(K*&:C/U(=@01VHKGF0>FS*P.T0JG#R3T(%&8"0;T!^T51.*.="F=EIONN6Q8+Q MJ8B_8H/VQF,I/+A#'>D[H&<1K_!XCQQ`VQ(7$Z,15`\P-9]OQXM;$0KLSW"UR;)QL-+UB'(,> MH]Z-"`P[YQX-@MC7M.G&B/!W102[!8_0;&M"1*\'W`6N%RK\%`B/Z57$)6?4 MTV&8W,X!5+`WY-,->4,E@LQ!,=1/;:L:[$=,^U,3TY(W&<9^V)NZHJDQ11(^ M##P%DJ,82RBW:1',;L1WU8RX!@F(F)+10J>@2&`_4ZN:;X0P\ESX*`D"!VB8 MR%+E5MP*;3?F^]K&'*$Q]5@D,QBY%L'>M%5->TZ#^94G[H,A=YD$1Y7;M`AF M-^:')C-3#T+,*'OSV.7`7=O4L*FEL\- M\@4+'$\$H80[>%!GGG#^FW*&;SBHW;5^UKGT&@N_I,XHDS^3KT0-GJO:7D[!:O!^X=Y@VMBQ%`CGX#J1C/&WKK-K(OYDL^4 M^8@Q&F.VGC/`]81IN@C4)&FW?S]O_Q1U$^$S]/=>T##,*[3$7'@NR.#R:\C4 M2L,V=8#JU.RV?UL(]BG"_R81Z;W)FYG\`B8*IV>DQ#M)>4`=S613H]>A9S?[ M42'D1Z/A6IZBNY_K3>=Z.`G@:X@?+Y?Z>\VYO17;;M2?BHE;0HA$E/;V?,X4 M/6G88:J^)FFW_+OF*3MYDWS:UU>?U3ONZ,3;J6_$!.V>\?XIGA&-L/>+Y]C5 MU7"'*G3L7O"AX@YO;_)OE_'5<(#Z5.WN4*CIE6=_>V^H=LMAK4]Q!X,V+Z-@5YCZ:C4%[# M$KRC:T8GS$-NDY#_%`)VDQ?*>:D)'@]!&$^G`/J8/I3$#$2.2&JHO3?4](:U MZ=)I5:6(7P/3;O]"26];LK>/YCLRNJ4:7\GTM?'M#E`H[EGK^7LWV-E*4*C) M5TOU*J+9C5XL_I44\O>VWEF<3W9,Z0U3M3A?'=-N\4+1;\LN;F_S7=D\]+S5 MP!=2L7_`O0/I7PM:M&\YE-V6A3*=H4+69(BF0S2AO=5JY^?9TY2*V^\J2':; M%HINA>.8_=3$9OV/WHZ.84K,^Z=C_?CGM!,P?^'A7CAJH]+1^/:74[V%%`N0 M>N/22\@F!`K8V:=:QFER^HNY2BC,)4Q/.PNVZ";/@GO?0[,OR6?6=V@I+CHD9XZ<.W+2\N2?2H\UHXAI`%17_K M)GA=W=3MO^T>]0\>`C=FL0X'&T77XR#!J\M!Z8O&JF,G"'K0=Y6&LSX,W3:L M&;+T)6H//!6L:74WM.IKO_`(M)(2\EA:$Q^U^OOOG\)"ZOUJ338$_]R,$]M+ MWR<81K?4MQ$CN)6XE)A(<_>%)@Q=?]%8:/X46?]["1?S$ MU[!QVADXC@S!C0OTND04O?D)I7X=5Z@L8PS_NP9*M""9Q^_'ON"8=\K54(&O M4[4.H9-`2=Q)GG:FU#,+C@'$A8@)]\Z@1M%6)5V3Z`W?:<>1@+EMAW#F>?H< M\;2CD"?4%*;!N):$6D^_21$NDM$9CEJN@3,)U)F/IKIPI;D)J;>I:0WNJ71O M#$,;!53'2,OOAM%;M5KR)T@[D50_RM&UFB7U]`[A$U6A9&J5%^\1L);)A#L@ MQF>F('6#L1!2`PP;1&4`;O+I(H8 MW8%0KCJ>(Z9TPHE1WV/B%>K.F-@9Q*!,1AOT-Q;T,>L)OO&M81!@3+R)O2HK MF`WNB1ZYCH\[$2D*9Y_`GX!,BY!MCUDVO\YQ[`J?LM+Y_XW,$/$V6D3'UNB5 M+`"WR'P!X-F6)ADKJ@3)P@% M3]O2WR:/JWWO7@M6"RDCK4K:7VZATLP/T=FE^G2V&L,4VW$T MW9&M!-=`:65I>,U_FM]\;=@*U"8OU0L_KA[I4Y75F9!2W*.VSW!_?!/E-72& M8)<>FS$<[PS'!3=.>(,Q.(#NFUF5=TSV:6G6+D]`&PGVA4^>1V,VPFW2V=>0 MN;K&H+.2692BY4.Y%:A-,^8S*$S!I@SGML)61-29V"WU(#@#W/?HH!;]"03= M)63^*M!&Y*=3>A5KQ&?!S0\*)T7E@8,KG39T84/Y.&2+-B?F]S)P,ZC)#&8S M"3,,\3?(DL,6U!O#(MHG#GP],],RUD)[#?E[.C(518HD&8,+_B)B)%%%7;P6 M;;;3K*^G<7S;HES`(E0[Q5F"O&834=B+64#:%)UO]+.L@7F659"@V-4JSH59 M!/1%T2B\Y_8*V_I?P2VE9M6._[]"1QV),%XT4X5!?"7:6#*]UT+F,7$5&%96 MF.5`W2ZU0]/3I3X;CV[K8G6MI/;,2R%MT2^ MT]N=?*"V`K4I9.N_X>>&GCY&U\?)9_GCY-16YFRU`8E/$*)G`.A8^H^P96LD M.R?@72K'`\X$_(6G!#G1K9FD%Q9*6RPZ^"T2M:F!ES74@>X M8D9[B&"`$E$/%XTI(!<2LL=]WV"H%B7]C:4=@PXAC@+7Y!Y?.%/!;SKW`'?( M\T^%GG>43%S39((7U*?M+D#)06Q5^!;5/.R_#)PM:%:!;>4!;?%N5)GQ;$!M MLEB!S[R9M@&TUS9#K@,G6X)>HN_N\?/J+Y#B%I;`"ZM>5816+7F:Z>@Y4I!Z M0:J7Z9QDVX#2QGOY%YBWX6(1-5`OWJ9&C]R&^D^(<3`7C/]@:GXM^$P+H%\@ MI"1MAOX:=H%)YI5WVWQ[F[SS;@X2!E,%A1IAL:=-?,>N<_FP8!'5BTSRMZ4[ M,Y.PY<5.T?3[FI+K)KGF-BE`Q0````(`,^$!T'X-Q<=%G@``+MS`P`0`!@```````$```"D@0````!P M:7`M,C`Q,C`V,S`N>&UL550%``/&?"%0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`SX0'0=U>E`8`#```0Y\``!0`&````````0```*2!8'@``'!I<"TR M,#$R,#8S,%]C86PN>&UL550%``/&?"%0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`SX0'05ON6(4\)````(8"`!0`&````````0```*2!KH0``'!I<"TR M,#$R,#8S,%]D968N>&UL550%``/&?"%0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`SX0'0<9D&-"@3P``Q?D#`!0`&````````0```*2!.*D``'!I<"TR M,#$R,#8S,%]L86(N>&UL550%``/&?"%0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`SX0'0>@G&UL550%``/&?"%0=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`SX0'0;,Z=6O_#```J8$``!``&````````0```*2!:AX!`'!I<"TR M,#$R,#8S,"YX`L``00E#@``!#D!``!02P4&``````8` ,!@`4`@``LRL!```` ` end XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Condensed Consolidated Balance Sheets (USD $)

Jun. 30, 2012

Dec. 31, 2011

Current assets:

Cash and cash equivalents $ 11,776,921 $ 11,236,771

Accounts receivable (billed) 3,444,830 4,424,442

Unbilled accounts receivable 4,786,304 3,021,208

Prepaid expenses and other current assets 675,047 830,585

Restricted cash 100,000

Total current assets 20,683,102 19,613,006

Property and equipment, net 625,534 788,666

Other long term assets and deferred costs 150,479 53,384

Goodwill 2,348,453 2,348,453

Total assets 23,807,568 22,803,509

Current liabilities:

Accounts payable 2,062,718 1,445,700

Accrued expenses and other liabilities 3,141,947 3,169,642

Current portion of long term debt 454,548

Total current liabilities 5,659,213 4,615,342

Other long term liabilities 564,860 449,709

Long term debt, less current portion 1,983,544

Derivative instruments 2,054,505 1,886,652

Total liabilities 10,262,122 6,951,703

Stockholders' equity:

Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively 4,835 4,824

Additional paid-in-capital 209,662,510 208,525,917

Accumulated other comprehensive income 1,003,989 1,010,522

Accumulated deficit (197,125,888) (193,689,457)

Total stockholders' equity 13,545,446 15,851,806

Total liabilities and stockholders' equity $ 23,807,568 $ 22,803,509

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 11,776,921	$ 11,236,771
Accounts receivable (billed)	3,444,830	4,424,442
Unbilled accounts receivable	4,786,304	3,021,208
Prepaid expenses and other current assets	675,047	830,585
Restricted cash		100,000
Total current assets	20,683,102	19,613,006
Property and equipment, net	625,534	788,666
Other long term assets and deferred costs	150,479	53,384
Goodwill	2,348,453	2,348,453
Total assets	23,807,568	22,803,509
Current liabilities:
Accounts payable	2,062,718	1,445,700
Accrued expenses and other liabilities	3,141,947	3,169,642
Current portion of long term debt	454,548
Total current liabilities	5,659,213	4,615,342
Other long term liabilities	564,860	449,709
Long term debt, less current portion	1,983,544
Derivative instruments	2,054,505	1,886,652
Total liabilities	10,262,122	6,951,703
Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,345,984 and 48,236,172 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively	4,835	4,824
Additional paid-in-capital	209,662,510	208,525,917
Accumulated other comprehensive income	1,003,989	1,010,522
Accumulated deficit	(197,125,888)	(193,689,457)
Total stockholders' equity	13,545,446	15,851,806
Total liabilities and stockholders' equity	$ 23,807,568	$ 22,803,509

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Jun. 30, 2012	Jun. 30, 2011
Operating activities
Net loss	$ (3,436,431)	$ (4,513,270)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt recovery		(400,695)
Change in fair value of derivative instruments	167,853	(3,176,686)
Depreciation and amortization expense	162,358	234,319
Gain on the disposal of property and equipment	(66,626)
Share-based compensation expense	1,060,705	1,255,325
Deferred income taxes	166,538
Non-cash interest expense	40,470
Changes in operating assets and liabilities:
Accounts receivable	979,612	760,274
Unbilled accounts receivable	(1,765,096)	1,114,139
Prepaid expenses and other current assets	248,707	1,611,860
Accounts payable	617,014	(674,723)
Accrued expenses and other liabilities	(87,483)	404,230
Net cash used in operating activities	(1,912,379)	(3,385,227)
Investing activities
Purchases of property and equipment		(30,364)
Proceeds from the sale of property and equipment	67,400
Net cash provided by (used in) investing activities	67,400	(30,364)
Financing activities
Proceeds from issuance of long term debt	2,500,000
Deferred financing costs	(216,460)
Change in restricted cash requirements	100,000
Proceeds from issuance of common stock and warrants	38,983	5,862,558
Other	(32,960)	(64,362)
Net cash provided by financing activities	2,389,563	5,798,196
Effects of exchange rates on cash	(4,434)	(7,334)
Increases in cash and cash equivalents	540,150	2,375,271
Cash and cash equivalents, at beginning of period	11,236,771	11,785,327
Cash and cash equivalents, at end of period	11,776,921	14,160,598
Supplemental disclosure of cash flow information
Cash paid for interest	73,911	30,608
Noncash financing activity
Warrants issued to lender in connection with loan	$ 69,876

Commitments and Contingencies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	1 Months Ended
	Jun. 30, 2012 Initial Maximum Maintenance Failure Obligation	Jun. 30, 2012 Every 30 days until failure is cured	Sep. 30, 2011 PharmAthene	Sep. 30, 2011 PharmAthene Maximum
Commitments and Contingencies [Line Items]
SIGA breach of contractual obligation awarded, percentage of net profits			50.00%
SIGA breach of contractual obligation award period following initial commercial sale				10 years
SIGA net profits from sales before distribution for breach of contract			$ 40
Awarded 1/3 reasonable attorney's fees and expert witness fees			2.4
Percentage of aggregate principal amount of convertible Notes	1.00%	1.00%
Aggregate principal amount of obligation	$ 0.2	$ 0.2

Financing Transactions - Additional Information (Detail) (USD $)	6 Months Ended			1 Months Ended		6 Months Ended
	Jun. 30, 2012	Mar. 30, 2012	Dec. 31, 2011	Jun. 30, 2011 PharmAthene	Jun. 30, 2012 Percentage Over Libor	Jun. 30, 2012 Year One	Jun. 30, 2012 Year Two	Jun. 30, 2012 Year Three [Member]	Jun. 30, 2012 There After	Jun. 30, 2012 Term Loan	Mar. 30, 2012 Credit Facilities Term Loan	Jun. 30, 2012 Senior Secured Credit Facility Term Loans	Jun. 30, 2012 Senior Secured Credit Facility Term Loans Revolving Line Of Credit	Mar. 30, 2012 Senior Secured Credit Facility Term Loans Revolving Line Of Credit
Line of Credit Facility [Line Items]
Senior secured debt facility	$ 2,500,000										$ 2,500,000
Line of credit facility, maximum borrowing capacity														5,000,000
Revolving line of credit used														900,000
Percentage of withdrawal from revolving loan qualified billed												85.00%
Percentage of withdrawal from revolving loan qualified unbilled												80.00%
Available loan agreement to borrow													100,000
Fixed interest rate on term loan	10.14%
Variable interest rate	1.50%
Fixed portion of the variable rate					5.00%
Interest rate on revolving line of credit	6.50%
Term loan and line of credit, maturity date	2015-09
Term loan , payment terms	Payments on the term loan are interest-only for the first 10 months, which may be extended to 12 months if certain conditions described in the Loan Agreement are met. Subsequently, the term loan will fully amortize over its remaining term.
Percentage of prepayment premium						3.00%	3.00%	2.00%	2.00%
Percentage of final payment premium										3.00%
Warrants issued to purchase shares of common stock	46,584	46,584		371,423
Common stock at an exercise price	$ 1.61
Fair value attributable to the warrant	69,876
Debt financing costs	216,000
Common Stock Share issued	48,345,984		48,236,172	1,857,143
Common Stock issued price				$ 3.50
Warrant exercise price		1.61		3.50
Gross proceeds from issuance of stock				6,500,000
Net Proceeds from issuance of stock				$ 5,800,000

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	48,345,984	48,236,172
Common stock, shares outstanding	48,345,984	48,236,172

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2012	Aug. 01, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2
Trading Symbol	PIP
Entity Registrant Name	PHARMATHENE, INC
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		48,365,984

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Segment	Jun. 30, 2011	Dec. 31, 2011
Significant Accounting Policies [Line Items]
Number of operating segment			1
Deferred revenue	$ 19,000		$ 19,000		$ 500,000
Cost reimbursed to offset research and development expenses	400,000	100,000	1,000,000	400,000
Share-based compensation forfeitures rate	12.00%	12.00%
Stock options granted	185,000	208,000	200,948	304,000
Restricted stock granted	0	0	0	0
Unrecognized share-based compensation expense related to unvested awards	2,900,000		2,900,000
Income tax expense	$ 16,133		$ 166,538
Anti-dilutive securities excluded from computation of earnings per share	11,600,000			10,900,000
Maximum
Significant Accounting Policies [Line Items]
Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period	2 years 1 month 6 days
Liquidity \| Maximum
Significant Accounting Policies [Line Items]
Cash liquidity maturity period			3 months

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		6 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue	$ 6,316,998	$ 6,428,840	$ 12,466,050	$ 12,766,562
Operating Expenses:
Research and development	4,918,655	5,984,098	9,624,012	11,804,472
General and administrative	2,780,099	3,409,372	5,728,580	8,349,026
Depreciation and amortization	76,448	116,690	162,358	234,319
Total operating expenses	7,775,202	9,510,160	15,514,950	20,387,817
Loss from operations	(1,458,204)	(3,081,320)	(3,048,900)	(7,621,255)
Other income (expense):
Interest income	4,819	3,381	7,807	6,535
Interest expense	(111,353)	(15,173)	(114,381)	(30,608)
Other income (expense)	519	(32,722)	53,434	(44,628)
Change in fair value of derivative instruments	823,809	688,221	(167,853)	3,176,686
Total other income (expense)	717,794	643,707	(220,993)	3,107,985
Net loss before income taxes	(740,410)	(2,437,613)	(3,269,893)	(4,513,270)
Income tax expense	(16,133)		(166,538)
Net loss	$ (756,543)	$ (2,437,613)	$ (3,436,431)	$ (4,513,270)
Basic and diluted net loss per share	$ (0.02)	$ (0.05)	$ (0.07)	$ (0.10)
Weighted average shares used in calculation of basic and diluted net loss per share	48,325,945	46,631,396	48,297,919	46,454,968

Stockholders' Equity - Additional Information (Detail)			12 Months Ended
Stockholders' Equity - Additional Information (Detail)	Jun. 30, 2012	Mar. 30, 2012	Dec. 31, 2008 2007 Long Term Incentive Plan	Jun. 30, 2012 2007 Long Term Incentive Plan	Aug. 03, 2007 2007 Long Term Incentive Plan	Jun. 30, 2012 Expiration 2015	Jun. 30, 2012 Expiration 2017
Stockholders Equity [Line Items]
Common stock reserved			4,600,000		3,500,000
Options award term			10 years
Shares approved for issuance				8,200,000
Shares available to be issued				1,600,000
Warrants issued to purchase shares of common stock	46,584	46,584				2,572,775	100,778
Warrant exercise price		1.61				2.50	3.97
Warrant expiration date		Mar. 30, 2022				Jan. 28, 2015	Mar. 30, 2017

Share-based Compensation Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
Share-based Compensation Expense (Detail) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 512,041	$ 544,700	$ 1,060,705	$ 1,255,325
Research and Development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	127,076	216,997	244,143	458,431
General and Administrative Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 384,965	$ 327,703	$ 816,562	$ 796,894

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2012
Subsequent Events	Note 7 – Subsequent Events On July 31, 2012, the DoD exercised its option to continue to fund an advanced expression system for the bioproduction of PharmAthene’s rBChE nerve agent medical countermeasure program, under a contract initially awarded in 2011. The value of the option was $2.5 million out of a potential total contract value of $5.7 million.

Subsequent Events - Additional Information (Detail) (U.S. Department of Defense, USD $) In Millions, unless otherwise specified	Jul. 31, 2012
U.S. Department of Defense
Subsequent Event [Line Items]
Value of Option exercised	$ 2.5
Potential total contract value	$ 5.7

Summary of Changes in Fair Value of Our Level 3 Liabilities (Detail) (Fair Value, Inputs, Level 3, Warrants, USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Fair Value, Inputs, Level 3 \| Warrants
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning Balance	$ 1,886,652	$ 8,362,995
New Liabilities in 2011		668,640
Unrealized (Gains) Losses	167,853	(3,176,686)
Ending Balance	$ 2,054,505	$ 5,854,949